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ABSTRACT 
ANALYSIS OF MEMBERS OF THE SLIT-ROBO PATHWAY AS DIAGNOSTIC 
AND PROGNOSTIC TOOLS IN HEPATOCELLULAR CARCINOMA WITH 
SPECIAL FOCUS ON ROBO2-ASSOCIATED CELLULAR PHENOTYPE  
Mehmet Ender Avcı 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Tamer Yağcı 
August 2009, 126 pages 
 
Hepatocellular carcinoma is the sixth most common cancer in the world, with an annual 
incidence exceeding half a million. It is associated mainly with hepatitis B and C viral 
infections; and is the main cause of death among cirrhotic patients. Aflatoxin B1 exposure, 
chronic alcohol consumption and virtually all cirrhosis-inducing conditions are of the other 
etiologies. For early diagnosis of HCC, surveillance of the risk groups is a crucial task 
requiring the development of novel markers for HCC with stronger sensitivity and specificity. 
In addition, description of biomarkers specific to hepatocellular carcinoma subtypes could 
identify novel targets for therapy. In this study, we analyzed members of the SLIT-ROBO 
gene families as novel diagnostic and prognostic markers in hepatocellular carcinoma. We 
defined an expression signature for members of the SLIT-ROBO gene families in HCC cell 
lines and tissues by real-time quantitative RT-PCR analysis. We showed that ROBO1 was 
overexpressed as stage and differentiation of the HCC proceeds. Furthermore, ROBO4 
downregulation and SLIT2 overexpression marked late stage and poorly differentiated HCCs. 
Our results suggest that the expression of ROBO1 and ROBO4 can be used in early diagnosis 
of HCC. As another focus, we stably knockdowned ROBO2 expression in a model AFP 
positive cell line Huh7 and characterized the associated cellular phenotype. ROBO2 
downregulation caused a significant decrease in proliferation rate whereas in wound-healing 
assay no significant difference in migration rate was observed. In addition, we performed a 
microarray experiment and found the differentially expressed genes between stable ROBO2 
knockdown and negative clones. In this analysis, we found an overexpression of CK19, 
CD44, ABCG2/ BCRP1 hepatic progenitor cell markers and CD133 that is also a putative 
cancer stem cell marker of HCC, in stable ROBO2 knockdown clones. In addition KLF4 
expression was augmented in these ROBO2 knockdown clones. We propose a genetic 
association between SLIT-ROBO pathway and CD133 at transcriptional level.  
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ÖZET 
ROBO2’YE BAĞLI HÜCRESEL FENOTİPE ÖZEL ODAKLA SLIT-ROBO YOLAĞI 
ÜYELERİNİN HEPATOSELÜLER KARSİNOM TANI VE TAKİBİNDE ARAÇ 
OLARAK ANALİZİ  
Mehmet Ender Avcı 
Moleküler Biyoloji ve Genetik Doktora Tezi 
Tez Yöneticisi: Yrd. Doç. Dr. Tamer Yağcı 
Ağustos 2009, 126 Sayfa 
 
Hepatoselüler karsinom, yıllık yarım milyonu aşan yeni vaka sayısıyla, dünya çapında en sık 
rastlanan altıncı kanser türüdür. Hepatoselüler karsinom, siroz hastalarının temel ölüm 
sebeplerinden hepatit B ve C enfeksiyonuyla ilişkilendirilmiştir. Aflatoxin B’ye maruz kalma, 
kronik alkol kullanımı ve sirozu tetikleyen bütün etkenler diğer etiyolojilerdir. Hepatoselüler 
karsinomun erken tanısı için risk gruplarının takibi önemlidir ve bu kansere karşı spesifisitesi 
ve duyarlılığı daha yüksek yeni belirteçlerin geliştirilmesi gerekmektedir.  Bunun yanında 
hepatoselüler karsinom alt tipleri için biyobelirteçlerin tanımlanması yeni terapi 
metodolojilerini de mümkün kılabilir. Bu çalışmada, SLIT-ROBO gen aileleri üyelerinin 
hepatoselüler karsinom tanı ve takibinde yeni belirteçler olarak kullanılabilirliğini inceledik. 
Gerçek zamanlı kuantitatif RT-PCR yöntemiyle SLIT-ROBO yolağı genlerinin hepatoselüler 
karsinomda ifadesini belirleyen bir imza tanımladık. ROBO1 gen ifadesinin hepatoselüler 
karsinom derecesine ve diferensiyasyonuna bağlı olarak değiştiğini gösterdik. Bununla 
beraber ROBO4 ifadesindeki azalma ve SLIT2 ifadesindeki artış, ileri derece ve kötü 
diferensiye hepatoselüler karsinom dokularını belirledi. Sonuçlarımız, ROBO1 ve ROBO4 
ifadelerinin hepatoselüler karsinomun erken tanısında kullanılabileceğine işaret etti. Diğer bir 
odak olarak; AFP ifadesi bulunan iyi diferensiye bir model olan Huh7 hücrelerinde, ROBO2 
gen ifadesini kalıcı bir şekilde baskıladık ve bu etkiyle ilişkili hücre fenotipini tanımladık. Bu 
şekilde elde edilen kalıcı tek-tip hücrelerde, ROBO2 geninin baskılanması hücrelerin bölünme 
hızını etkilerken yara-iyileşmesi (wound-healing) deneylerinde ölçülen göç hızına istatiksel 
olarak anlamlı etkisi görülmedi. Bağlantılı bir mikrodizi çalışmasında ROBO2 ifadesi 
baskılanmış bu hücrelerle, ROBO2’yi ifade eden kontrol hücreler arasında farklı ifadelere 
sahip genleri inceledik. Bu incelemede CK19, CD44, ABCG2/BCRP2 hepatik öncül hücre 
belirteçleri ve ayrıca insanda HCC kanser kök hücre belirteci olarak öne sürülen CD133 
ifadelerinin, ROBO2 ifadesi baskılanmış hücrelerde arttığını bulduk. Bunlara ek olarak KLF4 
ifadesi ROBO2 ifadesi baskılanmış bu hücrelerde arttı. SLIT-ROBO yolağı ve CD133 
arasında transkripsiyon seviyesinde genetik bir etkileşim bulunduğunu öne sürüyoruz. 
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1 INTRODUCTION 
 
1.1 Hepatocellular carcinoma 
Being the largest organ inside the body, liver has several physiological functions such as bile 
production and excretion; excretion of bilirubin, hormones, and drugs; metabolism of fats, 
proteins, carbohydrates; activation of enzymes; storage of glycogen, vitamins and minerals; 
synthesis of plasma proteins and clotting factors; blood detoxification and purification. 
 
Liver cancer contains diverse, histologically distinct primary hepatic neoplasms, which 
include hepatocellular carcinoma (HCC), intrahepatic bile duct carcinoma 
(cholangiocarcinoma), hepatoblastoma, bile duct cystadenomacarcinoma, hemangiosarcoma 
and epitheloid hemangioendothelioma (Anthony 2002). Among these, hepatocellular 
carcinoma is the most common kind of liver cancers comprising 83% of all cases (American 
cancer society 2005 (Piper, Nurcombe et al. 2002)). 
 
1.1.1 Pathogenesis of hepatocellular carcinoma 
The molecular pathogenesis of HCC is a complex process involving different genetic and 
epigenetic alterations, chromosomal aberrations, gene mutations, and altered molecular 
pathways (Farazi and DePinho 2006). HCC arises in normal livers, abnormal but noncirrhotic 
livers, and in cirrhotic livers in 80% of cases resulting from several environmental risk factors 
(Llovet, Burroughs et al. 2003; Bruix and Sherman 2005). 
 
Beginning from stem cells or mature hepatocytes, a multistep process occurs during 
transformation of cirrhotic liver into cancer by the accumulation of genetic alterations. 
Increased levels of transforming growth factor-α (TGF-α) and insulin-like growth factor-2 
(IGF-2), lead to increased rate of hepatocyte proliferation in chronic HCV patients 
(Thorgeirsson and Grisham 2002; Bruix, Boix et al. 2004; Farazi and DePinho 2006; 
Villanueva, Newell et al. 2007). There is experimental evidence suggesting HCV core protein 
as a Wnt ligand, a transactivator of Ras signaling and a p53 inactivator (Branda and Wands 
2006). In the case of chronic HBV infection; promoter activation of oncogenes, DNA 
rearrangements and chromosomal instability occur as a result of nonrandom HBV-DNA 
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integration (Ferber, Montoya et al. 2003). In addition, oxidative stress induced genomic and 
mitochondrial DNA damage arises because of the chronic inflammation of the liver (Hussain, 
Schwank et al. 2007). At preneoplastic stages, presence of genetic aberrations (allelic 
deletions) and epigenetic alterations (aberrant methylation) results in proliferation of selected 
cell populations into dysplastic nodules, which are HCC precursors. These cells gradually 
increase their telomerase activity in order to gain replicative potential. Ultimately, survival 
and proliferation related pathways are activated that brings on the malignant phenotype 
(Figure 1.1).   
 
 
Figure 1.1: Histopathologic progression and molecular features of HCC. After hepatic injury incurred by 
any one of several factors (HBV, HCV, alcohol and aflatoxin B1) there is necrosis followed by hepatocyte 
proliferation. Continuous cycles of this destructive-regenerative process foster a chronic liver disease condition 
that culminates in liver cirrhosis. Subsequently, hyperplastic nodules are observed, followed by dysplastic 
nodules and ultimately hepatocellular carcinoma (HCC). Telomerase reactivation, loss and/or mutation of p53 
and genomic instability also characterize hepatocarcinogenesis (Farazi and DePinho 2006). 
 
1.1.2 Molecular subtypes of hepatocellular carcinoma 
In an effort to combine Vogelstein’s solid tumor development concept- stating the 
requirement of the disruption of three critical intracellular signaling networks- and the famous 
“Hallmarks of cancer” description of Hanahan and Weinberg; Llovet and Bruix proposed that 
HCCs have common disturbances and additionally more specific alterations identifying 
distinct classes (Hanahan and Weinberg 2000; Vogelstein and Kinzler 2004; Llovet and Bruix 
2008). Common to half of the cases; first, the cell cycle checkpoint is inactivated through 
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TP53 point mutations or loss of heterozygosity, p16 or Retinoblastoma (Rb) gene silencing, 
or cyclinD1 overexpression. Secondly, in early stages of hepatocarcinogenesis, 
autocrine/paracrine vascular endothelial growth factor (VEGF), platelet-derived growth factor 
(PDGF), or angiopoietin-2 or VEGFA gene amplification results in abnormal angiogenesis. 
Third, aberrantly proliferating cells evade apoptosis through inactivation of p53 or 
overexpression of anti-apoptotic Bcl2. Finally, telomerase reverse transcriptase is reactivated 
to guarantee replicative immortality.  
 
In gene expression studies, more specific alterations in cell proliferation and survival genes 
have defined molecular subtypes of HCC. One such class shows activation of Wnt signaling 
showing predominant mutations in CTNNB1. The protein product of CTNNB1 gene; β-catenin 
escapes from ubiquitination through mutations or deletions in exon 3 of CTNNB1, resulting in 
nuclear translocation and target gene activation in the absence of Wnt ligands. Along with 
high proliferation and chromosomal instability, activation of RAS/mitogen-activated protein 
kinase kinase (MAPKK), insulin-like growth factor (IGF), c-met, or Akt/mammalian target of 
rapamycin (mTOR) signaling pathways defines another HCC subclass. Stemness 
characteristics, indicating progenitor cell origin, are associated with this subclass. Linked with 
leukocyte infiltration, interferon signaling represents a third class. The role of nuclear factor-
κβ signaling, Janus kinase-signal transducer and activator of transcription (Jak-Stat), TGF-β, 
and hedgehog signaling activation is ambiguous. Another class represents the molecular 
mechanisms responsible for cell dissemination, invasiveness, and metastasis (Breuhahn, 
Vreden et al. 2004; Lee, Heo et al. 2006; Boyault, Rickman et al. 2007; Chiang, Villanueva et 
al. 2008; Llovet and Bruix 2008).         
 
1.1.3 Genetic aberrations described in HCC 
Contemporary use of high-throughput technologies like single-nucleotide polymorphism 
array, complementary cDNA microarray and protein mass spectrometry has brought a new 
perspective in our understanding of genetic aberrations in HCC. These aberrations can be 
grouped under four main titles: genome-wide alterations, mutations, genomic instability 
(being structural alterations) and epigenetic alterations. Table 1.1 summarizes the most 
frequent molecular aberrations in HCC that can be targeted therapeutically (Villanueva, 
Newell et al. 2007).  
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Table 1.1: Key molecular aberrations described in hepatocellular carcinoma 
Function Gene 
Gene 
Expression Mutations/Copy Alterations 
Aberrant 
Methylation 
Growth factors and 
receptors IGF-II Increased     
  
IGFR-II 
(M6PR) Decreased 25%/LOH 60%   
  EGF Increased     
  EGFR Increased 0%   
  TGF-α Increased     
  K-Ras - 11% (3%-42%)   
  RASSF1 Decreased   85% 
  PIK3CA - 12% (0%-35%)   
  PTEN Decreased 0%-11%   
  HGF/c-MET Increased     
          
Proliferation and 
differentiation β-catenin Increased 
17% (0%-44%); 58% 
hepatoblastoma   
  E-cadherin Decreased   Hyper: 46% 
  c-myc Increased   Hypo 
  APC Decreased   77% 
  VEGFA Increased Amplification (5%)   
          
Angiogenesis VEGFR-2 Increased     
  Angiopoietin-2 Increased     
          
Metastasis MMP-14 Increased     
  MMP-9 Increased     
  
Topoisomerase 
2A Increased     
  Osteopontin Increased     
  Rb Increased 15%   
  cyclin D1 Decreased Amplification (7%)   
          
Cell cycle p53 Decreased 27% (0%-67%)   
  p16 Decreased 13% Hyper: 56% 
  p27kip Decreased     
  Survivin Increased     
 
 
1.1.3.1 Genome-wide alterations 
c-myc (8q), Cyclin A2 (4q), Cyclin D1 (11q), Rb1 (13q), AXIN1 (16p), p53 (17p), IGFR-
II/M6PR (6q), p16 (9p), E-Cadherin (16q), SOCS (16p), and PTEN (10q) are among the 
candidate genes in hepatocarcinogenesis. Virtually, in all tumors chromosomal amplifications 
or deletions are found. The most prevalent amplifications are in 1q (58%-78%), 6p, 8q, 17q, 
and 20q, and deletions are in 4q, 8p, 13q, 16q, and 17p. The regions harboring cyclin D1 and 
VEGFA are found to have high-level amplifications: 11q13 (5% of cases) and 6p21 (4%-6% 
of cases), respectively (Thorgeirsson and Grisham 2002; Chiang, Villanueva et al. 2008).    
 5
 
1.1.3.2 Mutations 
Somatic mutations of HCC are seen very scarcely and needs further investigation by the use 
of high-throughput sequencing technology (Villanueva, Newell et al. 2007). TP53 is mutated 
in 27% of cases (range 0%-67%); correlative to its functions in cell cycle control, DNA 
repair, apoptosis, and differentiation. In Africa and Asia, Aflatoxin B exposure is associated 
with p53 G-to-T mutation at the third position of codon 249 (Puisieux, Lim et al. 1991). β-
catenin mutations in exon 3 are present in 17% of cases of HCC, and in 58% of cases of 
hepatoblastoma. Somatic mutations of AXIN1, phosphoinositol 3-kinase A (PI3KA), and K-
Ras have been described, rarely. In contrast to the other cancers with mutations of epidermal 
growth factor receptor (EGFR), Her2/nu phosphatase and tensin homolog (PTEN), or H-Ras; 
in HCCs these mutations are hard to find. In addition, till now no germline mutations were 
described for these genes in HCCs (Llovet and Bruix 2008). 
 
1.1.3.3 Genomic instability 
HBV integration in the TERT locus, amplification of the gene encoding the telomerase RNA 
component (TERC), or allelic loss of chromosome 10p, a region encoding a telomerase 
repressor culminates in increased telomerase activity, in nearly 90% of human HCCs. Being 
prevalent in HBV-related HCCs, high genomic instability has been associated with the 
proliferation subclass of HCC (Farazi, Glickman et al. 2003; Llovet and Bruix 2008). 
 
1.1.3.4 Epigenetic alterations 
Epigenetic silencing of gene expression occurs by abnormal methylation of gene promoter 
regions. Liver cancer cells have certain areas of dense hypermethylation over a background of 
global hypomethylation. Hypermethylation affects CpG islands localized in promoter regions 
of tumor suppressor genes like p16INK4a, E-cadherin, NORE1A, RASSF1, IGFR-II/MP6, 
and BRCA1 (Thorgeirsson and Grisham 2002; Bruix, Boix et al. 2004; Farazi and DePinho 
2006; Villanueva, Newell et al. 2007). 
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1.1.4 Disrupted signaling pathways and molecular targets for HCC therapy 
Disrupted signaling pathways put protein kinases forward as the main targets for liver cancer 
therapy. Upon the characterization of the whole kinome the emergence of novel oncology 
drugs has paced up. The key signaling pathways connected to the pathogenesis of HCC and 
the monoclonal antibodies and small molecules targeting these pathways are summarized in 
Figure 1.2 (Llovet and Bruix 2008).   
 
 
 
Figure 1.2: Molecular targeted therapies in HCC. Representation of monoclonal antibodies against ligands 
(VEGFR: bevacizumab; EGFR: cetuximab) tyrosine kinase inhibitors (VEGFR: sorafenib, sunitinib; PDFGR: 
sorafenib, sunitinib; EGFR: erlotinib, lapatinib; AEE788, Her2/nu: lapatinib, AEE788), serine/threonine kinase 
inhibitors (Raf: sorafenib; mTOR: rapamycin, everolimus; PI3K: XL-765 ) in preclinical studies or clinical trials 
in HCC (Llovet JM and Bruix J, 2008). 
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1.1.4.1 EGFR-Ras-MAPKK pathway 
Binding of the cognate receptors by the ligands EGF, hepatocyte growth factor (HGF), PDGF, 
and VEGF activate the RAS/MAPK signaling pathway and induce transcription of genes of 
the AP1 family such as c-fos and c-jun, which are key elements for cell proliferation 
(Robinson, Wu et al. 2000). The EGFR is a member of a family of four related receptors 
(Her2/Neu, ErbB3, and ErbB4) that upon ligand binding trigger tyrosine kinase activity and 
consequently initiate signal transduction. Gain of function of EGFR classically occurs as a 
result of point mutations, amplification, or increase in ligand-receptor interaction (Baselga 
and Arteaga 2005). 
 
Monoclonal antibodies against EGFR (cetuximab) or ErbB2/Her2/neu (trastuzumab) 
antagonize the tyrosine kinase activities of these receptor and thus blocks downstream 
signaling. Small molecule inhibitor erlotinib acts against the catalytic domain of EGFR and 
lapatinib acts against both EGFR and Her2 (Shepherd, Rodrigues Pereira et al. 2005; Bonner, 
Harari et al. 2006; Geyer, Forster et al. 2006; Jonker, O'Callaghan et al. 2007). In HCC, 
Ras/MAPK pathway activation might result from aberrant upstream signals (EGFR signaling, 
IGF signaling) or inactivation of tumor suppressor genes by aberrant methylation, as 
NORE1A (Calvisi, Ladu et al. 2006). Mutations of Raf and Ras are rare findings in HCC. 
Potent drugs blocking Ras/MAPK signaling are still at the exploratory phase, except for 
sorafenib, which has activity inhibiting B-Raf at nanomolar concentrations (Wilhelm, Carter 
et al. 2006; Llovet and Bruix 2008). 
 
1.1.4.2 c-Met signaling 
During injury-induced heaptocyte regenaration, hepatocyte growth factor is secreted by 
stellate cells and binds to the c-MET receptor (Fausto, Campbell et al. 2006). Although the 
direct link between HGF-cMet signaling and HCC has not been established, dysregulation of 
c-Met and HGF was observed in HCC (Takami, Kaposi-Novak et al. 2007; Villanueva, 
Newell et al. 2007). Several compounds have been developed that target the MET pathway, 
including antibodies against HGF or MET receptor, or selective small-molecule MET 
inhibitors, but none of them are yet in an advanced stage of research in HCC (Comoglio, 
Giordano et al. 2008). 
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1.1.4.3 IGF signaling 
IGF-I has been associated with high risk of neoplasm development, but not in HCC. In fact, 
experimental studies suggest the potential role of this molecule in improving cirrhosis. IGF-II 
is overexpressed in around 30% of human HCCs and the tumor suppressors IGF binding 
protein-1 (IGFBP-1), IGFBP-3, and IGFBP-4 are down-regulated. More important, the tumor 
suppressor IGFR-II, whose main action consists of binding and degrading IGF-II, is down-
regulated in a subgroup of HCCs as a result of chromosomal deletions in the IGFR-II locus 
(6q) or point mutations. Several monoclonal antibodies and small molecules blocking IGF-1R 
are under early clinical investigations (A12, XL228) (Breuhahn, Longerich et al. 2006; Llovet 
and Bruix 2008). 
 
1.1.4.4 PI3K/Akt/mTOR pathway 
Although the role of pAkt in HCC needs further investigation, recent studies have suggested a 
worse prognosis for tumors with activated Akt. An important mediator of the PI3K-Akt 
pathway is mTOR, which acts as a central regulator of cell growth and proliferation, by 
sensing nutritional status and allowing progression from G1 to S phase. The mTOR pathway 
is activated in a subset of HCCs, and its blockade with rapamycin or everolimus inhibits 
growth in HCC cell lines, and in experimental models. Everolimus (a rapamycin analog) and 
termsirolimus are approved for the treatment of renal cancer. Novel compounds are currently 
being tested in early clinical trials. These molecules (rapamycin and analogs) are already 
approved as immunosuppressive treatments after liver transplantation (Sabatini 2006; Llovet 
and Bruix 2008; Schmitz, Wohlschlaeger et al. 2008). 
 
1.1.4.5 Wnt/β-Catenin pathway 
The Wnt-βcatenin pathway is implicated in colon cancer and HCC. Unfortunately, it 
constitutes the most undruggable pathway. Activation of the Wnt cascade has been shown in 
one third of HCCs, particularly in HCV-induced HCCs. Mutations in β-catenin occurs in 
around 17% of cases (ranging from 0%-44%) (Table 1.1); and association between Wnt 
pathway activation and the nuclear sequestration of β-catenin has been described by 
immunohistochemistry. Wnt canonical pathways can also be activated by aberrant 
methylation of the tumor supressors APC (adenomatous polyposis coli) and E-cadherin or by 
increase of autocrine/paracrine secretion of Wnt ligands. Noncanonical activation of Wnt in 
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HCC deserves further research. New drugs targeting this pathway are under early clinical 
development (Laurent-Puig, Legoix et al. 2001; Moon, Kohn et al. 2004; Villanueva, Newell 
et al. 2007; Chiang, Villanueva et al. 2008; Llovet and Bruix 2008). 
 
1.1.4.6 Hedgehog signaling 
Overexpression of Sonic Hedgehog has been recently described in 60% of 115 human HCCs 
and its effective blockage leads to down-regulation of Gli related target genes. Moreover, 
tumorigenic activation of Smo can mediate c-myc overexpression, which plays an important 
role in hepatocarcinogenesis (Osipo and Miele 2006; Llovet and Bruix 2008). 
 
1.1.4.7 Apoptotic pathways 
Apoptosis is one of the mechanisms leading to cell death when cells have sustained damage to 
their DNA or cytoskeleton. Evasion of this mechanism is one of the hallmarks of cancer. 
Several proapoptotic receptor agonists targeting the extrinsic apoptosis pathway (including 
the ligand recombinant human Apo2L/tumor necrosis factor-related apoptosis inducing ligand 
[TRAIL]) and the intrinsic apoptotic pathway (BCL-2 antisense) are in development. 
Synergistic effects have been described with the combination of small molecules and agonists 
of Apo2L/TRAIL pathway in experimental models. For instance, sorafenib has been shown to 
sensitize resistant human cancer cells to TRAIL-induced death, providing the rationale for 
testing these combinations (Hanahan and Weinberg 2000; Ashkenazi and Herbst 2008; Llovet 
and Bruix 2008). 
 
1.1.5 Novel markers used in early diagnosis of hepatocellular carcinoma 
Cirrhosis is the strongest and the most common known risk factor for hepatocellular 
carcinoma (HCC), particularly cirrhosis related to hepatitis C virus (HCV) and hepatitis B 
virus (HBV) infections. In addition, HBV acquired in the perinatal period and early childhood 
is associated with increased risk of HCC even in the absence of cirrhosis (El-Serag, Marrero 
et al. 2008). Thus, there is a need for surveillance of the risk groups for early diagnosis of 
HCC.  
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Nowadays, early HCC diagnosis is feasible in 30–60% of cases in developed countries and 
this enables the application of curative treatments. In fact, while tumors less than 2 cm in 
diameter represented <5% of the cases in the early nineties in Europe, now they represent up 
to 30% of cases in Japan (Figure 1.3) (Llovet and Bruix 2008). However, detection of minute 
nodules of ~2 cm poses a diagnostic challenge as they are difficult to characterize by 
radiological or pathological examination. These nodules are defined as pre-neoplastic lesions. 
Dysplastic lesions should be followed by regular imaging studies, since one third of them will 
develop a malignant phenotype. Conversely, early tumors are treated with potentially curative 
procedures- albeit expensive- such as resection, transplantation and percutaneous ablation. 
Therefore, accurate diagnosis of small liver nodules is of paramount importance.  
 
 
Figure 1.3: Representation of the switch in the presentation of HCC in developed countries, as a result of 
implementation of surveillance among cirrhotic patients. Estimates of applicability of potentially curative 
therapies have been divided in three periods: until 1990: 5–10% of cases; 1990–2010: 30–40% of cases; 2010–
2020: 40–60% of cases (Llovet and Bruix 2008- Journal of Hepatology). 
 
 
The major diagnostic techniques for HCC include serum markers, various imaging modalities 
and histological analysis (Gomaa, Khan et al. 2009). Immunostaining with CD34 and alpha 
fetoprotein (AFP) has significant diagnostic limitations (Park, Yang et al. 1998). Serum 
 11
biomarkers such as AFP, des-γ-carboxyprothrombin (DGCP) and AFP-L3 fraction are not 
accurate for the early diagnosis of HCC (Bruix and Sherman 2005). Non-invasive radiological 
criteria have been developed by using state-of-the-art radiological techniques, unfortunately 
their sensitivity is modest: only 30% of the HCC cases are confirmed by non-invasive criteria 
and this highlights the need for complementary tools. Recently, genome-wide DNA 
microarray or quantitative real time reverse-transcriptase polymerase chain reaction (RT-
PCR) studies have attempted to identify markers of early HCC, such as heat shock protein 70 
(HSP70), Glypican-3 (GPC3), telomerase reverse-transcriptase (TERT), serine/threonine 
kinase 15 (STK6) and phospholipase A2 (PLAG12B) (Capurro, Wanless et al. 2003; Marrero 
and Lok 2004). A molecular index including a 13-gene set has also been proposed (including 
TERT, TOP2A and PDGFRA) (Paradis, Bieche et al. 2003). A microarray-generated 
signature of 120 genes was reported to discriminate between dysplastic nodules and HCC in 
HBV patients (Nam, Park et al. 2005). Proteomic studies in tissue have not identified 
informative HCC markers so far (Paradis, Degos et al. 2005). More recently a 3-gene set 
(Glypican- 3, LYVE1, and survivin) has been proposed as molecular diagnosis of early HCC 
with accuracy rates of 85–95% in training and validation sets in more than 70 samples. 
Immunostaining for Glypican- 3 was also identified as highly predictive of HCC in 75 
samples (Llovet, Chen et al. 2006; Llovet and Bruix 2008). 
 
1.1.6 Epithelial-mesenchymal transition and HCC metastasis 
Epithelial to mesenchymal transition (EMT) is a process in which epithelial cells lose their 
phenotypic characteristic and acquire mesenchymal features. These include switch from an 
apical-basolateral, polarized epithelial phenotype to a spindle-shaped, fibroblast-like 
mesenchymal phenotype. In their natural state, epithelial cells exist as tight cell clusters that 
maintain cell-cell or cell-to-matrix contacts, whereas mesenchymal cells are loosely 
organized, unpolarized cells with reduced adhesion and enhanced migratory tendencies. EMT 
is well known in embryonic development, but has been recently recognized as a central event 
in cancer progression, leading to an invasive, mesenchymal-like phenotype important for 
tumor cell spreading and metastatic dissemination (Thiery and Sleeman 2006; Moustakas and 
Heldin 2007; van Zijl, Mair et al. 2009).  
 
In the liver, hepatic stellate cells (HCS) are considered as the major fibrotic precursor cells 
that transdifferentiate to fibrogenic, extracellular matrix producing myofibroblasts in 
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inflammatory liver tissue upon TGF-β signaling, whereas hepatocytes undergo apoptosis upon 
signaling by this cytokine. However, identification of different fibrogenic populations apart 
from resident stellate cells, as well as convergent results of recent studies have challenged the 
paradigm of HSC as the essential source of liver myofibroblasts and inferred a prominent role 
for hepatocytes in liver fibrogenesis (Gressner, Rizk et al. 2008; Battaglia, Benzoubir et al. 
2009). HCC progression frequently associates with an epithelial to mesenchymal transition 
(EMT) of hepatocytes caused by the collaboration of STAT5b with the hepatitis B protein, 
HBX, or by the cooperation of laminin 5 and TGF-β (Giannelli, Bergamini et al. 2005; Lee, 
Man et al. 2006). In addition, EMT has been reported to occur in cirrhotic liver-derived 
hepatocytes that exhibited enhanced cell survival dependent on MAPK signaling (Nitta, Kim 
et al. 2008; van Zijl, Mair et al. 2009).  
 
A key feature in the initiation and execution of EMT is the downregulation of E-cadherin 
expression. TWIST, Snail1 (SNAI), SLUG and SIP1 (ZEB2) are known transcriptional 
reppressors of E-cadherin (Thiery 2002; Zhou, Deng et al. 2004; Yook, Li et al. 2005; 
Matsuo, Shiraha et al. 2009). Vimentin, fibronectin and α-smooth muscle actin (ASMA) 
expression is characteristic of mesenchymal cells and they are not usually expressed in 
epithelial cells. The atypical expression of these mesenchymal markers in epithelial cancer 
cells might be associated with local invasiveness and metastasis potential.  
 
1.1.7 Cancer stem cells in HCC 
Cancer stem cells (CSCs) are a minority population of self-renewing stem cells that are 
entirely responsible for sustaining the tumor as well as giving rise to proliferating but 
progressively differentiating cells responsible for much of the cellular heterogeneity. With the 
development of non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice for 
the xenografting of human tumors came the first good in vivo evidence for the existence of 
CSCs in leukaemia, breast and brain tumours and also in HCC (Alison, Islam et al. 2009). 
 
Chiba and colleagues have reported that two of the four HCC cell lines that they studied had 
SP cells comprising 0.25% (for Huh7) and 0.8% (for PLC/PRF/5) of the cell population. 
These cells were highly proliferative and relatively resistant to apoptosis in vitro. Microarray 
analysis indicated that several genes implicated in stemness, like Wnt pathway genes, were 
substantially up-regulated in the SP cells in comparison to non- SP cells. Using the gold-
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standard NOD/SCID mouse assay for CSCs, they found that transplanting 103 liver SP cells 
consistently yielded tumours, whereas transplantation of 106 non-SP cells failed to give rise to 
tumors (Chiba, Kita et al. 2006).  
 
CD133 (PROM1) is a pentaspan membrane protein, whose function is as yet unclear, has 
been suggested as a CSC marker in many different tumors, including colon, pancreas, brain 
and prostate, although its utility has recently been called into question. Using the CD133/1 
antibody, a number of studies have suggested that the CD133-positive fraction enriches for 
HCC CSCs. As might be expected of CSCs, they appear as a minority (<2%) population in 
primary tumors, although continued passaging has resulted in considerable enrichment of 
CD133+ cells in some HCC cell lines, up to 90% (Ma, Chan et al. 2007). HCCs with higher 
than the median number (1.32%) of CD133-positive cells are correlated with shorter survival, 
higher recurrence rates and higher tumor grade, and CD133+ cells appear highly resistant to 
conventional therapeutic drugs, such as 5-FU and doxorubicin (Ma, Lee et al. 2008; Song, Li 
et al. 2008). It has also been suggested that HCC CSCs are descendents of normal 
parenchymal stem cells that have lost sensitivity to the inhibitory growth effects of TGF-β, 
while cell selection based on Thy-1 (CD90), a disputed marker of oval cells, in combination 
with CD44, has also produced cells with aggressive tumorigenic potential (Tang, Kitisin et al. 
2008; Yang, Ho et al. 2008; Yang, Ngai et al. 2008). 
  
1.2 Slit and Robo gene families 
The intricate patterning of nervous system is the result of an extraordinary ability of axons 
and dendrites to detect and identify their correct partners among a plethora of possible 
interactions. In adult humans, each of over a trillion neurons makes connections with, on 
average, over a thousand target cells. Axons and dendrites are equipped with a highly motile 
and sensitive structure called the growth cone at their very tips in order to navigate correctly 
in such a messy environment. Extracellular guidance cues can either attract or repel growth 
cones, and can operate either at close range or over a distance. By responding to the 
appropriate set of cues, growth cones are able to select the correct path toward their target 
(Tessier-Lavigne and Goodman 1996; Dickson 2002). 
 
In 1970’s and 80’s, the introduction of various in vitro assays enabled scientist to uncover the 
mechanisms of axon guidance in developing nervous systems of both vertebrates and 
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invertebrates. As a result, in the early 1990’s several conserved families of axon guidance 
molecules were discovered. Slit and Robo families are among these molecules interacting 
with each other and acting as repellent cues (Dickson 2002).   
 
1.2.1 Slit ligands 
Slit family of axon guidance cues consists of large extracellular and membrane-associated 
glycoproteins that are produced by cells of the central nervous system (CNS). Drosophila slit 
mutants were identified in screens for embryonic patterning and commissural axon 
pathfinding defects (Nusslein-Volhard C 1984; Seeger, Tear et al. 1993; Hummel, 
Schimmelpfeng et al. 1999). In these mutants, both ipsilateral and commissural axons unite in 
the midline rather than growing along it (Rothberg, Jacobs et al. 1990; Battye, Stevens et al. 
1999; Kidd, Bland et al. 1999).  
 
Although there is a single Slit in invertebrates, there are three vertebrate Slits: Slit1, Slit2, and 
Slit3. Vertebrate Slit is secreted from ventral floor plate. The distinctive feature of Slit is its 
four N-terminal leucine-rich repeat (LRR) domains, abbreviated as D1-D4. C-terminus to 
LRRs; six epidermal growth factor (EGF)-like domains, a laminin G (LG)-like domain and 
either one (in invertebrates) or three (in vertebrates) consecutive EGF-like domains, and a C-
terminal cystein knot follow. Drosophila slit and mammalian Slit2 are proteolytically cleaved 
between their fifth and sixth EGF-like domains both in vivo and in vitro. In vitro studies have 
revealed that N-terminal cleavage product is biologically active whereas C-terminal fragment 
is inactive (Figure 1.4 B) (Brose and Tessier-Lavigne 2000; Hohenester 2008).  
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Figure 1.4: Basic structures of Slit and Robo proteins. A) Robo domain organization: Ig, immunoglobulin-
like domain; FN3, fibronectin type 3 domain; TM, transmembrane region; CC0-3, conserved cytoplasmic motifs 
and phylogenetic analysis of Robo family proteins prepared by using extracellular sequences only. B) Slit 
domain organization: LRR, leucine-rich repeat; EGF, epidermal growth factor–like repeat; lamG, laminin G 
domain; Cys, cysteine-rich domain, arrowhead indicates cleavage site in vertebrate and Drosophila Slits and 
phylogenetic analysis of Slit family proteins. C) Organization of Robo cytoplasmic domains. Color bars indicate 
presence of individual CC motifs. Gray indicates that the relevant sequence is unavailable. Alignment of selected 
CC motifs, showing consensus sequences and known binding partners (Dickson and Gilestro, 2006). 
 
1.2.2 Robo receptors 
Similar to slit, Drosophila robo was identified in a screen for axon guidance defects in which 
both ipsilateral and commissural axons pass midline several times, thus given the name 
“roundabout” (Robo for short) (Seeger, Tear et al. 1993). There are four Robo genes in 
mammals: Robo1, Robo2, Robo3 (Rig-1) and Robo4 (Magic Roundabout). Subsequently, Slit 
was defined as a chemorepellent for Robo (roundabout) receptor, and this was evolutionarily 
conserved (Brose, Bland et al. 1999; Kidd, Bland et al. 1999).  
 
In Caenorhabtidis elegans, there is a single roundabout receptor known as Sax-3. In 
Drosophila three (Robo, Robo2, Robo3) and in vertebrates four Robo receptors 
(Robo1/Dutt1, Robo2, Robo3/Rig-1, Robo4/Magic roundabout) exist. Drosophila robos are 
expressed at midline and when bound to Slits they all act as repellent cues specifying lateral 
A) 
B) 
C) 
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positioning of the longitudinal axon tracts. In vertebrates, Robos are expressed at CNS floor 
plate, and Robo3 inhibit the repellent functions of Robo1 and Robo2 like the Commisureless 
protein in Drosophila (Sabatier, Plump et al. 2004).  
 
Except Robo4, all vertebrate Robos have the same extracellular domain organization 
resembling a cell adhesion molecule (CAM): from N-terminus to C terminus, five Ig domains 
and three fibronectin type 3 domains. Robo4 has only two Ig and two fibronectin type 3 
repeats (Huminiecki, Gorn et al. 2002). A transmembrane domain link the extracellular part of 
the protein to the cytosolic part which shows considerable variation with only four conserved 
motifs, CC0-CC3. The conserved cytosolic domains are present in different combinations in 
different Robos. Since the cytosolic parts of Robos lack a uniform organization with a ~500 
a.a. sequence, it is plausible that they interact with many adaptor proteins at the same time 
(Hohenester 2008) (Figure 1.4 A).  
 
Indeed, the cytosolic domains of Robos are catalytically inactive. Abl (Abelson tyrosine 
kinase) is associated with Robo and plays an important role in mediating the interaction of 
Robo with N-cadherin (Bashaw, Kidd et al. 2000; Rhee, Mahfooz et al. 2002). Upon Slit 
binding to Robo, the adaptor protein Cables is recruited to Robo-associated Abl and forms a 
multimeric complex by binding directly to N-cadherin-associated β-catenin. Complex 
formation results in Abl-mediated phosphorylation of β-catenin on tyrosine 489, leading to a 
decrease in its affinity for N-cadherin, loss of N-cadherin function, and targeting of phospho-
Y489-β-catenin to the nucleus. Nuclear β-catenin combines with the transcription factor 
Tcf/Lef and activates transcription. Thus, Slit induced formation of the Robo-N-cadherin 
complex results in a rapid loss of cadherin-mediated adhesion and has more lasting effects on 
gene transcription (Rhee, Buchan et al. 2007) (Figure 1.5).  
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Figure 1.5: Model depicting the formation of the Slit-induced Robo/Abl–Ncadherin/β-catenin complex. 
Fyn and Fer are tyrosine kinases associated with the cadherin complex through p120–catenin25,32. PTP1B, 
protein tyrosinephosphatase bound directly to N-cadherin; CRPs and BTFs, chromatin remodelling proteins and 
basal transcription factors, respectively, associated with transcriptionally active β-catenin (Rhee, Buchan et al. 
2007). 
 
 
srGAP1 (Slit–Robo Rho GTPase-activating protein 1) has been shown to bind to the proline-
rich CC3 motif of mammalian Robo1 and mediate the Slit-dependent inactivation of the Rho 
family GTPase, Cdc42 (cell division cycle 42). The adaptor protein Dock/Nck also binds to 
CC3 (as well as to CC2) and mediates the Slit-dependent recruitment of SOS (Son of 
sevenless), which in turn activates another Rho GTPase, Rac (Wong, Ren et al. 2001; Fan, 
Labrador et al. 2003; Yang and Bashaw 2006). These examples illustrate how Slit–Robo 
signalling could alter cytoskeletal dynamics through regulation of Rho family members. In 
addition, Ena/VASP proteins bind to CC1 and CC2 (Bashaw, Kidd et al. 2000) and the Rho 
family GTPase activating protein (GAPs) Vilse/crGAP binds to CC2 (Lundstrom, Gallio et al. 
2004; Hu, Li et al. 2005) (Figure 1.4 C). Inhibitor studies have also implicated PI3K 
(phosphoinositide 3-kinase), MAPKs (mitogen-activated protein kinases) and localized 
protein synthesis, but the adaptor molecules linking Robo activation to these pathways have 
yet to be identified (Wang, Xiao et al. 2003; Piper, Anderson et al. 2006). Furthermore, the 
cytosolic domains of DCC (deleted in colorectal cancer) and Robo receptors have been shown 
to interact physically, and Slit-activated Robo has been suggested to silence the attractive 
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Netrin-DCC signal once an axon has reached the CNS midline (Stein and Tessier-Lavigne 
2001). 
 
1.2.3 Structural basis of Slit-Robo interaction 
All Robos, other than Robo4, were shown to bind to Slit ligands. This interaction is 
evolutionarily conserved (Brose, Bland et al. 1999). Concave face of Slit D2 domain was 
described as the minimum Robo binding domain and contains the common binding residues 
(Drosophila Slit residues Tyr402, Leu424, Tyr450 and His472) for all Drosophila Robos 
(Howitt, Clout et al. 2004). Also in vertebrates Slit D2 is responsible for Robo binding, 
containing the four conserved amino acids: Tyr356, Leu378, Tyr404 and His426 for human 
Robo1 (Morlot, Thielens et al. 2007) and it has the biological activity as a repellent 
demonstated on Xenopus axon growth cones (Hussain, Piper et al. 2006).  
 
Extracellular IG1 and IG2 domains of Robo proteins are required for Slit interaction (Liu, 
Patel et al. 2004) and the observed stoichiometry of minimum Slit-Robo interaction is 1:1 
(Hussain, Piper et al. 2006). Although Robo IG2 lies far C-terminus to Slit interacting IG1, its 
deletion has dramatic effects on Slit binding, so the contribution of IG2 should further be 
clarified (Hohenester 2008).  
 
1.2.4 Role of Slit-Robo interactions in normal development and physiology 
 
1.2.4.1 Regulation of commissural axon pathfinding 
The slit mutant was identified first in the classic genetic screen for embryonic patterning 
defects in Drosophila and subsequently in screens for commissural axon pathfinding defects. 
The mutants are characterized by the collapse of axon tracts onto the midline. robo was also 
initially identified through genetic studies in Drosophila; specifically, in the screen for 
mutants with commissural axon pathfinding defects. In robo mutant embryos, too many axons 
cross the midline, including both ipsilateral axons that aberrantly cross and commissural 
axons that recross (Nusslein-Volhard C 1984; Rothberg, Jacobs et al. 1990; Seeger, Tear et al. 
1993; Kidd, Brose et al. 1998; Hummel, Schimmelpfeng et al. 1999; Kidd, Bland et al. 1999). 
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Vertebrate commissural neurons are born in the dorsal spinal cord, and their axons are first 
drawn to the midline by the chemoattractants netrin and sonic hedgehog, which emanate from 
the ventral floor plate (Kennedy, Serafini et al. 1994; Serafini, Kennedy et al. 1994; Charron, 
Stein et al. 2003). These axons then cross the floor plate and turn longitudinally on the 
opposite (contralateral) side, growing right alongside the floor plate, laterally. Drosophila 
commissural neurons also require netrins for crossing (Harris, Sabatelli et al. 1996; Mitchell, 
Doyle et al. 1996) (Figure 1.6). 
 
Figure 1.6: Commissural axon pathfinding in the mouse spinal cord and Drosophila ventral nerve cord. 
(a) Schematic of E9.5 mouse embryo. (b) Spinal cord section from E12.5 mouse embryo (as indicated by dashed 
lines in a). Examples of commissural (white) and ipsilateral (black) neurons are shown. (c) “Open-book” 
preparation, obtained by dissecting the spinal cord along the dashed line as indicated in b and laying it flat. (d ) 
Stage 16 Drosophila embryo, at the end of embryogenesis. (e) Dorsal view of two segments of the ventral nerve 
cord, showing examples of intersegmental commissural (white) and ipsilateral (black) neurons. A, anterior; P, 
posterior; D, dorsal; V, ventral; L, lateral (Dickson and Gilestro, 2006). 
 
 
In Drosophila, commisureless sorts robo to endosomes during midline crossing, thus prevents 
Slit’s repulsive effect (Keleman, Rajagopalan et al. 2002). In vertebrates, Robo3 has a similar 
effect and suppresses Robo1 activity in precrossing axons. However, in postcrossing axons 
Robo3 action is relieved allowing Robo1 to be expressed and arrest DCC activity.  In 
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addition, Slit interaction with Robo1 blocks floor plate recrossing in these postcrossing axons 
(Stein and Tessier-Lavigne 2001; Sabatier, Plump et al. 2004) (Figure 1.7).  
 
      
Figure 1.7: Robo3 antagonizes Robo1 to allow crossing in mice. In precrossing commissural axons, Robo3 
levels are high, and Robo1 levels low. Robo3A is thought to inhibit Robo1-mediated repulsion in these axonsso 
that they are instead attracted to the floor plate by netrin-1 and sonic hedgehog. After crossing, Robo3 levels are 
low, and Robo1 levels high. Axons are now repelled by signaling of Slit through Robo1. In addition, attraction to 
netrin-1 may be downregulated, possibly owing to a Slit-dependent interaction between Robo1 and the netrin 
receptor DCC (Deleted in colorectal cancer) (Dickson and Gilestro, 2006). 
 
 
Lateral positioning of longitudinal axon fascicles are also determined by Robo homologs. In 
Drosophila, loss- and gain-of-function experiments have showed that there are mainly three 
longitudinal paths with respect to Robo expression: lateral fascicles express Robo1, Robo2 
and Robo3; intermediate fascicles express Robo1 and Robo3; while medial fascicles express 
only Robo1 (Rajagopalan, Vivancos et al. 2000; Simpson, Bland et al. 2000) (Figure 1.8). 
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Figure 1.8: A Robo code for lateral positioning in Drosophila. Schematic showing the division of the 
longitudinal axon tracts into three major zones, according to the Robo code (Dickson and Gilestro, 2006). 
 
1.2.4.2 Role of Slit2-Robo2 interaction in kidney development 
Studies examining SLIT/ROBO signaling during kidney development bring this issue to the 
fore, with the recent analysis of Slit2-/- mice suggesting a new role for SLIT2 signaling in 
regulating transcription (Grieshammer, Le et al. 2004). In contrast, efforts to demonstrate an 
established role for SLIT2 as a branching factor in kidney have been unsuccessful (Piper, 
Nurcombe et al. 2002).  
 
In the absence of Slit2 and also in Robo2-/- mice multiple ureteric buds form in developing 
mouse kidney. In Slit2-/- animals Gdnf gene dosage reduction results in rescue of the 
observed supernumerary bud phenotype. Expression analysis reveals Slit2 transcripts in the 
nephric duct and in the anterior nephrogenic mesenchyme, where Robo2 is also expressed. In 
contrast, Gdnf transcripts are expressed throughout the nephrogenic mesenchyme, but over the 
course of development they become progressively restricted to the posterior region where the 
ureteric bud forms. In the light of the available data, a model is proposed describing that 
SLIT2 signals through ROBO2 to suppress supernumerary bud formation (Figure 1.9). These 
 22
findings suggest that ROBO mediated signaling may have roles in cell fate specification by 
regulating transcription or translation of key determinants (Grieshammer, Le et al. 2004; 
Hinck 2004). 
 
 
Figure 1.9: SLIT2-ROBO2 signaling is essential for proper kidney development in mice. SLIT2 signaling 
through ROBO2, restricts the anterior expression of Gdnf. In the posterior region, lack of ROBO2 prevents SLIT 
signaling, allowing Gdnf expression and consequently the appropriate outgrowth of the ureteric bud (Hinck L, 
2004). 
 
1.2.4.3 Role of Slit-Robo in lung development 
Transcripts of Slit2, Slit3, Robo1 and Robo2 are expressed in the lung (Xian, Clark et al. 
2001; Anselmo, Dalvin et al. 2003; Greenberg, Thompson et al. 2004). A small cell lung 
cancer line expresses a mutated Robo1 gene termed Dutt1, for deleted in U2020, which is 
missing the first immunoglobulin repeat in the extracellular domain (Sundaresan, Chung et al. 
1998). Mice engineered to express only Dutt1 frequently die at birth due to respiratory failure, 
and histological analyses of their lungs reveal abnormally dense mesenchyme, surrounding 
smaller and irregularly shaped bronchioles (Xian, Clark et al. 2001). Since SLIT-ROBO 
interaction shown to promote axon branching in the nervous system, possibly these irregularly 
shaped bronchioles are a result of inappropriate branching (Wang, Brose et al. 1999; Ozdinler 
and Erzurumlu 2002; Hinck 2004).  
 
 23
1.2.5 Slit-Robo in cancer and other pathologies 
 
1.2.5.1 SLIT-ROBO expression in tumors of various tissues 
Although no more than a decade has passed from their discovery, there is mounting evidence 
on the involvement of SLITs and ROBOs in cancers. So far, no somatic point mutation of 
ROBO1 (or of its ligands SLITs) was reported in tumors. A targeted mutation of mouse robo1 
was generated by deletion of exon 2, mimicking a deletion that naturally occurs in human 
small cell lung cancer cell line NIH-H219X, and resulted in the removal of Robo1 Ig1. In 
total, 63% of Robo1-/- homozygous mice die in the first 24 hours because of respiratory 
failure due to abnormal lung development. A few homozygous mice survive up to 1 year and 
show epithelial bronchial hyperplasia, but no spontaneous tumor formation was detected. 
Later on tumor susceptibility of Robo1 heterozygous mice was analyzed. During their second 
year of life, Robo1 heterozygotes develop lymphoma and carcinomas, such as invasive lung 
carcinomas. In malignant tumor samples from Robo1+/- mice, the expression of Robo1 is 
undetectable. Moreover, the study of the remaining allele showed that its promoter is 
hypermethylated. Overall, these studies support a role for Robo1 as a tumor suppressor gene, 
at least in the mouse (Xian, Clark et al. 2001; Xian, Aitchison et al. 2004; Chedotal, Kerjan et 
al. 2005).  
 
The expression of SLIT-ROBO genes are analysed by quantitative RT-PCR in prostate tumor 
samples. SLIT1 and SLIT3 are found to be overexpressed in prostate tumors (Latil, Chene et 
al. 2003). SLIT2 is expressed in many tumor cell lines such as human melanoma (A375), 
bladder squamous carcinoma (SCaBER), neuroblastoma (SK-N-SH), small cell lung cancer 
(NCI-H446), carcinoma of urinary bladder (T24), colon adenocarcinoma (LoVo), breast 
cancer (ZR-75-30), nasopharyngeal carcinoma (CNE), hepatocellular carcinoma (SMMC-
7721), salivary gland carcinoma (Acc), rhabdomyosarcoma (A673) and primary tumors 
(melanoma, invasive breast carcinoma, colorectal carcinoma, etc.). SLIT2-ROBO1 signaling 
increased microvessel density and tumor mass in a xenograft model (Wang, Xiao et al. 2003). 
Slit2 acts as a potent chemoattractant for breast cancer cells specifically metastasizing to brain 
suggesting a role for Slit/Robo signaling in brain metastasis. In addition, ROBO1 is 
overexpressed in breast carcinoma tissue samples (Schmid, Rezniczek et al. 2007). 
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1.2.5.2 Epigenetic regulation of SLIT-ROBO genes 
SLIT2 was proposed to be a tumor suppressor gene, which was silenced epigenetically in 
lung, breast, colon cancers and gliomas. In addition, SLIT2 suppressed growth of colorectal 
carcinoma cells (Dallol, Da Silva et al. 2002; Dallol, Krex et al. 2003; Dallol, Morton et al. 
2003). SLIT3 was silenced by promoter hypermethylation in gliomas and colorectal cancers 
whereas SLIT1 was inactivated epigenetically in only gliomas (Dickinson, Dallol et al. 2004). 
In these studies, epigenetic inactivation of ROBO1 was shown in carcinomas of lung, breast 
and kidney (Dallol, Forgacs et al. 2002). Recently, gradual increase in promoter 
hypermethylation of SLIT1, SLIT2, SLIT3, ROBO1 and ROBO3 was reported during 
progression into cervical cancer (Narayan, Goparaju et al. 2006). 
 
1.2.5.3 Role of SLIT-ROBO signaling in cancer cell migration and immune cell 
chemotaxis 
Tumor cells often migrate to distant organs leading to secondary tumor formation and 
chemokines play a role in this process. Slit2 was shown to be a potent inhibitor of stromal-
derived factor (SDF)-1 induced leukocyte chemotaxis. This effect requires the interaction of 
CXCR4 with Robo1 that are both expressed by leukocytes. Breast cancer cells and human 
melanoma also express CXCR4, ROBO1 and ROBO2 and chemokines such as CXCL12 that 
stimulate the migration of cancer cells. It has been shown that Slit inhibits CXCL12/CXCR4-
induced breast cancer cell (DU4475) chemotaxis, chemoinvasion and adhesion. Slit inhibits 
CXCL12-induced phosphorylation of the focal adhesion component FAK and RAFTK/Pyk2 
and paxillin. It also inhibits CXCL12-induced Src kinase and PI3-kinase activities, p44/42 
MAP kinase and activity of the matrix metalloproteinase MMP-2 and MMP-9 (Wu, Feng et 
al. 2001; Prasad, Fernandis et al. 2004; Chedotal, Kerjan et al. 2005; Prasad, Qamri et al. 
2007). SLIT2 overexpression in MCF7 breast carcinoma cells induces tumor suppressive 
effect by increasing β-catenin/E-cadherin mediated cell-cell adhesion (Prasad, Paruchuri et al. 
2008). SLIT2-ROBO1 system suppresses HGF-dependent invasion in melanoma, endometrial 
and ovarian carcinoma cells (Stella, Trusolino et al. 2009). 
 
1.2.5.4 Endothelial cell migration and angiogenesis 
The most recently discovered member of the Roundabout family is magic roundabout or 
ROBO4. It was identified in a bioinformatics study for endothelial specific genes (Huminiecki 
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and Bicknell 2000; Huminiecki, Gorn et al. 2002). There are other SLIT-ROBO members 
which are expressed in endothelial cells. Slit2 and Slit3 mRNAs but not Slit1 were expressed 
in the rat endothelial cells (Wu, Feng et al. 2001). Robo1 was expressed on vascular 
endothelial cells and Slit2-Robo1 signaling was involved in angiogenesis. This increased 
microvessel density and tumor mass in a tumor xenograft model (Wang, Xiao et al. 2003). 
Recent findings indicated that SLIT2-ROBO4 interaction inhibited angiogenesis. It was 
shown that ROBO4 maintains the vascular integrity by inhibiting the pathologic angiogenesis 
and endothelial hyperpermeability. The mechanism of inhibition of pathologic angiogenesis is 
through the inhibition of VEGF-165 by Robo4/Slit2 axis. This inhibition also decreases the 
permeability levels of the vascular network (Jones, London et al. 2008).  
 
1.2.5.5 Disease association of mutations in ROBO1, ROBO2 and ROBO3 genes 
In 2004, mutations in ROBO3 were described in patients with horizontal gaze palsy with 
progressive scoliosis (HGPPS) (Jen, Chan et al. 2004). Dyslexia- which is a difficulty in 
reading and writing despite normal intelligence, senses and adequate education- may be 
caused by partial haplo-insufficiency for ROBO1 in rare families. It has shown that ROBO1 
gene was disrupted by a chromosome translocation in a dyslexic individual. In a large 
pedigree with 21 dyslexic individuals genetically linked to a specific haplotype of ROBO1, 
the expression of ROBO1 from this haplotype was absent or attenuated in affected individuals 
(Hannula-Jouppi, Kaminen-Ahola et al. 2005). As its role in kidney development in mice, 
human ROBO2 was shown to be essential for proper kidney and urinary tract development in 
human (Lu, van Eerde et al. 2007). Later in 2008, mutational gene variants of ROBO2 were 
associated with Familial Vesicoureteral Reflux (Bertoli-Avella, Conte et al. 2008). 
 
1.2.5.6 Regulation of SLIT-ROBO genes in hepatocarcinogenesis 
Despite the compiling evidence of SLIT-ROBO deregulation in various tumors, only few 
reports with apparent controversies exist with regard to the expression pattern of these genes 
in hepatocellular carcinoma (HCC). The overexpression of ROBO1 in HCC was recently 
reported and this receptor was proposed as an HCC marker in human (Ito, Funahashi et al. 
2006). In contrast, another study reported that Robo1 heterozygous mice developed 
spontaneous HCC tumors (Xian, Aitchison et al. 2004). It was shown by 
immunohistochemical staining that SLIT2 protein also was present in HCC tumor sections 
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(Wang, Xiao et al. 2003). SLIT1, SLIT2, SLIT3 are present in only poorly differentiated HCC 
samples at a low level (Ito, Funahashi et al. 2006).  
 
Epigenetic silencing of SLIT2 was recently described in HCC. Downregulation of SLIT2 was 
detected in 6 of 8 (75%) HCC cell lines by quantitative real-time RT-PCR (qRT-PCR), and 
the downregulation of SLIT2 was generally dependent on the degree of methylation at the 
promoter region. Furthermore, expression of SLIT2 was restored in relatively low-expressing 
cell lines after treatment with 5-aza-2-deoxycytidine (5-Aza-dC). Downregulation of SLIT2 
expression was also detected in 45 of 54 primary HCC samples (83.3%), and the decrease in 
expression was significantly correlated with CpG island hypermethylation. This decrease of 
SLIT2 expression was also associated with lymph node metastasis in HCC. Moreover, 
overexpression of SLIT2 in SMMC-7721 cells suppressed cell growth, migration, and 
invasion (Jin, You et al. 2009). 
 27
2 OBJECTIVES AND RATIONALE 
 
Hepatocellular carcinoma is the sixth most common neoplasm in the world, with more than 
half a million new cases annually, and the main cause of death among cirrhotic patients 
(Llovet, Di Bisceglie et al. 2008). It is associated mainly with hepatitis B and C viral 
infections, Aflatoxin B1 exposure and chronic alcohol consumption etiologies. For early 
diagnosis of HCC, surveillance of the risk groups is a crucial task. The major diagnostic 
techniques for HCC include serum markers, various imaging modalities and histological 
analysis (Gomaa, Khan et al. 2009). Nowadays, early HCC diagnosis is feasible in 30–60% of 
cases in developed countries and this enables the application of curative treatments. Detection 
of minute nodules of ~2 cm poses a diagnostic challenge as they are difficult to characterize 
by radiological or pathological examination. These nodules are defined as pre-neoplastic 
lesions. Dysplastic lesions should be followed by regular imaging studies, since one third of 
them will develop a malignant phenotype. Therefore, accurate diagnosis of small liver 
nodules is of paramount importance. However, current molecular diagnostic methodologies 
have restraints. Immunostaining with CD34 and alpha fetoprotein (AFP) has significant 
diagnostic limitations (Park, Yang et al. 1998). Serum biomarkers such as AFP, des-γ-
carboxyprothrombin (DGCP) and AFP-L3 fraction are not accurate for the early diagnosis of 
HCC (Bruix and Sherman 2005). Therefore, the development of novel markers for HCC with 
stronger sensitivity and specificity is important for the surveillance of patients with liver 
cancer risk. 
 
Hepatocellular carcinoma is a complex and heterogeneous tumor with different genetic and 
epigenetic alterations, chromosomal aberrations, gene mutations, and altered molecular 
pathways (Farazi and DePinho 2006). With the implementation of high-throughput 
technologies like microarrays, molecular subclasses of cancers are better defined and led to 
the development of molecularly targeted therapies. A good example is the therapeutic use of 
trastuzumab (Herceptin) in ErbB2 positive breast cancers. Description of biomarkers specific 
to hepatocellular carcinoma subtypes could identify novel targets for therapy. In this study, 
we aimed to identify novel diagnostic and prognostic hepatocellular carcinoma markers; 
initially by database searches and then with expression analyses for validation and 
confirmation. 
 
 28
Our preliminary efforts directed us to investigate the SLIT-ROBO gene families in HCC. 
SLIT-ROBO gene family members initially described for their roles in axon guidance during 
development. Subsequently, their involvement in cancers of various tissues has been 
identified. ROBO1 is located to a genomic region that is deleted in lung carcinomas. 
Immunoglobulin1 domain deletion of ROBO1 was identified in lung cancer cell lines. 
Epigenetic inactivation of SLIT1, SLIT2, SLIT3 and ROBO1 genes were described in human 
tumor cell lines and tissues. ROBO4 overexpression and SLIT2-ROBO1 signaling is 
implicated in angiogenesis and tumor cell migration. Despite the compiling evidence of SLIT-
ROBO deregulation in various tumors, only few reports with apparent controversies exist with 
regard to the expression pattern of these genes in hepatocellular carcinoma (HCC). We aimed 
to describe the expression of members of the SLIT-ROBO families in HCC cell lines and 
tissues. ROBO2 gene expression signature emerged as a good distinction marker between 
AFP positive and negative HCC cell lines: with ROBO2 overexpression in AFP positive cell 
lines. The absence of ROBO2 expression in AFP negative cell lines with higher migration 
capacity and the role of SLIT-ROBO interaction as a chemokine signaling in cellular 
migration led us to hypothesize that SLIT-ROBO signaling may affect migratory behavior of 
HCC cells. We proposed that ROBO2 gene knockdown in a model AFP positive cell line 
would unravel the cellular phenotype associated with ROBO2.   
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 Reagents 
All laboratory chemicals were analytical grade from Sigma-Aldrich (St.Louis, MO, USA), 
Farmitalia Carlo Erba (Milano, Italy) and Merck (Schucdarf, Germany) with the following 
exceptions: ethanol and methanol were from Riedel-de Haën (Germany). Agar, tryptone and 
yeast extract were obtained from Gibco (Carlsbad, CA, USA), BRL Life Technology Inc. 
(Gaithersburgs, MD, USA). 
 
3.1.2 Bacterial strains 
The bacterial strain used in this work was E.coli DH5α. 
 
3.1.3 Enzymes 
Restriction endonucleases used for gene cloning were purchased from Jena Bioscience 
(Germany). BsrG1 restriction enzyme was purchased from New England Biolabs (Ipswich 
MA, USA-Catalog No: RO575S). T4 DNA ligase was purchased from Fermentas GmbH 
(Germany). DyNAzyme II DNA Polymerase was purchased from Finnzymes (Espoo, 
Finland).  
 
3.1.4 DNA and protein molecular weight markers 
DNA molecular weight standards were purchased from Fermentas GmbH (Germany) (100 bp-
SM0241, 1kb-SM0311) and Jena Bioscience (Germany) (low range DNA ladder 50-1000 bp, 
high range DNA ladder 0.5-10kb). All protein molecular weight markers used in this study 
were obtained from Fermentas GmbH (Germany).  
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3.1.5 Oligonucleotides 
The oligonucleotides used in polymerase chain reactions were synthesized and supplied from 
Iontek Inc. (Istanbul, Turkey) and Alpha DNA (Germany). 
 
3.1.6 Plasmids 
pSECneo vector (Cat #5774) was purchased from Ambion (Austin, TX, USA). pGIPZ 
shROBO1, shROBO2, and non-targeting vectors were purchased from OpenBiosystems 
(Huntsville, USA) while pDEST26-ROBO2 overexpression vector was purchased from 
ImaGenes GmbH (Berlin, Germany). pDEST™26 Gateway® Vector (Cat. No.11809019) was 
purchased from Invitrogen (Carlsbad, CA, USA).  
 
3.1.7 Electrophoresis, autoradiography, photography and spectrophotometer 
Electrophoresis grade agarose was obtained from Sigma Biosciences Chemical Company Ltd. 
(St. Louis, MO, USA). Horizontal electrophoresis apparatuses were from E-C Apparatus 
Corporation (Florida, USA). The power supply Power-PAC300 and Power-PAC200 was from 
Bio Rad Laboratories (CA, USA). The Molecular Analyst software used in agarose gel profile 
visualizing was from Vilber Lourmat (France). Mini-PROTEAN3 cell system and Trans-Blot 
SD semi-dry electrophoretic transfer cell were purchased from Bio-Rad (CA, USA). 
Immobilen-P transfer (PVDF) membrane was from Millipore (MA, USA) and 3MM filter 
paper was from Whatman International Ltd. (Madison, USA). The films used for 
autoradiography were Kodak and the development of the films was performed with 
Hyperprocessor (Amersham, UK). ECL-Plus Western Blotting detection reagent was 
purchased from GE Healthcare Life Sciences (Buckinghamshire, UK). Beckman 
Spectrophotometer Du640 was purchased from Beckman Instruments Inc. (CA. USA) and 
Nanodrop ND-1000 Full-spectrum UV/Vis Spectrophotometer was purchased from Thermo 
Fisher Scientific (Wilmington, DE, USA).  
 
3.1.8 Tissue culture reagents and cell lines 
Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640, trypsin, non-essential amino 
acids, penicillin/streptomycin mixture and fetal calf serum were obtained from HyClone 
(South Logan, UT, USA). Tissue culture flasks, petri dishes and cryotubes were purchased 
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from Costar Corp. (Cambridge, England). Geneticin-G418 sulfate was purchased from 
GibcoBRL (Carlsbad, CA, USA). 
 
3.1.9 Transfection reagents 
FuGene HD (Roche, Mannheim, Germany) and Licofectamine 2000 (Invitrogen, Carlsbad, 
CA, USA) transfection reagents were used in this study. OptiMEM I serum free medium was 
purchased from Invitrogen (Carlsbad, CA, USA). 
 
3.1.10 Kits 
RNeasy Mini Kit was obtained from Qiagen (Hilden, Germany). NucleoSpin RNA II Kit was 
obtained from Macherey-Nagel (Duren, Germany). DyNAmo cDNA Synthesis Kit and 
DyNAmo™ HS SYBR® Green qPCR Kit were purchased from Finnzymes (Espoo, Finland). 
TissueScan Liver Cancer Tissue qPCR Array 1 was purchased from Origene Technologies 
(Rockville, MD, USA-Catalog No: LVRT501). Silencer Express Kits (Human H1 and Human 
U6) were purchased from Ambion (Austin, TX, USA). Qiaprep spin mini-prep kit (for small 
scale DNA isolation), Qiafilter plasmid midi kit (for medium-scale DNA isolation), Qiaquick 
PCR purification and gel extraction kits (for recovery and extraction of DNA from agarose 
gel) were from Qiagen (Hilden, Germany). UltraClean Tissue DNA Isolation Kit was 
purchased from MOBIO Laboratories (Carlsbad, CA, USA). 
 
3.1.11 Antibodies 
SLIT1, SLIT2, SLIT3, ROBO1, ROBO2, ROBO4 antibodies were purchased from Santa 
Cruz (USA). Additionally, mouse monoclonal anti-human ROBO2 antibody was purchased 
form RD Systems (USA). Rabbit polyclonal anti-human CD133 antibody was purchased from 
AbCam (USA). BrdU Mouse Monoclonal Antibody, used at a dilution of 1:500 in BrdU 
incorporation assay, was purchased from DAKO (Glostrup, Denmark). Anti-mouse and anti-
rabbit HRP conjugated secondary antibodies were obtained from Sigma (USA). Anti-mouse 
and anti-rabbit AlexaFluor Red 568 and AlexaFluorGreen 488 secondary antibodies were 
purchased from Invitrogen, Carlsbad, CA, USA). 
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3.2 SOLUTIONS AND MEDIA 
 
3.2.1 General solutions 
Tris-acetic acid-EDTA (TAE): Stock solution (50XTAE) was prepared by addition of 121g 
Tris-base, 18.6g EDTA, and 28.55ml glacial acetic acid to 500ml ddH2O. pH of the stock 
solution was adjusted to 8.5. Working solution (1XTAE) was prepared by dilution of 
50XTAE to 1X with ddH2O. 
 
Ethidium bromide: 10mg/ml in water (stock solution), 30ng/ml (working solution). 
 
6X Agarose gel loading dye: A mixture of 0.009g bromophenol blue (BFB), 0.009g xylene 
cyanol (XC), 2.8ml ddH2O, 1.2ml 0.5M EDTA was prepared. The total volume was brought 
to 15ml by addition of glycerol. 
 
3.2.2 RNA solutions 
 
DEPC-treated water: 1ml DEPC was added to 1L ddH2O and stirred under hood overnight. 
DEPC was inactivated by autoclaving. 
 
Formaldehyde (FA) gel buffer: Stock solution (10XFA Gel Buffer) was prepared by 
dissolving 20.927g MOPS, 3.40g NaAc and 1.86g EDTA in 500ml ddH2O. pH of the stock 
solution was adjusted to 7.0. Working solution was prepared by diluting the stock solution to 
1X with ddH2O. 
 
5X RNA loading buffer: Bromophenol blue solution 16 µl, 500 mM EDTA pH 8.0 80µl, 
37% formaldehyde 720µl, 100% glycerol 2ml, formamide 3084µl, 10XFA gel buffer 4ml, 
RNase free (DEPC treated) water to 10ml. 
 
3.2.3 Microbiological media, reagents and antibiotics 
Luria Bertani (LB) medium: Per liter; 10g bacto-tryptone, 5g bacto-yeast extract, 10g NaCl. 
For LB agar plates, 15g/L bacto agar was added. 
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Glycerol stock solution: A final concentration of 25% glycerol in LB was added to bacterial 
culture. 
 
Ampicillin: 100mg/ml solution in ddH2O, sterilized by filtration and stored at -20°C (stock 
solution). Working solution was 100μg/ml.  
 
Kanamycin: 300mg/ml solution in ddH2O sterilized by filtration and stored at -20°C (stock 
solution). Working solution was 30μg/ml. 
 
SOB medium: Per liter; 20g tryptone (2%), 5g yeast extract (0.5%), 0.584g NaCl (10mM), 
0.1864g KCl (2.5mM) autoclaved to sterilize. Then, 2.46g MgSO4 and 2.03g MgCl2 (10mM) 
are added. 
 
SOC medium: SOB + 20mM glucose from filter sterilized 1M glucose stock solution in 
ddH2O. 
 
Transformation buffer (TB): 10mM PIPES, 55mM MnCl2, 15mM CaCl2, 250mM KCl. 
Filter sterilized and stored at 4oC. 
 
3.2.4 Tissue culture solutions 
DMEM/RPMI-1640 growth media: 10% FBS, 1% penicillin/streptomycin, 1% non-
essential amino acid were added and stored at 4oC.  
 
Freezing solution: 10% DMSO and 90% FCS were mixed freshly. 
 
Phosphate buffered saline (PBS): Stock solution (10XPBS) was prepared by dissolving 80g 
NaCl, 2g KCl, 17.8g Na2HPO4.2H2O, and 2.4g KH2PO4 in 1L ddH2O. Working solution 
(1XPBS) was prepared by dilution of 10XPBS to 1X with ddH2O. pH of the working solution 
was adjusted to 7.4. 
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Geneticin (G418) sulfate: 500mg/ml solution in ddH2O. Sterilized by filtration and stored at 
-20°C (stock solution). 500µg/ml was used as working solution for stable cell line selection 
and 250µg/ml was used as working solution for maintenance of stable cell lines. 
 
Puromycin: 2mg/ml solution in ddH2O. Sterilized by filtration and stored at -20°C (stock 
solution). 2µg/ml was used as working solution for selection. 
 
3.2.5 Protein extraction, quantitation and western blotting solutions 
Radio immuno-precipitation assay (RIPA) buffer: 150mM NaCl, 50mM Tris-HCl pH 8.0, 
1% NP-40, 0.1% SDS and 1X protease inhibitor mix (Roche, Basel, Switzerland) were mixed 
in ddH2O. 
 
Bradford stock solution: 17.5mg coomassie brilliant blue was dissolved in 4.75ml ethanol 
and 10ml phosphoric acid and completed to 25ml final volume with ddH2O. 
 
Bradford working solution: 1.5ml bradford stock solution was mixed with 0.75ml 95% 
ethanol and 1.5ml phosphoric acid and completed to final volume up to 25ml with ddH2O. 
Filtered through whatman paper and prepared freshly. 
 
Acrylamide-bisacrylamide solution: 29g acrylamide and 1g bisacrylamide were dissolved in 
100 ml ddH2O and stored in the dark at 4oC (stock solution).  
 
10% Ammonium persulfate (APS): 0.1g APS was dissolved in 1ml of ddH2O, prepared 
freshly.  
 
1.5M Tris-HCl, pH 8.8: 54.45g Tris base (18.15g/100ml) ~150ml distilled water. Adjust to 
pH 8.8 with 1N HCl. Completed to 300ml with distilled water and stored at 4°C. 
 
1M Tris-HCl, pH 6.8: 12.14g Tris base ~ 60ml distilled water. Adjust to pH 6.8 with 1N 
HCl. Completed to 100ml with distilled water and store at 4°C. 
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Coomassie brilliant blue solution: Per liter; 100mg Coomassie brilliant blue G-250, 50ml 
95% ethanol, and 100ml 85% phosphoric acid. Filtered through whatman paper and stored at 
4°C. 
 
5X SDS-gel loading buffer: 5g SDS, 25mg bromophenol blue, 15.7ml 1M Tris pH 6.8, 
21.8ml glycerol (from 87% stock) were mixed and completed to 50ml with ddH2O. Before 
use, β-mercaptoethanol was freshly added to a final concentration of 5% to reach 1% when 
mixed with protein samples. 
 
10X SDS-gel electrophoresis buffer: Per liter; 30.3g Tris base, 144.0g glycine, 10.0 g SDS. 
Diluted to 1X for working solution. Stored up to 1 month at 4°C. 
 
Semi-dry transfer buffer: Per liter; 48mM Tris base, 39mM glycine, 0.037% SDS, 20% 
methanol. 
 
Wet transfer buffer: 3.03g Tris and 14.4g glycine was mixed with 1ml 10% SDS and 20% 
methanol and completed to final volume of 1 liter. For high molecular weight proteins 
methanol was decreased by half.   
 
10X Tris buffered saline (TBS): 30g Tris base, 80g NaCl and 2g KCl were dissolved in 1 
liter of ddH2O and the pH was adjusted to 8 (stock solution). Diluted to 1X and pH was 
adjusted to 7.6 with HCl just before use. 
 
TBS-Tween (TBS-T): 0.1% Tween-20 was added into 1X TBS solution.  
 
Blocking solution: 5% (w/v) non-fat milk, 0.1% Tween-20 in 1XTBS (prepared freshly). 
 
3.2.6 Immunoflourescence solutions 
H33258 fluorochrome dye: 1mg/ml solution in ddH2O and stored at -20°C. Working 
solution was 1μg/ml. 
 
DAPI (4', 6-diamidino-2-phenylindole): 0.1-1 μg/ml (working solution in ddH2O). 
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2% paraformaldehyde: 2g paraformaldehyde dissolved in 100ml 1X PBS, pH 7.4. Stored in 
dark, at -20oC. 
 
PBS-TritonX-100 (PBS-T): 0.1 Triton X-100 in 1X PBS. 
 
Blocking solution: 2% BSA (bovine serum albumin) in 1X PBS. 
 
3.2.7 BrdU incorporation assay solutions 
BrdU stock solution: 10mg/ml BrdU in ddH2O. 
 
2N HCl: 9.1ml of stock 37% HCl (~11N), completed to 50ml with ddH2O. 
 
PBS-TritonX-100 (PBS-T): 0.1TritonX-100 in PBS. 
 
3.3 METHODS 
 
3.3.1 General methods 
 
3.3.1.1 Bacterial transformation 
 
3.3.1.1.1 Super-competent E.coli preparation 
Super-competent E.coli preparation was described by Inoue (Inoue, Nojima et al. 1990). 
E.coli DH5α cells were grown in SOB medium at 30oC to an O.D.600 of 0.5-0.6 with vigorous 
shaking at 225rpm and cooled down on ice for 10 minutes. Cells were transferred to 500ml 
centrifuge bottles and centrifuged at 2500g for 10 minutes (Beckman JA10 rotor, pre-cooled 
to 4oC). The pellet was resuspended in ice-cold transformation buffer (1/3 of initial culture 
volume) by gently swirling and kept on ice for 10 minutes. The suspension was then 
centrifuged at 2500g for 10 minutes. The pellet was gently re-suspended in ice-cold 
transformation buffer (1/12.5 of initial culture volume) then DMSO was added with gently 
swirling to a final concentration of 7% and incubated on ice for 10 minutes. Super-competent 
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cells were aliquotted to 1.5ml eppendorf tubes, then immersed in liquid nitrogen to snap-
freeze and stored at -80oC. 
 
3.3.1.1.2 Super-competent E.coli transformation 
Super-competent cells were thawed on ice for ~15minutes. From this, 150µl of cells were 
pipetted to pre-chilled transformation tubes and immediately mixed with the ligation products 
or 10ng intact plasmid.  Then the complex was incubated on ice for 30 minutes, after which a 
heat-shock at 42oC for 30-45 seconds applied. Heat-shocked cells were immediately replaced 
on ice for 2 minutes and consequently 850µl LB medium was added. For antibiotic resistance 
gene to be expressed, the cells were rotated at 225rpm for 1hour in a 37oC shaker. If ligation 
product was used then the cells were pelleted and re-suspended in 100µl LB; otherwise when 
intact plasmid was used, 100µl from 1ml total culture was taken and spread on agar plates 
with suitable selection antibiotic. Under aseptic conditions, plates were left to drain for 
~10minutes and then placed in an inverted position into 37oC incubators for overnight (12-16 
hours). Next day the emerging colonies were collected for mini-prep. 
 
3.3.1.2 Long term storage of bacterial strains 
To keep bacterial cells including plasmid in it or as empty for future experiments and to have 
a stock of strain in a laboratory is necessary. The most frequently used method is “Glycerol-
Stock” method. A single colony picked from either an agar plate or a loop-full of bacterial 
stock was inoculated into 5ml LB (with a selective agent if necessary) in 15ml screw capped 
tubes. Tubes were incubated overnight at 37oC and at 225rpm. For glycerol stock, 500μl of 
saturated culture was added into 700µl of 50% glycerol v/v. This mix was frozen/stored at -
80oC. 
 
3.3.1.3 Plasmid DNA preparation 
Small scale isolation of plasmid DNA was performed with Qiaquick spin mini-prep kit 
according to the manufacturer’s instructions. This procedure yields approximately 200ng/μl of 
plasmid DNA for 1ml of LB culture. For large-scale preparation of pure plasmid DNA, the 
Qiafilter plasmid midi kit was used by following the manufacturer’s instructions. This 
procedure yields approximately 1μg/μl of plasmid DNA for 100 ml of LB culture. 
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3.3.1.4 Preparation of genomic DNA from cultured cells 
Cultured cells were grown in 100mm tissue culture dishes to 70-80% confluency, trypsinized, 
and washed with 1XPBS. Genomic DNA was isolated by using UltraClean Tissue DNA 
Isolation Kit (MOBIO Laboratories, Carlsbad, CA, USA) following manufacturer’s 
instructions. 
 
3.3.1.5 Extraction of total RNA from tissue culture cells 
Exponentially growing monolayer cultures were washed twice with ice-cold PBS, scraped 
with a scraper, pelleted at +4oC and stored at -80oC until needed for RNA preparation. The 
total RNA isolation from cell line pellets was performed directly by use of NucleoSpin RNA 
II kit according to the manufacturer’s instructions. The RNAs were eluted in a total volume of 
40μl. The concentration of the isolated RNA and O.D.260/280 ratio were measured with the 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA). 
Isolated RNAs were snap-frozen with liquid nitrogen and stored at -80oC. 
 
3.3.1.6 Quantification and qualification of nucleic acids and proteins 
Concentration and purity of the double stranded nucleic acids (plasmid and genomic DNAs) 
and total RNAs were determined by using the RNA and double-stranded(ds) DNA methods 
on Nanodrop ND-1000 Full-spectrum UV/Vis Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA). Concentration and purity of proteins were determined by using the 
Beckman Instruments Du Series 600 Spectrophotometer software programs on the Beckman 
Spectrophotometer Du640 (Beckman Instruments Inc. CA. USA). 
 
3.3.1.7 Restriction enzyme digestion of DNA 
Restriction enzyme digestions were routinely performed in 20μl or 50μl reaction volumes and 
typically 5-10μg DNA was used. Reactions were carried out with the appropriate reaction 
buffer and conditions according to the manufacturer’s recommendations. Digestion of DNA 
with two different restriction enzymes was also performed in the appropriate common 
reaction buffer and conditions recommended by the manufacturer. 
 
 39
3.3.1.8 Agarose gel electrophoresis 
 
3.3.1.8.1 Agarose gel electrophoresis of DNA 
DNA fragments were fractionated by horizontal gel electrophoresis in 1-2% (w/v) agarose gel 
by using 1XTAE buffer. DNA fragments less than 1 kb were generally separated on 1.0% or 
2.0 % agarose gel, those greater than 1 kb (up to 11 kb) were separated on 1 % agarose gels. 
Agarose was completely dissolved in 1XTAE electrophoresis buffer in the desired 
percentages and ethidium bromide solution was added to final concentration of 30ng/ml. 
6XDNA loading dye was added to 10μl of quantitative real time RT-PCR (QRT-PCR) 
products and 20μl of normal PCR products such that the final dye concentration will be 1X, 
and total volume was loaded to each well. Nucleic acids were visualized under ultraviolet 
light (long wave, 340nm) and GeneRuler (Fermentas) DNA size markers was used to estimate 
the fragment sizes.1 kb DNA ladder was loaded for products sizes of over 1kb and 100 bp 
ladder for product sizes of below 1kb. 
 
3.3.1.8.2 Agarose gel electrophoresis of RNA 
Total RNA samples were fractionated by horizontal gel electrophoresis in 1.2% (w/v) agarose 
gel by using 1XFA gel buffer. After 1.2% agarose gel solution was prepared, the mixture was 
cooled and 1.8ml of 37% formaldehyde and 1μl of ethidium bromide from a stock of 
10mg/ml solution were added into 100ml of gel. The gel was poured in a laminar flow hood. 
2μg of total RNA from each sample was mixed with 1 volume of 5X loading buffer per 4 
volumes of RNA sample and incubated for 5 minutes at 65oC, and chilled on ice then loaded 
to the gel. The gel was run at 5-7V/cm in 1XFA gel running buffer. Transilluminator (Bio-
Rad, California, USA) was used to visualize the DNA bands under ultraviolet light (long 
wave, 340nm). MultiAnalyst (Bio-Rad, California, USA) software was used to take 
photographs of the gels. 
 
3.3.2 Database and computer analysis 
The sequences of ROBO2, ROBO3, ROBO4 and AFP were obtained from NCBI (National 
Center for Biotechnology Information). The exon-intron information of these genes was 
derived using Ensembl Genome Browser (http://www.ensembl.org). Restriction endonuclease 
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maps of the plasmid DNAs were analyzed by using the online NEBcutter2 
(http://tools.neb.com/NEBcutter2/) and Webcutter2 (http://rna.lundberg.gu.se/cutter2/) tools. 
Primers were designed by using Primer3 online primer design tool (http://frodo.wi.mit.edu/) 
(Rozen and Skaletsky 2000). The results of the DNA sequencing of engineered constructs 
were visualized using Chromas-v1.45 available for download at 
http://www.technelysium.com.au/chromas14x.html. The alignments of nucleic acid or protein 
sequence were performed by using the NCBI Blast2Sequences algorithm available at the web 
page http://www.ncbi.nlm.nih.gov/BLAST/ and ClustalW algorithm provided by EMBL-EBI 
at http://www.ebi.ac.uk/Tools/clustalw2/index.html (Thompson, Gibson et al. 1997).  
 
For ROBO2 siRNA target design, online siRNA Design Software was used 
(http://i.cs.hku.hk/~sirna/software/sirna.php). The secondary structure of the target siRNA 
sequence on ROBO2 mRNAs was analyzed by mFOLD program that is available online 
(http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi) (Mathews, Sabina et al. 1999; Zuker 
2003). ROBO2 and ROBO2-AS (alternative spliced form described by (Dalkic, Kuscu et al. 
2006) targeting sense and anti-sense oligos were purchased from Iontek (İstanbul, Turkey). 
 
Human Plasma Membrane Receptome Database (http://www.receptome.org/HPMR/) was 
browsed for the members of 17 receptor families present (Ben-Shlomo, Yu Hsu et al. 2003). 
Oncomine Cancer Profiling Database (Rhodes, Yu et al. 2004) can be accessed after a free 
“academic” or “non-profit” registration (http://www.oncomine.org/). Selected members of 
Netrin, Plexin, Roundabout, and Ephrin receptor families with their cognate ligands, a total of 
51 genes, are analyzed in Oncomine 2.0 for differential expression in HCC; specifically 
between normal liver and hepatocellular carcinoma of the liver. As a result, members of the 
SLIT-ROBO families were targeted.  
 
Another database used in this study is OncoDB.HCC- Oncogenomic Database of 
Hepatocellular Carcinoma (Su, Chao et al. 2007). Possible genomic gain/amplification or loss 
associated to members of SLIT-ROBO families were analyzed using OncoDB.HCC.  
 
3.3.3 Vector construction 
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3.3.3.1 Construction of pSEC-shROBO2 vector using Ambion’s Silencer Express 
system 
siRNA Expression Cassettes (SECs) were used to express siRNAs in mammalian cells 
(Castanotto et al 2002). SECs consist of an RNA polymerase promoter (either human H1 or 
U6) adjacent to a hairpin siRNA template (ROBO2, ROBO2-AS: alternatively spliced) and an 
RNA polymerase terminator. ROBO2 and ROBO2-AS mRNA target sequences identified by 
siRNA Design Software and their scrambled negative control sequences along with GAPDH 
target sequences (suggested in the kit’s manual) are presented in Table 3.1.   
 
Table 3.1: Target mRNA and oligo sequences for constructing siRNA expression cassettes (SECs) 
Oligo ID Oligo sequence 5'-3': 
siROBO2 sense AGACTACACAAATCTTAGTGTGTAATCGTCTCGGTGTTTCGTCCTTTCCACAAG 
neg.ROBO2 sense AATCTACACAAAATTATTCTTGTCTGTGGACCGGTGTTTCGTCCTTTCCACAAG 
siROBO2-AS sense AGGCTACACAAACCTGTTCTTGTAAGGCTGGCCGGTGTTTCGTCCTTTCCACAAG
neg.ROBO2-AS sense ACTCTACACAAAAGTTACTTTGGGTCGCTGCCGGTGTTTCGTCCTTTCCACAAG 
siROBO2 anti-sense CGGCGAAGCTTTTTCCAAAAAAAGACGATTACACACTAAGACTACACAAATCTT 
neg.ROBO2 anti-sense CGGCGAAGCTTTTTCCAAAAAAGTCCACAGACAAGAATAATCTACACAAAATTA 
siROBO2-AS anti-sense CGGCGAAGCTTTTTCCAAAAAACCAGCCTTACAAGAACAGGCTACACAAACCTG 
negROBO2-AS anti-sense CGGCGAAGCTTTTTCCAAAAAAGCAGCGACCCAAAGTAACTCTACACAAAAGTT 
Oligo ID mRNA target sequence: 
siROBO2 sense AGACGATTACACACTAAGA 
neg.ROBO2 sense GTCCACAGACAAGAATAAT 
siROBO2-AS sense CCAGCCTTACAAGAACAGG 
neg.ROBO2-AS sense GCAGCGACCCAAAGTAACT 
 
 
Two step PCR amplification with two oligos (sense and anti-sense, separately) was used to 
produce the precursor SECs (pre-SECs) as described by the manufacturer (Figure 3.1 A). In 
the first PCR, sense oligos were used. Briefly, 5X mix for both human H1 and human U6 
promoters were prepared by mixing 5µl promoter element, 5µl promoter primer, 10µl 10X 
PCR buffer, 10µl 2.5mM dNTP mix, 64µl nuclease free water and 1µl HotStar Taq 
polymerase (Qiagen). Then; 1µl from 10µM stocks of ROBO2, ROBO2-AS, Negative control 
or GAPDH sense oligo was added to 19µl aliquots of either H1 promoter mix or U6 promoter 
mix.  In the second PCR, anti-sense oligos were used. Briefly, 4.5X mix for both human H1 
and human U6 promoters were prepared by mixing 4.5µl promoter primer, 9µl 10X PCR 
buffer, 9µl 2.5mM dNTP mix, 57.6µl nuclease free water and 0.9µl HotStar Taq polymerase 
(Qiagen). Then; 1µl from 10µM stocks of ROBO2, ROBO2-AS, Negative control or GAPDH 
anti-sense oligo along with 1:100 diluted products from the 1st PCR was added to 18µl 
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aliquots of either H1 promoter mix or U6 promoter mix (PCR conditions for both reactions 
were the same and given in Table 3.2).   
 
 
Figure 3.1: Overview of the Silencer Express procedure. A) SECs were produced with ROBO2, ROBO2-AS, 
Negative control or GAPDH sense (first PCR) and anti-sense (second PCR) oligos using two-step PCR 
procedure. Both H1 promoter and U6 promoter involving constructs were produced. B) PCR amplified SECs 
were reaction purified and run on 2% agarose gel for 25min at 100V and complete forms of SECs were observed 
at the expected molecular weights.  
 
 
In a consequent PCR reaction, mature SECs were generated from pre-SECs. Briefly, a 10X 
reaction mix was prepared by mixing 100µl of 10X PCR buffer, 100µl 2.5mM dNTP mix, 
665µl nuclease free water, 40µl terminator PCR primer and 5µl HotStar Taq polymerase 
(Qiagen). Then, 91µl was aliquotted from the mix and 5µl from 1:100 diluted pre-SEC PCR 
product along with the respective promoter PCR primer (either H1 or U6) added to the mix 
and the PCR reaction was run according to the profile in Table 3.3. Following the PCR 
reaction, SECs were reaction purified and run on 2% agarose gel for 25min at 100V (Figure 
3.1 B). 
 
Table 3.2: Precursor SEC amplification PCR profile 
  
 
 
Hot start 95oC for 15 minutes 
25 cycles 94oC for 30 seconds 
  50oC for 30 seconds 
  72oC for 30 seconds 
ROBO2 ROBO2A  GAPDH NEG.ROBO2  ROBO2A  GAPDH  NEG. 
 
--Human H1 promoter--   -- Human U6 promoter-- 
434bp 
167bp 
A) B) 
1st PCR 
2nd PCR 
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Table 3.3: SEC amplification PCR profile 
Hot start 95oC for 15 minutes 
25 cycles 94oC for 30 seconds 
  50oC for 30 seconds 
  72oC for 30 seconds 
Final extension 72oC for 5 minutes 
 
 
Like siRNA prepared in vitro, SECs are quick and easy to synthesize, and they can be cloned 
into one of Ambion’s pSEC™ siRNA expression vectors for long-term reduction of target 
gene expression. SECs were double digested using EcoRI and HindIII restriction enzymes and 
cloned into linearized (EcoRI, HindIII double digested) pSEC neo vector (Figure 3.2). For 
stable cell line generation, pSECneo plasmids containing ROBO2 targeting and scrambled 
negative SECs with H1 promoters were used. 
 
 
Figure 3.2: Ambion’s pSEC neo vector map. 
 
 44
3.3.3.2 Construction of pDEST26 mock vector to be used as control in pDEST26-
ROBO2 overexpression experiments 
pDEST26-ROBO2 (IOH53663 clone) mammalian overexpression vector was purchased from 
ImaGenes GmbH (Berlin, Germany). pDEST™26 Gateway® Vector  (Cat. No.11809019) 
was purchased from Invitrogen (Carlsbad, CA, USA) and the sequences between BsrG1 cut 
sites (678, 1961, 2363) that are required for recombinational cloning (attR1 and attR2) and 
selection (CmR, ccdB) were removed by BsrG1 digestion (New England Biolabs, Ipswich 
MA, USA-Catalog No: RO575S) and the remaining vector backbone was agarose gel purified 
(Figure 3.3). Then, the purified vector backbone was re-ligated and used as mock control in 
ROBO2 overexpression experiments.  
 
  
Figure 3.3: Restriction map of the pDEST™26 Gateway® vector. Restriction enzyme digestion with BsrG1 
was done to remove attR1, attR2, CmR and ccdB regions and the remaining vector backbone was religated to be 
used as a mock control in ROBO2 overexpression experiments with pDEST26-ROBO2 vectors.  
 
3.3.4 Tissue culture techniques 
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3.3.4.1 Cell lines and stable clones 
13 hepatoma (Huh7, FOCUS, Mahlavu, Hep40, Hep3B, PLC/PRF/5, SK-Hep1, Snu182, 
Snu387, Snu398, Snu423, Snu449 and Snu475) and 1 hepatoblastoma (HepG2) cell lines 
were cultured as described previously (Celikkaya, Ciraci et al. 2007). The NTERA-2 cl.D1 
cell line is a pluripotent human testicular embryonal carcinoma cell line derived by NTERA-2 
cell line and it was grown in dishes and routinely scraped for splitting purposes since 
trypsinization causes differentiation of the cells (Andrews, Damjanov et al. 1984). Huh7-
derived isogenic clones were obtained by G-418 selection after transfection with pSEC-H1-
shNontargeting or pSEC-H1-shROBO2 plasmids. Cells were transfected using 
Lipofectamine2000 transfection reagent. 48 hours following transfection, cells were 
trypsinized and re-plated at lower density into 100cm plates. Cells were cultivated in the 
presence of geneticin G-418 sulfate (500μg/ml; GIBCO, Carlsbad, CA, USA) for 30 days; 
isolate single cell-derived colonies were selected by marking the bottom of the dishes under 
microscope, and then these colonies were picked with the help of a micropipette tip in the 
hood and expanded in the presence of 500μg/ml geneticin G-418 sulfate. For experiments 
where a defined number of cells were to be seeded, cell counting was performed. Following 
trypsinization, cells were resuspended in culture medium and counted manually with a 
hemocytometer. 
 
3.3.4.2 Thawing cryopreserved cells 
One vial of the frozen cells from the liquid nitrogen tank was taken and immediately put into 
ice. The vial was left 1 minute on the bench to allow excess nitrogen to evaporate and then 
placed into 37oC water bath until the external part of the cell solution was thawed (takes 
approximately 1-2 minutes). The cells were directly poured into a 15ml sterile tube containing 
10ml cold fresh medium. The cells were centrifuged at 1500rpm at 4oC for 5 minutes. 
Supernatant was discarded and the pellet was resuspended in 10ml 37oC culture medium to be 
plated into 100mm dish. After overnight incubation in a humidified incubator at 37°C 
supplied with 5% CO2, culture mediums were refreshed. 
 
3.3.4.3 Growth conditions of cell lines 
Focus, Hep40, Hep3B, Hep3B-TR, HepG2, HUH7, Mahlavu, PLC/PRF/5, SK Hep1 cells 
were cultured in low-glucose DMEM supplemented with 10% FBS, 100U/ml Penicillin-
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Streptomycin, and 0.1mM non-essential amino acids (HyClone, Utah, USA). SNU387, 
SNU398, SNU423, SNU449, SNU475 cells were cultured in RPMI1640 medium 
supplemented with 10% FBS, 100 U/ml Penicillin-Streptomycin, 0.1mM non-essential amino 
acids (HyClone, Utah, USA). The growth medium was aspirated and the cells were washed 
once with 1XPBS. Trypsin was added to the flask to remove the monolayer cells from the 
surface. The fresh medium was added and the suspension was pipetted gently to disperse the 
cells. The cells were transferred to either fresh petri dishes or fresh flasks using different 
dilutions (from 1:2 to 1:10) depending on requirements. All media and solutions used for 
culture were kept at 4°C (except stock solutions) and warmed to 37°C before use. NTERA-2 
cl.D1 [NT2/D1] cell line was grown in high-glucose medium supplemented with 10% FBS, 
100 U/ml Penicillin-Streptomycin, 0.1mM non-essential amino acids (HyClone, Utah, USA). 
The NTERA-2 cl.D1 cell line was grown in dishes and routinely scraped for splitting 
purposes since trypsinization causes differentiation of the cells. 
 
3.3.4.4 Cryopreservation of cell lines 
Exponentially growing cells were harvested by trypsinization and neutralized with growth 
medium. The cells were counted and precipitated at 1500rpm for 5min. The pellet was 
suspended in a freezing solution (10%DMSO, 20%FCS and 70%DMEM for adherent cells) at 
a concentration of ~4x106cells/ml. 1ml of this solution was placed into 1ml screw capped 
cryotubes. The tubes were first frozen at -20oC for 0.5-1hours and then left at -80°C 
overnight. The next day, the tubes were transferred into the liquid nitrogen storage tank. 
 
3.3.4.5 Transfection of cell lines 
Transfections were performed using FuGene HD transfection reagent (Roche Diagnostics, 
Mannhein, Germany- Catalog No: 04709705001) according to the instructions of the supplier. 
Exponentially growing cells were plated in 6 well-plates at a concentration of 2.5-5.0X 105 
cells/well according to the cell type used, a day before the transfection. The cells were 
incubated overnight and reached to 70-80% confluency. Transfection was performed in cell 
culture medium lacking Penicillin/streptomycin with a 6:2, FuGene HD to DNA ratio. Briefly 
for one well, 2µg of plasmid was pipetted into OptiMem I Reduced-Serum medium 
(Invitrogen, Carlsbad, CA, USA- Catalog No: 11058-021) or cell culture medium lacking 
FBS to a final 100µl volume. Subsequently, the vial of FuGene HD was vortexed for 1 second 
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and 6µl was added directly into DNA/diluent mix without contacting with the walls of the 
eppendorf. The final mix was immediately vortexed for 1-2 seconds and spinned down and 
left to room temperature for the formation of transfection complex for 20-30 minutes. 
Transfection complex was pipetted dropwise onto the cells with fresh Penicillin/streptomycin 
lacking medium. The medium was replaced with fresh complete medium after 4-8 hours. 
After 48-72 hours incubation, cells were harvested and used for subsequent experiments. 
 
3.3.4.6 Wound-healing assay 
Cells were seeded onto 6 well plates at a density 3X 105 cells/well. The day in advance, three 
vertical and two horizontal scratches with equal intervals were made in each well using 200µl 
micropipette tips. Immediately, the time 0 photos of the wounds were taken and the photo 
taken sites were marked. The medium was refreshed with either normal medium (10% fetal 
bovine serum) or medium lacking serum (serum starved condition). Then, the opened wounds 
were followed for 48 hours. At 24 and 48 hours photographs of the marked sites were taken. 
The relative migration distances were calculated by dividing the total healed wound distance 
(difference between initial and final wound sizes) by 2, for 10 different lines connecting 
horizontally the two sides of the wound. The average of these 10 calculations were used to 
construct the graphs and calculate the T-tests.  
  
3.3.5 cDNA synthesis 
cDNA was synthesized by using DyNAmoTM cDNA Synthesis Kit (Finnzymes, Espoo, 
Finland) according to manufacturer’s instructions. Briefly; for 1X reaction 1μg of total RNA, 
1μl of random hexamers and required amount of ddH2O were mixed in a total 8μl volume. A 
minus RT control sample was also prepared; including RNA from the sample with highest 
RNA concentration, in the case of vector transfected samples RNA from the vector 
transfected sample was used. Then the mixes were incubated at 65°C for 5min and chilled on 
ice. Consequently, 10μl of 2X RT reaction buffer and 2μl of M-MuLV RNase H+ reverse 
transcriptase (including RNase inhibitor) were added to complete the reaction volume to 20µl. 
Instead of reverse transcriptase, nuclease free water was added to RT minus control. It 
contained all the reaction components except for the reverse transcriptase. Then the reaction 
mixes were incubated in thermal cycler programmed as follows: 25oC for 10 minutes, 37°C 
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for 60 minutes, 85oC for 5 minutes and 4oC hold. Each cDNA sample was diluted at a ratio of 
1:2 with ddH2O and stored at -20oC to be used as a PCR template for further experiments.  
 
3.3.6 Primer design for expression analysis by semi-quantitative PCR 
The primer pairs that have been used in expression profile analyses were designed carefully. 
PCR primers for human SLITs, ROBO1 and ROBO2 were previously described (Latil, Chene 
et al. 2003). Remaining primers were designed using Primer3 and targeting exon-exon 
junctions or different exons in order to prevent amplification of possible contaminating 
genomic DNA (Primer 3 reference). The primer pair was either be able to produce a longer 
amplicon from genomic DNA or not be able to amplify from the covered genomic DNA 
region in a given PCR condition (critical parameter was extension time). Primer pair for the 
housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was described 
before (Sayan, Sayan et al. 2001). ACTB (beta-actin) primer pair was supplemented in 
TissueScan Liver Cancer Tissue qPCR Array 1 (Origene Technologies, Rockville, MD, 
USA). Primers used for expression analysis have been designed strictly considering these 
criteria, and listed in Table 3.4. 
 
Table 3.4: Application purposes and sequences of the primers used in this study 
Application/property Primer 5'-3' Sequence 
Expression SLIT1 F GACGTGGTCTGTCCCCACAA 
  SLIT1 R AATCTCATTGTTATTCAATCGCAGTT 
  SLIT2 F TCCTAACTCCAAAGGGATTCAAATGT 
  SLIT2 R GGCTCCGTTTTTACACTTGTTGTCT 
  SLIT3 F CCGCCTAACTACACAGGTGAGCTAT 
  SLIT3 R CGCTGTAGCCAGGGACACACT 
  ROBO1 F GCATCGCTGGAAGTAGCCATACT 
  ROBO1 R CTAGAAATGGTGGGCTCAGGAT 
  ROBO2 F GGGTTACTACATCTGCCAGGCTT 
  ROBO2 R AGGTGGAGGTCTATCTGTCAAAACAT 
  ROBO3-Old F CAGTGTCCGATGGAAGAAGG 
  ROBO3-Old R GTCCATCTCCTGCACATTGG 
  ROBO3-New F TACACCCTCACCTCCTGACC 
  ROBO3-New R ATGGGCTGGGATACACTGAG 
  ROBO3-MC F GCAGTCCTCCGTGATGATTT 
  ROBO3-MC R TTGGAGGCTACGCACACATA 
  ROBO4 F GACACTTGGCGTTCCACCTC 
  ROBO4 R AGAGCAAGGAGCGACGACAG 
  AFP F AAATGCGTTTCTCGTTGCTT 
  AFP R CCAACACCAGGGTTTACTGG 
Alternatively spliced ROBO2 expression ROBO2-hRF AGCACTGGACCAGACTCCTG 
  ROBO2-hRR AATGGGCTGGTAGGTCGAG 
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  ROBO2-hRRA TCCATCCAGCCTAAACCAG 
PLXNC1 ligand SEMA7A F AAGACGCCATTGTTCCACTC 
  SEMA7A R GGCTGGATCTCCATGATGTT 
Normalization GAPDH F GGCTGAGAACGGGAAGCTTGTCAT 
  GAPDH R CAGCCTTCTCCATGGTGGTGAAGA 
  ACTB F CCAACCGCGAGAAGATGACC 
  ACTB R GGAGTCCATCACGATGCCAG 
Array verification PLXNC1 F CATAACAGAGACGCCAACGA 
  PLXNC1 R TTTCAAGGGTGTGGATGACA 
  SEMA3C F TCAGCCGTGTGTGTGTATCA 
  SEMA3C R AATGCTCCTCCTGGACAAGT 
  NEO1 F TGGAAAACCAACTCCAACTGTGA 
  NEO1 R TGATTTCACCAGACCCAAAACTTGA 
  NRP1 F GGCTCTCACAAGACCTTCTG 
  NRP1 R GAAGTTGCCATCTCCTGTGT 
  NRP2 F GATCAGTGCCTCATCTACCT 
  NRP2 R CACCTGGAGATACTCCTTGT 
EMT marker Ecadherin F GACTCGTAACGACGTTGCAC 
  Ecadherin R GGTCAGTATCAGCCGCTTTC 
  Twist F CCGGAGACCTAGATGTCATTG 
  Twist R CACGCCCTGTTTCTTTGAAT 
  SNAI1 F CTCTAGGCCCTGGCTGCTAC 
  SNAI1 R TGACATCTGAGTGGGTCTGG 
  Slug F CCCTGAAGATGCATATTCGGAC 
  Slug R CTTCTCCCCCGTGTGAGTTCTA 
  SIP1 F TCCTGTCTGTCTCGCAAAAA 
  SIP1 R GCCTTGAGTGCTCGATAAGG 
  Vimentin F GCAGGAGGAGATGCTTCAGA 
  Vimentin R ATTCCACTTTGCGTTCAAGG 
  ASMA F TATCAGGGGGCACCACTATG 
  ASMA R GCTGGAAGGTGGACAGAGAG 
  Fibronectin F AATATCTCGGTGCCATTTGC 
  Fibronectin R CAGTAGTGCCTTCGGGACTG 
  Podoplanin F CATCGAGGATCTGCCAACTT 
  Podoplanin R TTGTCTGTGTGTCTCCATCCA 
CSC (Progenitor/Side population) marker CD133 F CGGCTCTAATTTTTGCGGTA 
  CD133 R TGTTGTGATGGGCTTGTCAT 
  CK19 F CCGCGACTACAGCCACTACT 
  CK19 R AGAGCCTGTTCCGTCTCAAA 
  AFP F AAATGCGTTTCTCGTTGCTT 
  AFP R CCAACACCAGGGTTTACTGG 
  CEACAM6 F ATGTGCCAAGCCCATAACTC 
  CEACAM6 R GTCTGGTCCAATCTGCCAGT 
  Albumin F ACTTTTATGCCCCGGAACTC 
  Albumin R CAGCTTTGGGAAATCTCTGG 
  CYP3A4 F CAAGACCCCTTTGTGGAAAA 
  CYP3A4 R CGAGGCGACTTTCTTTCATC 
  AREG F GGGAGTGAGATTTCCCCTGT 
  AREG R CCATTTTTGCCTCCCTTTTT 
  CK14 F GACCATTGAGGACCTGAGGA 
  CK14 R GGCTCTCAATCTGCATCTCC 
  MDR1 F GCTCCTGACTATGCCAAAGC 
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  MDR1 R TCTTCACCTCCAGGCTCAGT 
  BCRP1 F ATGGATTTACGGCTTTGCAG 
  BCRP1 R GAGATCGATGCCCTGCTTTA 
  CD44 F CGGACACCATGGACAAGTTT 
  CD44 R GAAAGCCTTGCAGAGGTCAG 
  CD90 F GTCCTTTCTCCCCCAATCTC 
  CD90 R ACGAAGGCTCTGGTCCACTA 
Pluripotency marker OCT4 F AGCGAACCAGTATCGAGAAC 
  OCT4 R TTACAGAACCACACTCGGAC 
  SOX2 F AGCTACAGCATGATGCAGGA 
  SOX2 R GGTCATGGAGTTGTACTGCA 
  NANOG F TGAACCTCAGCTACAAACAG 
  NANOG R TGGTGGTAGGAAGAGTAAAG 
  MYC F ACTCTGAGGAGGAACAAGAA 
  MYC R TGGAGACGTGGCACCTCTT 
  KLF4 F TCTCAAGGCACACCTGCGAA 
  KLF4 R TAGTGCCTGGTCAGTTCATC 
 
 
3.3.7 Fidelity and DNA contamination control in first strand cDNAs 
The fidelity and genomic DNA contamination of first strand cDNAs were checked before 
performing expression analyses. 2μl of diluted first strand cDNA was used for PCR 
amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript. 
GAPDH primer pair for this analysis was designed to produce a 151 bp fragment from cDNA 
and 250 bp fragment from genomic DNA. 
 
3.3.8 Expression analysis of a gene by semi-quantitative PCR 
 
3.3.8.1 Determination of optimal cycle of a gene for semi-quantitative PCR 
Using equal amount of templates for PCR amplifications of a gene of interest give 
comparable results at a certain number of PCR cycles. The number of optimal PCR cycle was 
determined by an initial study for each gene by performing 35-cycle PCR during which PCR 
amplicon samples were collected by 2-cycle intervals. Agarose gel analysis of samples with 
an equal load defined the minimum number of cycle to visualize the product on agarose gel 
and the saturation cycle. Agarose gels were analyzed by Densitometric Fluorescence-
Chemiluminescence image analyzer and The Molecular Analyst software (BioRad, Hercules, 
CA, USA). The determined cycle number was used for amplification of the gene of interest. 
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3.3.8.2 GAPDH normalization 
Equal volume (2μl) of all first strand cDNA samples was used for PCR amplification of 
GAPDH transcript using the pre-determined optimal cycle number for GAPDH (20 cycles). 
Then an equal volume of each sample was loaded onto agarose gel and intensity of each band 
was analyzed by Densitometric Fluorescence-Chemiluminescence image analyzer and The 
Molecular Analyst software. After intensities were determined, intensity of sample with the 
highest densitometric reading and 2 μl loading volume were used as reference points for 
normalization of input loading volume of other samples for expression analysis of both 
GAPDH and gene of interest by PCR amplification. Amplification products were analyzed by 
visualization under UV. 
 
3.3.9 Real time quantitative RT-PCR 
 
3.3.9.1 Real-time quantitative RT-PCR analyses of HCC cell lines 
In cell lines and tissues, the relative expression ratio (R) of SLIT-ROBO and AFP transcripts 
(target gene) was measured based on a modified ∆∆Ct formula (Pfaffl 2001) and normalized 
to GAPDH or ACTB (reference gene). In R= (Etarget) ∆Ct target (control-sample) / (Eref) ∆Ct ref (control-sample) 
formula, Etarget and Eref  reflect PCR efficiencies of the primers for target genes and reference 
genes, respectively. PCR efficiency values for each primer pair was obtained by constructing 
a standard curve using threshold cycle (Ct) values derived from 6 data points, corresponding 
to 2-fold decrements of an original cDNA stock (duplicates were prepared for each dilution). 
The slope of the resulting curve was used to calculate the E value of primer pairs according to 
E = 2-1/slope formula. ∆Ct was the difference between the Ct values of controls and samples. 
PCR efficiencies of the genes ranged around 1.9-2.0 (Table 3.5). 
 
Table 3.5: PCR efficiencies of the primer pairs used in QRT-PCR relative quantification analysis 
PRIMER EFFICIENCY 
ROBO1 2.04 
ROBO2 1.86 
ROBO4 1.88 
SLIT1 1.89 
SLIT2 1.99 
SLIT3 1.97 
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GAPDH 2.00 
CD133 2.00 
AFP 1.83 
ROBO2 hRF-hRRA 1.97 
 
 
In cell lines, GAPDH was the reference gene. ∆Ct values were obtained by subtracting Ct 
values of individual genes (sample) from the average Ct value of all cell lines for that gene 
(control). All reactions were performed in duplicates and repeated at least twice using 
different batches of RNA preparations. A no-template control of nuclease-free water was 
included in each run. Relative expression tables were established by representing ∆∆Ct values 
in log2 base, and in all subsequent analyses these values were used.  
 
Quantitative expression analyses were performed using DyNAmo™ HS SYBR® Green qPCR 
Kit (Finnzymes, Espoo, Finland) on an iCycler iQ real-time PCR detection system (Bio-Rad, 
Richmond, CA). The PCR reaction was set according to the manufacturer’s 
recommendations. Briefly for 1X reaction; 10µl of 2X SYBR Green PCR Master Mix, 10µM 
forward and reverse primers, and 1µl of template cDNA were mixed in a total volume of 
20µl. After an initial 15 minutes of denaturation at 95°C, thermal cycling was performed at 
94°C for 30sec, 60-62°C for 30sec (optimized for each primer pair), 72°C for 30sec for a total 
of 50 cycles and a final extension step at 72°C for 10min. In order to validate the production 
of a single target-specific PCR product, the amplification was followed by a melt curve 
protocol with an initial step at 55°C for 30sec and 80 repeats of 0.5°C increments with 15sec 
dwell time, from 55°C to 95°C.    
 
3.3.9.2 Real-time quantitative RT-PCR analyses of HCC tissues 
The expression of SLIT-ROBO and AFP genes in HCC was analyzed using a 96-well plate 
format TissueScan Liver Cancer Tissue qPCR Array 1 (Origene Technologies, Rockville, 
MD), which contained tissue cDNAs normalized against beta-actin. Clinicopathological 
characteristics of the tissues were presented in Table 3.6. Real-time PCR protocol was applied 
as described by the manufacturer. Briefly, 30µl of reaction mix containing 15µl 2X SYBR 
Green PCR Master Mix and 10µM forward and reverse primers was directly added to PCR-
plate wells. Plate was placed on ice for 15min for cDNAs to dissolve, and thermal cycling 
was performed according to above mentioned protocol. For each gene, mean Ct value of the 
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normal tissue cDNAs was set as the control group and relative quantitative expression values 
were calculated with the ∆∆Ct formula and were represented in log2 base by taking the ACTB 
Ct values as reference.      
 
Table 3.6: Clinicopathological characteristics of normal liver and HCC samples 
Sample # Appearance Diagnosis/Histology Differentiation Stage 
N1 Normal hcc tumor-adjacent normal 0 
N2 Normal hcc/adenocarcinoma tumor-adjacent normal 0 
N3 Normal hcc tumor-adjacent normal 0 
N4 Normal hcc tumor-adjacent normal 0 
N5 Normal granuloma tumor-adjacent normal 0 
N6 Normal nodular hyperplasia of liver, focal tumor-adjacent normal 0 
N7 Normal hcc tumor-adjacent normal 0 
N8 Normal hcc tumor-adjacent normal 0 
T1 Tumor hcc well 1 
T2 Tumor hcc moderate 1 
T3 Tumor hcc well 1 
T4 Tumor hcc N/A 1 
T5 Tumor hcc poor 1 
T6 Tumor hcc N/A 1 
T7 Tumor hcc moderate 1 
T8 Tumor hcc moderate 1 
T9 Tumor hcc N/A 1 
T10 Tumor hcc moderate 2 
T11 Tumor hcc/adenocarcinoma moderate 2 
T12 Tumor hcc/invasive N/A 2 
T13 Tumor hcc/adenocarcinoma poor 2 
T14 Tumor hcc well 2 
T15 Tumor hcc moderate 2 
T16 Tumor hcc well 2 
T17 Tumor hcc moderate 2 
T18 Tumor hcc/adenocarcinoma poor 2 
T19 Tumor hcc well 2 
T20 Tumor hcc/invasive N/A 2 
T21 Tumor hcc well 3a 
T22 Tumor hcc poor 3a 
T23 Tumor hcc moderate 3a 
T24 Tumor hcc moderate 3a 
T25 Tumor hcc moderate 3a 
T26 Tumor hcc well 3a 
T27 Tumor hcc moderate 3a 
T28 Tumor hcc moderate 3a 
T29 Tumor hcc well 3a 
T30 Tumor hcc poor 3a 
T31 Tumor hcc moderate 3a 
T32 Tumor hcc moderate 3a 
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T33 Tumor hcc moderate 3a 
T34 Tumor hcc moderate 4 
T35 Tumor hcc/from omentum poor 4 
 
3.3.10 Crude total protein extraction 
Adherent monolayer cells (both stable and parental cells) were grown to 80% confluency. For 
cytoplasmic or nuclear proteins analyses cells were collected by trypsinization. For membrane 
proteins cells were collected by scraping after washing twice with ice-cold PBS to remove 
any serum residue. Volume of the dry cell pellet was estimated and twice that volume of lysis 
buffer was pipetted onto the pellet. For nuclear proteins RIPA lysis buffer (150 mM NaCl, 50 
mM Tris-HCl pH 8.0, 0.5% sodium deoxycholate, 1 % NP-40, 0.1% SDS and 1X Complete 
Protein Inhibitor mix (Roche Diagnostics, Mannheim, Germany)) was used, and for 
cytoplasmic and membrane proteins NP-40 lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 
1X protease inhibitor cocktail (Roche) and 1.0% NP-40) was used. Complete lysis was 
achieved by pipetting of crude cell lysates several times and by incubating the lysates on ice 
for 30 min and with continuous agitation by vortexing at 5 minutes intervals. Then, the lysate 
was centrifuged at 10000G for 30 minutes. Total cell protein was collected as supernatant.  
 
3.3.11 Quantification of proteins 
After the cell lysates were prepared, their concentrations were detected by Bradford assay. 
Briefly, 2μl of the samples were diluted with 98μl deionised water and then 900μl of Bradford 
working solution was added to the samples and mixed well, as described in Table 3.7. 
Immediately, the protein amounts of the samples were measured at 595nm versus blank 
reagent (NP-40 lysis buffer was used as blank). Known concentrations of BSA were prepared 
according to Table 3.8 as a standard. After OD reading at 595nm, samples and standard 
values were plotted; unknown concentrations were calculated from the standard curve. 
 
Table 3.7: Protein sample preparation for Bradford assay 
Tube no 1 2 3 4 5 6
Sample (µl) 0 2 2 2 2 2
ddH2O (µl) 98 98 98 98 98 98
Bradford (µl) 900 900 900 900 900 900
Lysis buffer (µl) 2 - - - - - 
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Table 3.8: BSA dilutions for standard curve plot  
Tube no 1 2 3 4 5 6 7 8
Sample (µl) 0 2.5 5 7.5 10 12.5 15 20
ddH2O (µl) 100 97.5 95 92.5 90 87.5 85 80
Bradford (µl) 900 900 900 900 900 900 900 900
 
3.3.12 Western blotting 
After protein quantification, protein lysates were aliquoted into fresh tubes and, stored at –
80°C. 8% (25-200kD range), 10% (15-100kD range) or 12% (10-75kD range) resolving gel 
and 5% stacking gel was used in SDS-PAGE analysis of protein lysates. Mini Protean III 
(BioRad, Hercules, CA, USA) vertical gel system was set up according to manufacturer’s 
instructions. The standard SDS-electrophoresis buffer system was used. Equal amounts of cell 
lysates were solubilized in 5X SDS gel-loading buffer with 5% β-mercaptoethanol, denatured 
at 100°C for 5 min and incubated on ice for 2 min. After a quick spin, samples were loaded 
onto SDS-polyacrylamide gel. After electrophoresis at 80V for 20 minutes followed by 120 V 
for 1-2 hours, proteins were transferred onto Immobilon-P PVDF transfer membrane with 
0.45µm pore size (Millipore, Billerica, MA, USA) by using Transblot-Semi Dry (BioRad, 
Hercules, CA, USA) electroblotting apparatus according to the manufacturer’s instructions at 
15V for ~45 min. Membrane was immediately treated for an hour in blocking solution at 
room temperature and probed with primary antibody either for an hour at room temperature or 
overnight at 4°C. After washing 4 times for (5 min, 15 min, 5 min, 5 min) in TBS-T solution 
at room temperature, the membrane was incubated with appropriate HRP conjugated 
secondary antibody for 1 hr. The membrane was washed 3 times for 5 min in TBS-T solution 
at room temperature. After final wash, the blot was exposed to ECL western blot detection kit 
(GE Healthcare Life Sciences, Buckinghamshire, UK) according to manufacturer’s 
instructions. The chemiluminescence emitted was captured on X-ray film within 15sec to 
5min exposure times. 
 
3.3.13 Immunofluorescence  
Autoclaved-sterilized coverslips were placed into wells of 6well plates. 2-4 X 105 cells were 
seeded onto each coverslip depending on the cell line and grown overnight in 2ml growth 
medium. Cells were washed with PBS and fixed in 1ml of cold methanol or 2% 
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paraformaldehyde for 15 minutes. For paraformaldehyde fixed cells permeabilization with 
0.3% TritonX-100 in 1X PBS was applied. After fixation cells were blocked in 1ml blocking 
solution (2% BSA in 1X PBS) for 1 hour at room temperature. Coverslips were probed with 
primary antibody in appropriate dilution for 1hr at room temperature. After washing cells 
twice with 1X PBS, either appropriate secondary antibody (AlexaFluor Red/Green) was 
applied for 1hour at room temperature. Cells were washed 2 times with 1X PBS and DNA 
counter staining was performed with DAPI for 3 minutes. After DAPI was aspirated, 
destaining was done in double-distilled water for 5 minutes. Immediately after, coverslips 
were taken out from the wells and excess water removed by tissue paper. Coverslips were 
mounted onto slides with 50% glycerol (stock glycerol was 1/2 diluted in ddH2O). All steps 
after the addition of secondary antibody were performed in the dark. Stained cells were 
examined under fluorescence microscope (ZEISS) and pictures were captured in a digital 
ZEISS AxioCam MRc5 camera. 
 
3.3.14 BrdU incorporation assay 
Sub-confluent cells were labeled with the thymidine analogue BrdU (5-bromo-2-
deoxyuridine) for 24 hours in freshly added culture medium and tested for BrdU positivity. 
Briefly, cells were washed twice with 1X PBS, fixed with 70% ice-cold methanol and washed 
for 10 minutes with 1X PBS. Then the cells were incubated in 2N HCl for 20 minutes and 
washed three times for 5 minutes with 1X PBS. Following blocking with PBS-T plus 2% 
BSA for 15 minutes, 1:250 Alexa 488 secondary antibody incubation was performed for an 
hour. Cells were washed 2 times with 1X PBS and DNA counter staining was performed with 
DAPI for 3 minutes. After DAPI was aspirated, destaining was done in double-distilled water 
for 5 minutes. Immediately after, coverslips were taken out from the wells and excess water 
removed by tissue paper. Coverslips were mounted onto slides with 50% glycerol (stock 
glycerol was 1/2 diluted in ddH2O). All steps after the addition of secondary antibody were 
performed in the dark. Stained cells were examined under fluorescence microscope (ZEISS) 
and pictures were captured in a digital ZEISS AxioCam MRc5 camera. 
 
3.4 Microarray experiment and analysis 
Total RNAs were extracted form the stable clones. Quality of the RNAs was checked using 
Nanodrop ND-1000 Full-spectrum UV/Vis Spectrophotometer and by running in 
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formaldehyde gel and visual inspection of 28S and 18S rRNAs under UV. Pooled RNAs from 
eight stable ROBO2 knockdown clones (R2C3, R2C7, R2C8, R2C9, R2C10, R2C13, R2C14, 
and R2C17) were hybridized to one Affymetrix HG-U133plus2.0 chip and pooled RNA from 
four negative clones (NC4, NC5, NC6, and NC7) were hybridized to another Affymetrix HG-
U133plus2.0 chip. Microarray experiment was performed by Hilal Özdağ from Ankara 
University Biotechnology Instute. After the experiment, raw .cell files of the two chips were 
obtained; then quality controlled and RMA (robust multichip average) normalized in R 
environment. In MS Excel, using built-in functions, we obtained a fold change list and a 
differentially expressed gene list. To filter out non-relevant, noise-related genes we 
determined a cut-off of ± 0.8 fold; the probe sets having fold change values between +0.8 and 
-0.8 were eliminated. The obtained genelist was given as input file to Pathway Express tool in 
OntoTools suite for determining the associated pathways and their visualization 
(http://vortex.cs.wayne.edu/projects.htm). 
 
3.5 Statistical analysis 
Using one-way ANOVA in R, mean expression levels of each gene were compared between 
high and low AFP expressing groups of HCC cell lines; and also between normal and tumor 
tissues of liver with respect to differentiation or stage. Pairwise comparisons were made using 
Fisher’s multiple pairwise comparison method in Minitab® 13.20 Statistical Software 
(Minitab Inc. 2000). Furthermore, two-way hierarchical cluster analysis was used to group 
cell lines and liver tissues with respect to the SLIT-ROBO expression patterns using Cluster 
and TreeView (Eisen, Spellman et al. 1998). Pairwise correlations between SLIT-ROBO gene 
expression levels were calculated using Pearson’s correlation coefficient. Moreover, a 
Mantel’s association test was applied to compare cell line and tissue correlation matrices in R 
(R development core team, 2005). For comparison of two groups with equal sample numbers, 
built-in t-test statistic was used in MS Excel (using two-sample with unequal variance, with a 
two tailed distribution mode). In R environment, Wilcoxon rank sum test was applied to liver 
tissue relative expression data to predict if the clusters appeared in cluster analysis was 
dependent on differentiation state or staging of tumors.  
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4 RESULTS 
 
4.1 Expression analysis of members of the SLIT-ROBO gene families 
 
4.1.1 Oncomine cancer profiling database results for SLIT-ROBO gene 
expression in liver 
Human Plasma Membrane Receptome Database (http://www.receptome.org/HPMR/) was 
browsed for the members of 17 receptor families present (Ben-Shlomo, Yu Hsu et al. 2003). 
Oncomine Cancer Profiling Database (Rhodes, Yu et al. 2004) can be accessed after a free 
“academic” or “non-profit” registration (http://www.oncomine.org/). Selected members of 
Netrin, Plexin, Roundabout, and Ephrin receptor families with their cognate ligands, a total of 
51 genes, are analyzed in Oncomine 2.0 for differential expression in HCC; specifically 
between normal liver and hepatocellular carcinoma of the liver. As a result, members of the 
SLIT-ROBO families were targeted.  
 
Differential expression of SLIT-ROBO genes were analyzed using Diff/Ex function of 
Oncomine. Individual SLIT-ROBO genes were queried and then in the summary panel the 
significant differential expression data in liver was clicked. As default, P-value cutoff was 
selected 1E-4 by the database. The trend associated with each gene is summarized in Table 
4.1 for the genes that are significantly differentially expressed (ROBO2, ROBO3 and ROBO4 
did not have significant results with the above mentioned P-value). SLIT1, SLIT2, SLIT3 and 
ROBO1 mRNA expressions were found to be low in normal liver when compared to other 
tissues of normal histology (Su, Cooke et al. 2002; Shyamsundar, Kim et al. 2005; Roth, 
Hevezi et al. 2006). SLIT2 mRNA was upregulated in cirrhotic liver when compared to 
normal counterpart (Wurmbach, Chen et al. 2007). ROBO1 was overexpressed in 
hepatocellular carcinoma when compared to normal or dysplastic liver (Chen, Cheung et al. 
2002; Wurmbach, Chen et al. 2007).  
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Table 4.1: Significant differential expression results in liver obtained from Oncomine database 
Gene Study  Class1 Class2 T-stat P-value Reporter Regulation
SLIT1 Roth_Normal Other Tissues Liver 6.875 2.6E-8 1557615_a_at Down 
SLIT2 Roth_Normal Other Tissues Liver 16.911 8.3E-27 228850_s_at Down 
SLIT2 Wurmbach_Liver Normal Liver Cirrhotic Liver -6.644 1.5E-6 209897_s_at Up 
SLIT3 Su_Normal Other Tissues Liver 25.808 2E-33 35324_at Down 
SLIT3 Shyamsundar_Normal Other Tissues Liver 8.462 1.7E-6 H41160 Down 
SLIT3 Roth_Normal Other Tissues Liver 11.398 6.1E-6 203813_s_at Down 
ROBO1 Roth_Normal Other Tissues Liver 10.399 5.8E-5 213194_at Down 
ROBO1 Wurmbach_Liver Normal Liver Hepatocellular Carcinoma -11.91 3.9E-15 213194_at Up 
ROBO1 Chen_Liver Non-tumor Liver Hepatocellular Carcinoma -6.42 1.3E-9 IMAGE:595162 Up 
ROBO1 Wurmbach_Liver Dysplastic Liver Hepatocellular Carcinoma -6.866 3.2E-8 213194_at Up 
 
 
4.1.2 Onco.DB HCC database analysis for genomic gain/amplification or loss 
associated to SLIT-ROBO gene regions 
The OncoDB.HCC (http://oncodb.hcc.ibms.sinica.edu.tw) is based on physical maps of rodent 
and human genomes containing quantitative trait loci of rodent HCC models and various 
human HCC somatic aberrations including chromosomal data from loss of heterozygosity and 
comparative genome hybridization analyses, altered expression of genes from microarray and 
proteomic studies, and finally experimental data of published HCC genes (Su, Chao et al. 
2007). Onco.DB HCC database was searched for the regions that are lost or gained/amplified 
in hepatocellular carcinoma genomes. From the “Quick search” panel genomic regions of 
SLIT-ROBO genes were manually searched by analyzing comparative HCC regions section. 
There was no genomic loss or gains in the genomic regions corresponding to members of the 
SLIT-ROBO families. The genomic locations of the SLIT-ROBO genes are outlined in Table 
4.2. Moreover, in karyotyping analyses chromosomal gains/amplifications or losses have not 
been associated with genomic regions of SLIT-ROBO genes (Midorikawa, Yamamoto et al. 
2006; Midorikawa, Makuuchi et al. 2007).  
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Table 4.2: Genomic locations of the SLIT-ROBO genes 
Gene Genomic location 
SLIT1 10q23.3-24 
SLIT2 4p15.2 
SLIT3 5q35 
ROBO1 3p12 
ROBO2 3p12.3 
ROBO3 11q24.2 
ROBO4 11q24.2 
 
 
4.1.3 SLIT-ROBO genes are expressed in hepatocellular carcinoma cell lines at 
different levels 
The expression of SLIT-ROBO genes were determined by semi-quantitative RT-PCR in 13 
hepatocellular carcinoma and 1 hepatoblastoma cell line. After 40 cycles of PCR 
amplification which is a high cycle number possibly saturating the products, the PCR 
products were run in 2% agarose gel until the respective DNA molecular weight markers have 
separated and then photographed under UV light. All PCR products were at expected size. 
SLIT-ROBO transcripts were present in the investigated HCC cell lines at varying levels 
(Figure 4.1). ROBO1 and SLIT2 transcripts were present in all cell lines that were examined, 
except SNU398, which failed to display the SLIT2 transcript. ROBO2 and SLIT1 showed a 
similar yet more restricted expression pattern. Their transcripts were mainly confined to cell 
lines with epitheloid phenotype including Hep40, HUH7, Hep3B, Hep3B-TR, HepG2 and 
PLC/PRF/5. However, except SNU398, very weak or no expression of SLIT1 and ROBO2 
was found in diffusely spreading cell lines with fibroblastoid phenotype (Focus, Mahlavu, SK 
Hep1, SNU387, SNU423, SNU449 and SNU475). In striking contrast, sharp SLIT3 transcripts 
were observed in all cell lines with fibroblastoid phenotype, except SNU398, and in only 
Hep40 belonging to cell lines with epitheloid appearance. The expression of ROBO4 was 
variable among HCC cell lines, yet it tended to be enhanced in fibroblastoid cells. Except 
SNU398, ROBO3 transcript was barely detectable in the investigated HCC cell lines. 
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Figure 4.1: Semi-quantitative expression analysis of SLIT-ROBO genes in HCC cell lines. GAPDH 
equalized cDNA samples of HCC cell lines were amplified for 40 cycles with primers specific to SLIT-ROBO 
genes. Results are representative of two independent RT-PCR reactions, performed by cDNAs derived from 
different RNA preparations. A cDNA lacking negative control (-cDNA) was included in each experiment.  
 
 
4.1.4 AFP positivity is a distinctive marker for poorly- and well-differentiated 
HCC cell lines 
Previously, Lee and Thorgeirsson described two molecular subgroups of HCC cell lines that 
are characterized by low and high expression of AFP. They used 19 cell lines including the 13 
cell lines (except Mahlavu) used in this study. In their microarray study, cell lines with low 
AFP profile (including Focus, SK Hep1, Snu387, Snu423, Snu449 and Snu475) showed 
upregulation of genes related to metastasis and cell motility whereas cell lines with high AFP 
profile (HepG2, Hep3B, Hep3B-TR, Hep40, HUH7 and PLC/PRF/5) did not. The latter group 
was clustered together with a hepatoblastoma cell line (HepG2) indicating their origin from 
progenitor cells, or dedifferentiation during tumorigenesis (Lee and Thorgeirsson 2002). To 
confirm the cellular origin and reliability of our HCC cell lines, we checked the AFP 
expression of the HCC cell lines in our hands. 
 
AFP transcript was quantified using real-time quantitative RT-PCR. A total of 45 cycles was 
run. After each run, a melt-curve protocol was applied and relative quantity of AFP 
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expression was calculated using ∆∆Ct method. AFP expression in HCC cell lines was ploted 
in log2 base (Figure 4.2). The specificity of AFP PCR products were checked by both melt-
curve analysis and agarose gel electrophoresis. The HCC cell lines were correctly grouped 
into two depending on their AFP expression as in the above mentioned study except Snu398, 
which was an outlier cell line stemming from the low-AFP expressing subgroup, was placed 
into low-AFP expressing cell lines in our analysis. In addition, Mahlavu expressed AFP at 
low levels. 
 
Figure 4.2: Quantification of AFP transcript levels reveals two groups in HCC cell lines. GAPDH 
normalized AFP expression was quantified by real-time RT-PCR and expression values of individual cell lines 
are calculated relative to the Ct average of all cell lines, and represented in log2 base. Samples were run in 
duplicates and the data are representative of two independent experiments.  
 
 
4.1.5 SLIT-ROBO expression signature and their coordinate expression in HCC 
cell lines and liver tissues  
 
4.1.5.1 Quantitative real-time RT-PCR data for SLIT-ROBO genes in HCC cell lines 
Previously, the expression of SLIT-ROBO genes was analysed by quantitative RT-PCR in 
prostate tumor samples. SLIT1 and SLIT3 were found to be overexpressed in prostate tumors 
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(Latil, Chene et al. 2003). Using the described human SLIT1, SLIT2, SLIT3, ROBO1 and 
ROBO2 specific primers in that study and newly designed ROBO3 and ROBO4 primers, 
relative quantification of SLIT-ROBO genes were performed in HCC cell lines. Relative 
quantification was performed as described in materials and methods section by taking the 
mean expression values in all cell lines as the reference sample for each gene. The raw 
quantification values, along with the data for AFP, were log2 transformed and summarized in 
Table 4.3.  
 
Table 4.3: Relative expression values for SLIT-ROBO and AFP genes in HCC cell lines* 
  ROBO1 ROBO2 ROBO4 SLIT1 SLIT2 SLIT3 AFP 
Focus -1.53 -4.95 3.32 -1.72 1.85 -0.22 -4.86 
Hep40 2.05 4.88 1.67 3.23 2.08 3.83 2.19 
Hep3B 2.62 2.66 -0.78 1.10 2.88 -6.32 2.78 
Hep3B-TR 2.67 4.46 0.40 0.23 4.95 -7.35 8.94 
HepG2 2.52 -3.65 -2.27 1.35 -4.22 -4.77 11.03 
Huh7 1.55 7.44 -1.62 4.60 4.25 -5.00 11.19 
Mahlavu -0.93 -3.61 -0.87 -3.30 2.33 3.90 -5.07 
PLC 2.80 2.85 -0.89 -1.75 -3.95 -5.82 1.09 
SKHep1 0.45 -1.99 3.58 -1.87 3.68 6.93 -3.14 
Snu387 -5.58 -2.83 1.56 0.23 2.15 0.03 -3.86 
Snu398 0.35 5.54 -2.18 6.28 -6.65 -4.67 -4.87 
Snu423 -1.03 -3.56 -0.79 -2.05 -5.25 7.65 -9.94 
Snu449 -4.38 -3.65 -0.23 -3.57 -4.40 6.63 -5.43 
Snu475 -1.23 -3.93 -0.88 -1.37 -0.10 6.03 -0.04 
* For each gene, average expression value of all cell lines was used as the control sample when 
calculating relative expression values.  
 
Relative quantification data was mostly parallel to semi-quantitative expression data. ROBO2 
and SLIT1 expression were up-regulated in high-AFP group of cells, except HepG2, which 
underexpressed ROBO2. On the other hand, both genes were found to be overexpressed in 
SNU398, one of the low-AFP group of cell lines. SLIT3 transcript levels sharply contrasted 
those of ROBO2 and SLIT1. Except SNU398, increased SLIT3 expression was found among 
low-AFP expressing group of cell lines, and also in high-AFP expressing Hep40 cell line. 
Interestingly, widespread expression of ROBO1 transcripts that we observed in RT-PCR 
turned out to be enhanced in cell lines with high-AFP background. ROBO4 and SLIT2 
transcript levels remained variable among HCC cell lines and no phenotype-based association 
could be observed for these genes. Attempts to calculate PCR efficiency with two different 
ROBO3 primer pairs failed, so there is no qRT-PCR data for ROBO3. 
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4.1.5.2 Pearson’s correlation analysis revealed genewise expression parallels in HCC 
cell lines 
Pearson’s correlation analysis was performed in R environment for each possible gene pair 
using the relative expression values. The results are presented in Table 4.4. ROBO1 
expression showed a significant positive correlation with that of ROBO2 and AFP whereas 
ROBO1 expression showed a negative correlation with SLIT3. ROBO2 correlated in a positive 
manner with SLIT1 and in a negative manner with SLIT3. SLIT1 expression also showed a 
significant negative correlation with SLIT3. SLIT3 has a negative correlation with AFP, which 
is significant.    
 
Table 4.4: Genewise correlation of SLIT-ROBO and AFP genes in HCC cell lines 
Gene ROBO1 ROBO2 ROBO4 SLIT1 SLIT2 SLIT3 AFP 
ROBO1 1             
ROBO2 0.6060* 1           
ROBO4 -0.2721 -0.2653 1         
SLIT1 0.4027 0.7623* -0.3288 1       
SLIT2 0.1241 0.1891 0.5143 -0.0039 1     
SLIT3 -0.5698* -0.6072* 0.3681 -0.5451* -0.1003 1   
AFP 0.6533* 0.5108 -0.3016 0.4579 0.3544 -0.6605* 1 
* : p < 0.05. 
 
 
4.1.5.3 Cluster analysis identified two subgroups of HCC cell lines with respect to 
SLIT-ROBO expression 
Hierarchical clustering was performed using Cluster and TreeView tools. In terms of SLIT-
ROBO expression, low-AFP expressing SNU449, SNU423, SNU475, Mahlavu, SK Hep1, 
SNU387, and Focus cells grouped together (Group I), while high-AFP expressing HepG2, 
PLC/PRF/5, HUH7, Hep3B-TR, HEP-3B and Hep40 cell lines (Group II) clustered separately 
from the first group (Figure 4.3). Exceptionally, SNU398 cell line displayed a SLIT-ROBO 
expression pattern concordant with Group II despite its low-AFP background. In ANOVA, 
the expression of AFP significantly differed between the two groups (p = 0.0001): Mean 
expression of AFP in Group I and Group II cells was -4.65 + 2.75 and 6.20 + 4.68, 
respectively (Figure 4.4). 
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Figure 4.3: SLIT-ROBO expression establishes two groups, which predict AFP expression levels in HCC 
cell lines. The means of normalized expression values of individual SLIT-ROBO genes in each cell line were 
used to establish the hierarchical clustering in Cluster program, and the results were visualized as a heatmap by 
TreeView. Overexpression and underexpression of individual genes relative to Ct average of all cell lines are 
represented by red and green colors, respectively. Upper single-row heatmap displays the average expression of 
all six genes across all cell lines. The tree at the top of the heatmap represents samplewise clustering. Based on 
their AFP expression levels, HCC cell lines are represented in two main subgroups indicated as Group I (low-
AFP) and Group II (high-AFP) cells. The tree on the left of the heatmap (pink) represents genewise clustering.  
 
 66
 
Figure 4.4: One-way ANOVA for AFP expression between Group1 and Group2 cell lines. AFP expression 
significantly differed between the two groups (p = 0.0001): Mean expression of AFP in Group1 and Group2 cells 
was -4.65 + 2.75 and 6.20 + 4.68, respectively .  
 
 
Hierarchical clustering analysis also revealed a genewise segregation of SLIT-ROBO genes. 
Coordinate expression was observed in two main clusters, one of which grouping together 
ROBO1, ROBO2 and SLIT1, and the other ROBO4, SLIT2, and SLIT3, respectively (Figure 
4.3). One-way ANOVA was performed to identify individual SLIT-ROBO genes, which 
significantly separate HCC cell lines with high- and low-AFP expression. In this analysis, 
ROBO1 and ROBO2 expression were up-regulated in high-AFP group (p = 6.7 x 10-4 and p = 
0.013, respectively). Mean expression of ROBO1 in Group I was –1.73 + 2.15 while in Group 
II cells increased to 2.37 + 0.48. Similarly, ROBO2 mean expression values were found as -
2.37 + 3.31 and 3.11 + 3.73, for Group I and Group II, respectively. In sharp contrast, SLIT3 
was overexpressed in cell lines with low-AFP profile (MeanGroup1= 3.28 + 4.43 MeanGroup2= -
4.24 + 4.06, p = 6.9 x 10-3) (Figure 4.5). 
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Figure 4.5: Significant one-way ANOVA results of individiual SLIT-ROBO genes between Group1 and 
Group2 HCC cell lines. ROBO1 and ROBO2 expression were up-regulated in high-AFP group (p = 6.7 x 10-4 
and p = 0.013, respectively). Mean expression of ROBO1 in Group I was –1.73 + 2.15 while in Group II cells 
increased to 2.37 + 0.48. Similarly, ROBO2 mean expression values were found as -2.37 + 3.31 and 3.11 + 3.73, 
for Group I and Group II, respectively. In contrast, SLIT3 was overexpressed in cell lines with low-AFP profile 
(MeanGroup1= 3.28 + 4.43 MeanGroup2= -4.24 + 4.06, p = 6.9 x 10-3).  
 
4.1.5.4 Quantitative real-time RT-PCR data for SLIT-ROBO genes in normal liver and 
hepatocellular carcinoma tissues 
SLIT-ROBO expression in tumor-adjacent normal liver and hepatocellular carcinoma tissues 
were analyzed in TissueScan Liver Cancer Tissue qPCR Array 1 (Origene Technologies, 
Rockville, MD, USA). The panel contained 48 tissue cDNAs normalized against β-actin. The 
SLIT-ROBO expression in 8 normal and 35 hepatocellular carcinoma cDNAs were analyzed, 
the remaining five cDNAs were of other unrelated pathologies (Table 3.6). Relative 
quantification was performed as described in materials and methods section by taking the 
mean expression values in normal cDNAs as the reference sample for each gene. The raw 
A) B) 
C) 
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quantification values, along with the data for AFP, were log2 transformed and summarized in 
Table 4.5.  
 
Table 4.5: Relative expression values of SLIT-ROBO and AFP genes in normal liver and HCC samples* 
Sample # ROBO1 ROBO2 ROBO4 SLIT1 SLIT2 SLIT3 AFP 
N1 -0.66 -2.49 0.15 2.76 0.03 1.09 2.06 
N2 0.24 1.61 0.35 -1.04 1.63 1.09 1.98 
N3 0.04 -2.39 1.35 -0.94 0.43 -0.21 1.23 
N4 -0.66 -2.49 -0.75 -1.04 -1.88 0.09 -0.74 
N5 -0.06 1.81 -0.55 1.76 -0.78 -1.21 -0.96 
N6 1.34 3.71 1.05 -0.14 0.83 -0.21 -1.45 
N7 -0.06 -0.69 -1.85 -0.84 -1.18 -2.41 -1.3 
N8 -0.16 0.91 0.25 -0.54 0.93 1.79 -0.83 
T1 1.84 -0.79 -1.75 0.66 -2.68 -3.81 5.46 
T2 1.74 1.71 -0.65 -0.34 -1.48 -0.71 -2.24 
T3 0.74 -0.69 -1.05 0.76 -0.58 0.39 0.13 
T4 0.14 -1.59 -1.05 -0.14 -2.68 -2.41 0.08 
T5 2.04 0.51 -3.15 -0.34 0.83 -1.11 5.48 
T6 1.44 -0.99 0.25 0.46 2.63 1.89 0 
T7 -0.16 -1.49 -0.15 0.86 0.33 -0.11 -1.01 
T8 -0.16 -1.49 0.15 4.56 -0.38 -2.81 -1.77 
T9 -0.46 -1.39 0.15 0.06 0.43 -0.71 -0.99 
T10 3.84 0.91 -0.25 -1.04 0.73 1.59 8.68 
T11 3.44 -2.09 -0.35 -0.64 -4.98 -0.91 4.75 
T12 4.24 -2.69 -1.95 1.76 -7.68 -0.71 -0.09 
T13 1.54 1.01 -2.75 3.56 -1.68 -0.51 6.72 
T14 1.64 2.41 -0.35 -0.54 0.63 1.59 -0.07 
T15 3.04 1.61 -3.25 2.76 -5.38 -4.11 11.63 
T16 3.14 -0.99 0.35 0.46 -1.28 -0.01 5.09 
T17 2.94 -0.99 -1.25 0.46 -7.88 -2.81 -6.19 
T18 0.84 -2.89 0.45 -1.44 3.93 2.49 -1.81 
T19 1.54 -1.59 0.65 -0.14 1.03 1.59 3.13 
T20 -0.06 2.61 -0.95 0.06 -2.68 -3.01 0.87 
T21 1.14 -0.29 -1.95 1.16 -0.98 -1.91 4.09 
T22 4.34 -1.89 -0.35 -0.44 2.83 1.79 -0.73 
T23 1.44 -0.79 -1.05 5.96 1.03 2.59 -6.07 
T24 -1.06 2.41 -1.05 -0.34 1.13 5.09 -9.53 
T25 4.54 1.41 -1.55 -0.24 -6.38 -3.11 -4.18 
T26 -1.16 -3.49 1.15 -2.04 -1.28 -2.71 -10.13 
T27 3.64 0.71 0.25 -1.24 -0.78 0.69 -3.99 
T28 3.94 6.11 -1.95 -0.14 0.23 0.49 11.36 
T29 -0.46 -0.99 -1.85 0.46 0.13 0.59 -0.17 
T30 0.04 -0.99 -4.85 2.46 1.13 1.59 1.95 
T31 -0.26 1.11 -0.45 -0.44 -1.08 -0.31 2.41 
T32 1.44 -2.19 0.25 -0.74 0.63 1.29 1.94 
T33 1.04 -1.29 0.95 0.16 1.43 2.29 -2.67 
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T34 0.94 -2.19 -0.25 -0.74 2.33 0.39 -5.27 
T35 2.24 -1.99 -1.45 -0.54 -0.98 0.39 9.94 
* For each gene, average expression value of normal samples was used as the control sample when 
calculating relative expression values.  
 
 
In these analyes, only ROBO1 was found to be significantly overexpressed in tumor tissues 
(MeanNormal= 0 + 0.63 MeanTumor = 1.57 + 1.63, p = 0.011). Also, the ROBO4 expression was 
downregulated in tumor tissues with a p-value near significance (MeanNormal= 0 + 1.03 
MeanTumor = -0.89 + 1.30, p = 0.079). AFP displayed a highly variable expression, yet it was 
overexpressed in more than half of the tumors (18/35) (Figure 4.6).   
 
 
 
Figure 4.6: Significant one-way ANOVA results of individiual SLIT-ROBO genes between normal and 
HCC tissues. ROBO1 was found to be significantly overexpressed in tumor tissues (MeanNormal= 0 + 0.63 
MeanTumor = 1.57 + 1.63, p = 0.011) whereas ROBO4 was downregulated in tumor tissues with a p-value near 
significance (MeanNormal= 0 + 1.03 MeanTumor = -0.89 + 1.30, p = 0.079). AFP displayed a highly variable 
expression, yet it was overexpressed in more than half of the tumors (18/35).  
 
A) B) 
C) 
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4.1.5.5 SLIT-ROBO genewise clustering observed in HCC cell lines translates into liver 
tissues 
Hierarchical clustering was performed using Cluster and TreeView tools. Hierarchical 
clustering grouped SLIT-ROBO genes in a similar manner as in HCC cell lines. ROBO1, 
ROBO2 and SLIT1 clustered together, whereas ROBO4, SLIT2 and SLIT3 formed another 
cluster (Figure 4.7).  
 
 
 
  
Figure 4.7: Genewise clustering of SLIT-ROBO genes in HCC cell lines translates into liver tissues. The 
normalized expression values of individual SLIT-ROBO genes in liver tissue samples (n = 43) were used to 
establish the hierarchical clustering in Cluster program and the results were visualized as a heatmap by 
TreeView. Overexpression and underexpression of individual genes relative to Ct average of normal tissues (n = 
8) are represented by red and green colors, respectively. Upper single-row heatmap displays the average 
expression of all six genes across all tissues. The tree at the top of the heatmap represents samplewise clustering, 
and the tree on the left of the heatmap (pink) represents genewise clustering. T1-35: tumors; N1-8: normal 
tissues; 0: stage 0 (non-tumor); 1, 2, 3A, 4: stage 1, stage 2, stage 3A, stage 4 HCC, respectively; N: tumor-
adjacent normal tissue; W: well-differentiated; M: moderately differentiated; P: poorly differentiated; N/A: not-
assigned. 
 
 
Two main clusters appeared among tissue samples; however, no significant association of 
clusters was found with differentiation state or staging of tumors (Wilcoxon rank sum test) 
and AFP expression (one-way ANOVA).  
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4.1.5.6 Pearson’s correlation analysis revealed genewise expression parallels in liver 
tissues and a Mantel’s permutation test confirmed the significance of 
correlation patterns in HCC cell lines and liver tissues 
Expression correlation in individual SLIT-ROBO and AFP genes in liver tissues was analyzed 
by Pearson’s correlation analysis in R (Table 4.6). Accordingly, ROBO1 expression showed a 
significant positive correlation with that of AFP whereas ROBO1 expression showed a 
negative correlation with SLIT2. ROBO4 correlated in a positive manner with SLIT2 and in a 
negative manner with SLIT1 and AFP. SLIT2 expression showed a highly significant positive 
correlation with SLIT3. 
 
Table 4.6: Genewise correlation of SLIT-ROBO and AFP genes in liver tissues 
Gene ROBO1 ROBO2 ROBO4 SLIT1 SLIT2 SLIT3 AFP 
ROBO1 1             
ROBO2 0.1835 1           
ROBO4 -0.1879 -0.2134 1         
SLIT1 0.0298 0.002 -0.3793* 1       
SLIT2 -0.3679* -0.0078 0.3432* -0.1389 1     
SLIT3 -0.0973 -0.0027 0.2596 -0.0965 0.6844*** 1   
AFP 0.3679* 0.2324 -0.3699* 0.0924 -0.0769 -0.1638 1 
        ***: p < 0.001 ; *: p < 0.05. 
 
 
Mantel’s permutation test was performed in R environment in order to compare gene 
expression correlation matrices of cell lines and tissues (described in Table 4.4 and Table 4.6, 
respectively), and indicated that gene-to-gene correlation patterns in both sample groups were 
significantly associated (R = 0.49, p < 0.02). 
 
4.1.5.7 ROBO1 expression differentiates normal tissues from tumors with respect to 
both stage and differentiation status 
Using relative expression data of liver tissues, one-way ANOVA and subsequent Fisher’s 
multiple pairwise comparisons were applied in order to explore whether gene expression 
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characteristics of SLIT-ROBO family members discriminate among liver tissues with respect 
to differentiation status and staging of the samples. The tissue samples lacking stage or 
differentiation information in the pathological reports were left out of analysis. With these 
criteria, a total of 43 liver tissue samples for stage and of 38 tissue samples for differentiation 
status were analyzed. According to one-way ANOVA, ROBO1 differentiated liver tissue 
samples on both the stage (p = 0.018) and differentiation status (p = 0.031) dependent manner 
(Figure 4.8 A, B). ROBO4 expression significantly discriminated tissues only with respect to 
their differentiation status (p = 0.039) (Figure 4.8 C). Moreover, Fisher’s pairwise comparison 
analyses revealed that ROBO1, SLIT2 and ROBO4 significantly discriminated between 
different histopathological subgroups both in terms of differentiation status and/or tumor 
staging (Table 4.7).  
 
 
 
Figure 4.8: Significant one-way ANOVA results of individiual SLIT-ROBO genes between normal and 
HCC tissues. ROBO1 differentiated liver tissue samples depending on both A) the stage (p = 0.018) and B) 
A) B) 
C) 
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differentiation status (p = 0.031) dependent manner. C) ROBO4 expression significantly discriminated tissues 
only with respect to their differentiation status (p = 0.039).  
 
 
Table 4.7: Differentially expressed SLIT-ROBO genes between histopathological subgroups of liver tissues 
Stage n Mean expression (SE) Differentially expressed gene* 
0 8 0 (0.22) ROBO1 
2 11 2.37 (0.41)   
0 8 0 (0.22) ROBO1 
3 13 1.43 (0.57)   
1 9 0.79 (0.33) ROBO1 
2 11 2.37 (0.41)   
2 11 -2.29 (1.15) SLIT2 
3 13 -0.96 (0.44)   
Differentiation state n Mean expression (SE) Differentially expressed gene* 
Normal 8 0 (0.22) ROBO1 
Moderate 16 1.89 (0.44)   
Normal 8 0 (0.22) ROBO1 
Poor 6 1.84 (0.60)   
Normal 8 0 (0.36) ROBO4 
Poor 6 -2.02 (0.80)   
Well 8 -0.60 (0.43) ROBO4 
Poor 6 -2.02 (0.80)   
Moderate 16 -0.66 (0.25) ROBO4 
Poor 6 -2.02 (0.80)   
Moderate 16 -1.28 (0.78) SLIT2 
Poor 6 1.01 (0.88)   
     * Pairs of stage and differentiation subgroups were compared in Fisher’s pairwise comparison analysis and 
only the genes that significantly discriminate between subgroups were represented (p<0.05). SE: standard error. 
 
 
4.1.6 An alternatively spliced ROBO2 isoform ROBO2-tv2, which was initially 
described in zebrafish (Danio rerio) and rat (Rattus norvegicus); is also 
expressed in human HCC cell lines 
In 2006; Dalkic, Kuscu et al. described a novel conserved alternative exon (CAE) of robo2 
genes of zebrafish and rat. CAE is a 186-bp sequence that corresponds to a region in zebrafish 
chromosome 15 (from 40,471,855 to 40,472,040 bp and in between 21st and 22nd exons of 
Ensdart00000014877). CAE is predicted to yield an in-frame insertion without stop codons. It 
corresponds to a region between the second and the third cytoplasmic domains (between the 
 74
1311th and 1312th residues of NM_131633) of the zebrafish robo2 protein sequence. Rat 
robo2 mRNA (XM_213677) was reported to include the homolog of the zebrafish CAE, 
although some of the Ensembl-predicted isoforms differed in their usage of it 
(Ensrnot00000044621, Ensrnot00000043725, Ensrnot00000042437, Ensrnot00000050397) 
(Dalkic, Kuscu et al. 2006). 
 
With two sets of PCR primers, expression of ROBO2-tv1 and tv2 human orthologs was 
analyzed in HCC cell lines (Figure 4.9 B). ROBO2-hRF was a common forward primer. 
Reverse primer ROBO2-hRRA specifically complements to CAE and amplifies ROBO2-tv2 
(giving a 220bp PCR product) whereas reverse primer ROBO2-hRR spans CAE and amplifies 
both ROBO2-tv1 and tv2 in the same reaction (amplifying a 102bp fragment and a CAE 
spanning 285bp fragment, respectively). Another primer pair described by Latil, Chene et al. 
2003 was used to confirm the results. All reactions were run at 60oC of annealing temperature 
and for 40 cycles of amplification. Human ortholog of CAE mapped to Genscan predicted 
putative exonic site near the 3′ end of robo2 [human: Chr. 3: 77,764,315:77,764,497 bp, 
(Genscan00000045332)]. There are three different ROBO2 transcripts present in Ensembl 
genome browser: ROBO2-201 (ENST00000332191), ROBO2-202 (ENST00000398467) and 
ROBO2-203 (ENST00000403211). Primer pair described in Latil, Chene et al. 2003 binds to 
and amplifies all three transcripts. However, ROBO2-hRF and hRR binding sites are present 
in only ROBO2-201 and ROBO2-203. Thus, observed ROBO2-tv1 expression represents 
these two transcripts.  
 
Both ROBO2-tv1 and ROBO2-tv2 were present in AFP-positive, well-differentiated subgroup 
of HCC cell lines (Hep40, Hep3B, Hep3B-TR, Huh7 and PLC). In addition, they were present 
in Snu398 which is a poorly differentiated cell line. ROBO2-tv1 also was expressed in the 
poorly differentiated Snu387 and Snu475 cell lines. Expressions of the transcripts amplified 
by ROBO2 control primer pair (Latil, Chene et al. 2003) were strongly parallel to the 
ROBO2-tv2 expression. However, ROBO2 control primer pair also gave products in SK 
Hep1 and Snu449 cell lines (Figure 4.9 A).    
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Figure 4.9: Expression of transcript variant ROBO2-tv2 (including the described conserved alternative 
exon, CAE) and ROBO2-tv1 (lacking CAE) in HCC cell lines. A) With two sets of PCR primers, tv1 and tv2 
expression was analyzed in HCC cell lines. ROBO2-hRF was a common forward primer. Reverse primer 
ROBO2-hRRA specifically complements to CAE and amplifies tv2 whereas reverse primer ROBO2-hRR spans 
CAE and amplifies both tv1 and tv2 in the same reaction. Another primer pair described by Latil et al., 2003 was 
used to confirm the results. B) Schematic representation of the used primers and the expected product sizes. 
 
 
4.2 Characterization of ROBO2 knockdown associated cellular phenotype 
in HCC 
4.2.1    Stable knockdown of ROBO2 expression in Huh7 cell line 
The SLIT-ROBO expression data distinguished between AFP-positive and AFP-negative HCC 
cell lines correctly in the cluster analysis. When we analyzed the clustering pattern the most 
strikingly differentially expressed gene appeared as ROBO2. It was downregulated in poorly-
differentiated AFP-negative cell lines whereas it was highly expressed in well-differentiated 
AFP-positive cell lines, except in HepG2-which is a hepatoblastoma derived cell line- it was 
negative. Another feature of the ROBO2 downregulated cell lines was their motility. They 
overexpress genes associated with metastasis and motility (Lin, Ke et al. 1998; Seki, Kitada et 
al. 1999; Lee and Thorgeirsson 2002). The above menitioned literature data and the role of 
SLIT-ROBO interaction as a chemokine signaling in cellular migration led us to propose that 
interfering with ROBO2 function in one of the well-differentiated HCC cell lines may affect 
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the migratory behavior these cells. To this end, ROBO2 expression was stably knockdowned 
by transfecting Huh7 cells with ROBO2 mRNA targeting shRNA vector and as a control 
nontargeting scrambled vector. 
 
17 ROBO2 shRNA expressing vector transfected clones (hereafter referred as R2C-clone 
number) and 8 nontargeting scrambled shRNA transfected clones (hereafter referred as NC-
clone number) were obtained. ROBO2 expression was checked in these clones by both real-
time quantitative RT-PCR and westen blot analysis (Figure 4.10 and Figure 4.11, 
respectively). In selected clones, ROBO2 expression was found to be downregulated at both 
mRNA and protein levels. In addition we performed immunoflourescence experiments in 
R2C10 and NC4 clones (Figure 4.11 B). 
 
Figure 4.10: Relative ROBO2 expression in pSEC transfected stable Huh7 clones. ROBO2 expression was 
checked by real-time quantitative RT-PCR in Huh7 clones stably transfected with ROBO2 targeting (R2C-) or 
nontargeting (NC-) shRNA vectors. Relative expression was calculated using ∆∆Ct method and ROBO2 
expression in Huh7 was taken as the reference.   
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Figure 4.11: ROBO2 protein levels in pSEC transfected stable Huh7 clones. Western blots were performed 
to in selected stable clones. Membarnes were probed with ROBO2 and E-cadherin antibodies. Equal loading was 
controlled with two different antibodies, Calnexin and Actin.  
 
4.2.2 Expression of the epithelial-to-mesenchymal transition (EMT) markers 
and E-cadherin suppressors in stable clones 
Epithelial-to-mesenchymal transition (EMT) is a process occurring during development for 
the proper dissemination of cell groups and subsequent tissue formation. EMT is also 
observed in tumor cells during distant metastasis. Invasive front of the solid tumor surpasses 
through EMT and launches from the primary tumor. After intravasation and systemic spread, 
cells find a proper microenvironment and settles, this time by a process which is the reverse of 
the EMT: mesenchymal-to-epithelial transition (MET). Next, we characterized the expression 
of EMT markers and E-cadherin transcriptional suppressors that are specifically upregulated 
during EMT. Twist and SNAI primer pairs did not give the expected in none of the clones and 
the parental Huh7 cell line.  In RT-PCR experiments, there was no clear-cut differential 
expression of the analyzed genes between ROBO2 knockdown and control clones (Figure 
4.12). Only, SLUG was upregulated in R2C7, R2C9 and R2C17. We checked the expression 
of E-cadherin and its suppressors SLUG and SIP1 further in QRT-PCR experiments (Figure 
4.13). In these analyses, E-cadherin showed an upregulation whereas SIP1 and SLUG showed 
a downregulation trend in stable ROBO2 knockdown clones when compared to the negative 
clones. Individual clones differed in their expression patterns and there were outliers to the 
R
2C
17
 
Robo2 
Calnexin 
E-cadherin 
R
2C
7 
R
2C
9 
R
2C
13
 
N
C
3 
N
C
4 
N
C
6 
H
U
H
7 
Actin 
 78
general trend. β-catenin is known to make complex with E-cadherin in the cytosolic part of 
the membrane. Using a home-made antibody against β-catenin (9E10), we checked the 
cellular location of β-catenin in R2C10 and NC4 clones but both the location and signal did 
not change significantly (Figure 4.14).  
 
 
Figure 4.12: Evaluation of the EMT marker expression in stable clones. Mesenchymal markers vimentin, 
fibronectin, asma (alpha-smooth muscle actin) and E-cadherin suppressors slug and SIP1 expression was 
analyzed at 40 cycles. Since vimentin, asma and fibronectin products were saturated, semi-quantitative 
expressions at lower cycles were also analyze (20, 22 and 18 cycles respectively).  
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Figure 4.13: Quantitative expression of E-cadherin and its suppressors SLUG and SIP1 in stable clones. 
Relative expressions of E-cadherin, SIP1 and SLUG were measured taking the average expression in negative 
clones as the reference. Calculated values were plotted in log2 base. 
 
 
 
 
 
Figure 4.14: β-catenin immunoflourescence staining in R2C10, NC4 clones and parental Huh7 cells. 
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4.2.3 In wound-healing migration assay, there was no significant difference 
between the migration rates of ROBO2 knockdown and negative clones  
We addressed the migrational differences between stable ROBO2 knockdown and negative 
clones. To this end, we performed wound-healing assay by simply scratching near-confluent 
cell layers with a 200µl micropipette tip both in the presence and absence of serum in the 
medium. Then, the opened wound was followed for 48 hours. At 0, 24 and 48 hours 
photographs were taken.  
 
In serum positive conditions cells migrated faster as observed from the higher scale bar in the 
normal serum condition (Figure 4.15 A and B). The fastest healed clone was R2C17 and the 
slowest one was NC6 as can be seen in Figure 4.15 A. A representative assay photograph is 
given in Figure 4.16 showing the difference between these two fastest and slowest clones. 
Three ROBO2 knockdown (R2C7, R2C9, R2C17) and three negative clones (NC3, NC4, 
NC6) were averaged for their relative migration capacities and compared by t-test at 24 hours 
(p-value = 0.78) and 48 hours (p-value = 0.37) in the presence of serum (Figure 4.15 B) but 
there was no significant difference in their migration. Likewise, in the serum absent 
conditions the migratory behavior of the clones was not significantly different (t-test, p-value 
= 0.31 for 24 hours and p-value = 0.55 for 48 hours) (Figure 4.15 C and D). In both normal 
and serum starved conditions, individual clones differed in their migratory capacities. 
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Figure 4.15: Wound-healing assay results for stable clones in normal and serum starved medium. Wounds 
were made at time 0 and photos were taken. Subsequently, at 24th and 48th hours photographs were taken and 
the relative healed distances were calculated by dividing the total healed wound distance (difference between 
initial and final wound sizes) by 2, for 10 different lines connecting horizontally the two sides of the wound. The 
average of these 10 calculations were used to construct the graphs and calculate the T-tests. In A), cells were 
incubated in normal medium, and in B) cells were serum starved. T-test was applied for deducing the 
significance of the migratory differences between ROBO2 knockdown (R2C7, R2C9, R2C17 average values) 
and negative clones (NC3, NC4, NC6 average values) (C and D).    
 
 
 
Figure 4.16: Representative wound healing assay photographs. In normal serum present conditions the most 
rapid and slow migrating clones were R2C17 and NC6, respectively. The wound-healing pattern of these clones 
are photographed. 
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4.2.4 Microarray analysis of the differentially expressed genes between stable 
ROBO2 knockdown clones and negative clones 
In order to observe the general picture related to ROBO2 knockdown in stable clones, a 
microarray experiment was designed. Pooled RNAs from eight stable ROBO2 knockdown 
clones (R2C3, R2C7, R2C8, R2C9, R2C10, R2C13, R2C14, and R2C17) were hybridized to 
one Affymetrix HG-U133plus2.0 chip and pooled RNA from four negative clones (NC4, 
NC5, NC6, and NC7) were hybridized to another Affymetrix HG-U133plus2.0 chip. Quality 
of the RNAs was checked using Nanodrop ND-1000 Full-spectrum UV/Vis 
Spectrophotometer and by running in formaldehyde gel and visual inspection of 28S and 18S 
rRNAs under UV (Figure 4.17). Microarray experiment was performed by Hilal Özdağ from 
Ankara University Biotechnology Instute. After the experiment, raw .cell files of the two 
chips were obtained; then quality controlled and RMA normalized in R environment (Figure 
4.18). 
 
In MS Excel, using built-in functions we obtained a fold change list and a differentially 
expressed gene list. To filter out non-relevant, noise-related genes we determined a cut-off of 
± 0.8 fold; the probe sets having fold change values between +0.8 and -0.8 were eliminated. 
We have ended up with 668 upregulated and 744 downregulated probe sets. 
 
Figure 4.17: Visualization of 18S and 28S rRNAs in total RNAs isolated from stable clones in 
formaldehyde agarose gel. Before sending for microarray experiment total RNAs from stable clones were 
quality controlled in formaldehyde agarose gel. 18S and 28S rRNA bands were seen and no smear was observed, 
except in NC3, indicating the intactness of the RNA samples. Because of the observed smear pattern in NC3 
total RNA sample, it was excluded from microarray experiment.  
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Figure 4.18: Box- and MA-plots of shROBO2 RNA (2C) and negative RNA (NC) probed chips before and 
after RMA normalization. 
 
 
4.2.4.1 Pathway  analysis of microarray results using Pathway-Express tool 
Pathway-Express is a tool in the Onto-Tools ensemble that was designed to help in pathway 
analysis of microarray data. The goal of the Pathway-Express system is to automatically find 
interesting pathways. When the user submits a list of genes, the system performs a search and 
builds a list of all associated pathways. In principle, system weights a pathway associated 
with the gene list and gives an impact factor to the entire pathway. The impact factors of all 
pathways are used to rank the pathways before presenting them to the user. All pathways 
affected are presented regardless of their impact factors (Khatri, Bhavsar et al. 2004; Khatri, 
Sellamuthu et al. 2005). In addition, it also locates the differentially expressed genes into 
KEGG pathway charts and highlights down- and up-regulated genes with specific colors in 
order to ease in visualization. 
 
Raw Data 
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In Pathway-Express, querying our differentially expressed gene list resulted in a significance 
associated pathway list (Figure 4.19). The most prominently disturbed pathway was cell 
adhesion molecules (CAMs) pathway including 15 differentially expressed genes form the 
input list. Then come “phosphatidylinositol signaling system” and “complement and 
coagulation cascades” that were not previously associated with any of the SLIT-ROBO genes. 
Following in the list were “axon guidance”, “ECM-receptor interaction”, “focal adhesion” and 
“regulation of actin cytoskeleton” in which SLIT-ROBO genes are directly or indirectly 
functional. As a representative Pathway-Express result, axon guidance pathway and the 
differentially expressed genes in the pathway is presented in Figure 4.20. The perturbation in 
ROBO2 gene can be easily recognized with its blue color indicating downregulation. 
Interestingly; downstream to ROBO2, srGAP1 gene was upregulated suggesting the 
compensatory activity of other possible redundant mechanisms. 
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Figure 4.19: Significantly affected pathways identified in Pathway-Express. 
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Figure 4.20: Pathway-Express output of axon guidance pathway and the differentially expressed genes in 
the pathway. A total of 18 genes were found to be diferentially expressed. Upregulated genes were shown in 
red, and the downregulated ones were in blue.  
 
 
4.2.4.2 Microarray verification of selected differentially expressed genes by semi-
quantitative RT-PCR 
With CD133, CK19 and five other axon guidance gene primers microarray verification was 
performed in cDNAs of the stable clones by semi-quantitative RT-PCR (Figure 4.21). The 
fold change values associated with the genes were presented in the column at the right side of 
the figure. The observed expression pattern in semi-quantitative RT-PCR analyses was 
parallel to the fold change values obtained from microarray analysis. 
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Figure 4.21: Microarray verification with selected genes using semi-quantitative RT-PCR. Selected genes 
were amplified at semi-quantitative cycles to observe the microarray predicted differential expression. Gene 
associated fold change values obtained in microarray analysis were given in the column, located at the right side 
of the figure.  
 
4.2.5 Expression of the markers associated with side population, cancer stem cell 
and pluripotency phenotype was enriched in the stable ROBO2 knockdown 
clones 
Recently, side-population (SP) cells were described in 0.25-1% of Huh7 cell line and 
xenograft tumors of SP cells showed increased size and total number in SCID mouse. SP cells 
overexpress BCRP1 (ABCG2), MDR1, CK19 (KRT19) and CD133, and show increased 
invasion and chemoresistance capabilities (Chiba, Kita et al. 2006; Haraguchi, Utsunomiya et 
al. 2006). In another study, about 50% of Huh7 cells were found to be CD133+ and these cells 
formed tumor when xenografted to NOD/SCID mouse (Suetsugu, Nagaki et al. 2006). 
CD133+ Huh7 cells showed increased proliferation and clonogenic capacity. Even, 1x103 or 
5x104 cells were sufficient for tumor development in SCID or nude mouse, respectively. β-
catenin, Notch, SMO, Bmi and Oct3/4 genes are overexpressed in CD133+ subpopulation 
(Ma, Chan et al. 2007). KLF4, SOX2, C-MYC, and OCT3/4 transduction in somatic cells have 
been shown to induce pluripotency (Takahashi, Tanabe et al. 2007). Hepatic progenitor cells 
or oval cells are liver stem cells implicated in origination of HCC, and BCRP1 (ABCG2), 
KRT19 (CK19), AFP and CD44 are among the markers used in identification of these cells in 
damaged liver (Alison, Islam et al. 2009). We observed 1.6 fold BCRP1 (ABCG2), 2.4 fold 
KRT19 (CK19), 2.6 fold KLF4 and 2.0 fold CD133 (PROM1) overexpression in our 
microarray analysis. With this lead, we checked the expression of CD133, CK19, KLF4, 
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MYC, CD44, AFP, BCRP1, MDR1 and SOX2 in the stable clones with semi-quantitative RT-
PCR. We found that CD133, CK19, KLF4, CD44, BCRP1, SOX2 and to some extent MDR1 
expression was enriched in ROBO2 knockdown clones (Figure 4.22).  
 
 
Figure 4.22: Semi-quantitative expression analysis of side population, cancer stem cell and pluripotency 
associated genes in stable clones. At semi-quantitative cycles, RT-PCR expressions of CD133, CK19, KLF4, 
MYC, CD44, AFP, BCRP1, MDR1, and SOX2 genes were analyzed. 
 
4.2.6 Transient knockdown of ROBO2 did not change the expression of side 
population, cancer stem cell and pluripotency markers 
Huh7 is a heterogeneous cell line meaning that individual single cell clones isolated from 
Huh7 may not always have the same genetic background. To investigate whether the observed 
enrichment of CD133, CK19, KLF4, CD44, BCRP1, SOX2 and MDR1 expression in ROBO2 
knockdown clones was dependent on ROBO2 or was a by-product of this heterogeneous 
character of Huh7 clones, we transiently silenced the expression of ROBO2 in parental Huh7. 
Two different ROBO2 targeting shRNAmir vectors (R2-1 and R2-2, in pGIPZ backbone) 
were transfected either singly or together (Figure 4.23). pGIPZ vector with a scrambled-
nontargeting shRNAmir construct was used as control. No change was observed in the 
expression of above listed genes in these transiently transfected Huh7 cells. 
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Figure 4.23 Side population, cancer stem cell and pluripotency associated genes in shROBO2 transiently 
transfected cells. CD133, CK19, KLF4, CD44, BCRP1, SOX2 and MDR1 expression was semi-quantitatively 
checked in shROBO transient transfected Huh7 cells. ROBO2 expression after transfections was determined by 
real-time quantitative PCR (down left corner).  
 
In addition with immunoflourescence experiments, we checked the expression of ROBO2, 
CD133 and β-catenin (with 9E10 monoclonal antibody) in these transiently transfected Huh7 
cells. The transfected shRNAmir constructs have internal GFP expression in front of the 
shRNAmir construct linked with and internal ribosome entry sequence (IRES), so the 
individual shRNAmir expressiong cells were seen with green flourescence. ROBO2, CD133 
and β-catenin stainings were performed with Alexa 588 secondary antibody so the signal 
given by them was red. DAPI was used for counterstaining the nucleus (Figure 4.24).  
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Figure 4.24: CD133, ROBO2 and β-catenin staining in transient shROBO2 transfected Huh7 cells. 
Transient shROBO2 transfected Huh7 cells were stained with either CD133 (A), ROBO2 (B), or β-catenin (C) 
specific antibodies and labelled with a red-flourescence giving Alexa568 secondary antibody. The shRNAmir 
expressing cells were producing green flourescence, expressed from pGIPZ vector’s IRES-GFP sequence that is 
located 3’ to shRNAmir. Nucleus was stained with DAPI.   
 
4.2.7 CD133 expression in HCC cell lines 
CD133 was proposed to be a HCC cancer stem cell marker and CD133+ cells tumor cells 
showed increased xenograft tumor size and number (Ma, Lee et al. 2008). We checked the 
expression of CD133 mRNA and protein in selected HCC cell lines representing well- and 
poor-differentiated cells. In addition, we used two other cell lines: HEK293 and a known 
CD133+ cell line NTERA-2 cl.D1. CD133 mRNA and protein was present in Hep3B, PLC 
and Huh7 (Figure 4.25). In  QRT-PCR experiment NT2 was taken as the reference.  
 
Figure 4.25: CD133 expression in HCC cell lines. The expression of CD133 was confirmed by both QRT-PCR 
and western blot. The results were parallel and of the analyzed HCC cell lines; Hep3B, Huh7 and PLC cell lines 
were positive for CD133 expression. In  QRT-PCR experiment NT2 was taken as the reference.  
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4.2.8 Effect of ROBO2 expression on CD133 
In microarray analysis and semi-quantitative RT-PCR experiments, we observed a CD133 
upregulation in stable ROBO2 knockdown clones. We decided to further characterize the 
effect of ROBO2 on CD133 expression.  The expression of CD133 was confirmed in stable 
clones by QRT-PCR and western blot experiments. Parallel to the results obtained in both 
microarray analysis and semi-quantitative RT-PCR experiments, CD133 expression was 
found to be upregulated in stable ROBO2 knockdown clones (Figure 4.26). In addition we 
performed immunoflourescence experiments in R2C10 and NC4 clones (Figure 4.27). CD133 
is known to be a membrane protein. Interestingly, in immunoflourescence experiments 
nucleus located multiple spots were observed in both NC4 and Huh7. These spots were also 
present in R2C10 but there was also membrane staining.  
 
 
Figure 4.26: CD133 expression in selected stable clones. The expression of CD133 was confirmed by both 
QRT-PCR and western blot. The results were parallel with the previous microarray and semi-quantitative PCR 
experiments. In  QRT-PCR experiment parental Huh7 was taken as the reference.  
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Figure 4.27: CD133 immunoflourescence staining in R2C10, NC4 clones and parental Huh7 cells. 
 
In order to investigate the possible effect of ROBO2 overexpression to CD133 expression in 
stable ROBO2 knockdown clones, we re-introduced ROBO2 into stable ROBO2 knockdown 
clones with pDEST26-ROBO2 overepression vector. pDEST26-ROBO2 plasmid was 
transfected into R2C7, R2C9 and R2C10 clones and SK Hep1, Snu449 (which were originally 
negative for ROBO2 expression) and parental Huh7 HCC cell lines. Re-introduction of 
ROBO2 into R2C7, RC9 and R2C10 stable clones had no apparent effect on CD133 
expression (Figure 4.28). However in parental Huh7 cells ROBO2 overexpression decreased 
CD133 expression to some extent. The ROBO2 and CD133 non-expressing SK Hep1 and 
Snu449 cells were used as positive controls for ROBO2 overexpression.  
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Figure 4.28: ROBO2 re-introduction into selected stable ROBO2 knockdown clones had no apparent 
effect on CD133 expression. pDEST26-ROBO2 overexpression vector was transfected into R2C7, R2C9 and 
R2C10 clones and SK Hep1, Snu449 and parental Huh7 cell lines. Western blot experiments were performed 
using ROBO2 and CD133 antibodies. Tubulin was used for equal-loading. 
 
4.2.9 Proliferation rate of stable ROBO2 knockdown clones were diminished 
It was taking longer for ROBO2 knockdown clones to reach confluency than negative clones. 
This led us to test the proliferation rates of stable clones. We compared the proliferation rates 
of the stable clones by BrdU assay. We incubated our clones with BrdU for 24 hours and 
performed immunoflourescence staining using BrdU antibody. Cells that were positive as 
well as those that were negative for BrdU incorporation could clearly be distinguished under 
fluorescence microscope. Percent BrdU positivity was calculated and plotted for each stable 
lone (Figure 4.29 A). Average percent BrdU positivity of shROBO2 clones and shNon-
tergeting clones were calculated and T-test was applied (Figure 4.29 B). Proliferation rate of 
ROBO2 knockdown clones was significantly lower than that of negative clones. 
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Figure 4.29: Percent BrdU incorporation in stable clones after 24 hours incubation in the presence of 
BrdU. Cells were incubated with BrdU for 24 hours and then stained with anti-BrdU antibody. A) Stained cells 
were counted and plotted against DAPI stained total cell nımber and given as percent BrdU positive cells. B) 
Average of three shROBO2 and shNon-targeting clones were plotted and T-test was applied to find significance.   
 
 
In our microarray analysis p15 (CDKN2B), which is a cell cycle inhibitor, was found to be 
upregulated in stable ROBO2 knockdown clones by 1.3 fold. Thus, we suspected upregulation 
of p15 as the cause of the observed decrease in proliferation rate of ROBO2 knockdown 
clones. We checked p15 expression in selected stable clones by western blot and QRT-PCR. 
There was not an apparent difference in p15 protein levels between ROBO2 knockdown and 
negative clones (Figure 4.30 A). Although clones expressed p15 isoforms differentially, there 
was not any apparent trend associated with ROBO2 knockdown (Figure 4.30 B).  
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Figure 4.30: p15 expression in selected stable clones. The expression of p15 in selected stable clones and 
parental Huh7 was checked by western blot (A). Tubulin was used as equal loading control. In QRT-PCR 
experiments, expressions of both p15 isoforms were relatively quantified taking Huh7 as the reference sample 
(B).   
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5       DISCUSSION AND CONCLUSION 
 
5.1 Expression signature of SLIT-ROBO genes in HCC 
A collective analysis of expression of SLIT-ROBO family genes has not been assessed yet in 
liver tumor. In this study, we showed the co-regulation of SLIT-ROBO genes in HCC. In the 
HCC cell lines and liver tissues, ROBO1, ROBO2, SLIT1, and ROBO4, SLIT2, SLIT3 showed 
coordinate expression as two distinct modules, yet displayed high variability at gene level 
within each module. Additionally, SLIT-ROBO expression was able to predict AFP status of 
HCC cell lines, and thereby establishing two groups with low- and high-AFP expressions. All 
the analyzed genes were expressed at different levels, except ROBO3. A preferential up- and 
down-regulation of SLIT-ROBO genes occurred depending on the AFP expression status of 
HCC cell lines. ROBO1, ROBO2 and to a lesser extent SLIT1 were overexpressed, whereas 
SLIT3 was underexpressed in high-AFP group. ROBO4 also tended to be downregulated in 
this group. However, SLIT2 was expressed in most of the cell lines, regardless of the AFP 
expression status. 
 
AFP is the main component of mammalian fetal serum and is synthesized by visceral 
endoderm of the yolk sac and by fetal liver. The expression of AFP is reactivated in liver 
tumors and germ cell tumors such as yolk sac tumor and teratocarcinomas. About 50% to 
70% of HCC patients produce very high levels of AFP, whereas most hepatoblastoma patients 
produce AFP. Because AFP expression in germ cell tumors and hepatoblastoma is related to 
their cellular origin in yolk sac and fetal liver cells, it has been proposed that AFP expression 
in HCC could be related to its possible origin from progenitor liver cells, oval cells, or their 
close descendants (Sell 1993; Abelev and Eraiser 1999). Previously, Lee and Thorgeirsson 
described two molecular subgroups of HCC cell lines that are characterized by their AFP 
expression. They used 19 cell lines including the 13 cell lines (except Mahlavu) used in this 
study. In their microarray study, cell lines with low AFP profile (including Focus, SK Hep1, 
Snu387, Snu423, Snu449 and Snu475) showed upregulation of genes related to metastasis and 
cell motility whereas cell lines with high AFP profile (HepG2, Hep3B, Hep3B-TR, Hep40, 
HUH7 and PLC/PRF/5) did not. The latter group was clustered together with a 
hepatoblastoma cell line (HepG2) indicating their origin from progenitor cells, or 
dedifferentiation during tumorigenesis (Lee and Thorgeirsson 2002). In our clustering 
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analysis, HCC cell lines was subgrouped with respect to their SLIT-ROBO expression pattern 
and this clustering predicted the AFP positivity of the cell lines. HepG2, Snu398, PLC/PRF/5, 
HUH7, Hep3B-TR, Hep3B and Hep40 formed the AFP-positive group, namely Group2. 
These cell lines were mainly well-differentiated and possess the markers of their tissue of 
origin. Interestingly, Snu398 which was described as a poorly differentiated AFP-negative 
cell line clustered also in Group2. In this respect, Snu398 was a marginal cell line showing a 
quite unexpected SLIT-ROBO expression pattern. HepG2, another member of Group2, is a 
hepatoblastoma derived cell line. Co-clustering of other Group2 members with HepG2 
indicates that they show a progenitor cell phenotype. Indeed, recent findings propose CD133 
as a cancer stem marker and Hep3B, HUH7, PLC/PRF/5 to express this marker with differing 
levels. Our CD133 protein and mRNA expression analysis was in parallel to these findings 
and confirms the progenitor cell character of these cell lines in Group2. Hep3B-TR is a TGF-
β resistant clone derived form Hep3B, so their close neighboring was expected in cluster 
analysis. 
 
We also quantified SLIT-ROBO expression in 8 tumor adjacent normal liver tissues and 35 
HCC tumors. We found that genewise clustering observed in HCC cell lines were conserved 
in tissues: ROBO1, ROBO2, SLIT1 and ROBO4, SLIT2, SLIT3 were coordinately expressed, 
respectively. In cluster analysis, two main subgroups in tissue samples were observed but this 
was not dependent on AFP expression, converse to the case in HCC cell lines. AFP and 
ROBO1 expression was significantly correlated in both HCC cell lines and tissues. The 
observed difference between cell line and tissue data regarding AFP might be partly due to the 
heterogeneity of tissues. HCC cell lines were more homogenous when compared to tissue 
samples, which may contain stromal cells, endothelial cells, immune cells or any other tumor 
infiltrating cells. Moreover, our normal liver samples were tumor-adjacent tissues, which may 
harbor genetic changes of tumor microenvironment, and therefore may not reveal the actual 
molecular characteristics of a tumor free normal liver.         
 
In the entire HCC cell lines studied, ROBO1 transcript was present and it was significantly 
upregulated in the analyzed HCC tissues. In these tissues, ROBO1 was overexpressed in later 
stages and as tumors progress to a less differentiated state. During the course of this study, a 
research article was published suggesting ROBO1 as an HCC antigen and proposing it as both 
a diagnostic marker and therapeutic target for HCC. This result was in agreement with our 
findings in Oncomine database search and expression analyses. In most of the tissues and in 
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all of the HCC cell lines (although variable) SLIT2 was expressed. Such a variance in HCC 
cell lines might explain the clustering of SLIT2 in a different group than ROBO1 and ROBO2, 
yet it is likely to be the main ligand for ROBO receptors. This does not exclude interactions 
between other SLIT and ROBO members. In addition, possible ligand independent activities 
of ROBO receptors still remain in HCC. SLIT2 and ROBO1 were both upregulated in HCCs 
with advanced stages and poor differentiation status (Figure 4.8 and Table 4.7). These 
findings also are in agreement with the expression of SLITs specifically in poorly 
differentiated HCCs (Ito, Funahashi et al. 2006). In a tumor xenograft model, SLIT2-ROBO1 
signaling was shown to have a role in angiogenesis, which supports tumor growth and 
metastasis (Wang, Xiao et al. 2003). Thus, collective behavior of ROBO1, ROBO4 and SLIT2 
expression may be used as diagnostic markers in HCC progression.  
 
Prior studies showed that ROBO4 was specific to vasculature (Park, Morrison et al. 2003), but 
we observed varying levels of ROBO4 transcript in HCC cell lines. The ROBO4 transcripts in 
these cells might be partly explained by the presence of side population cells with stem cell 
characteristics that express markers of the vascular endothelium (Ma, Chan et al. 2007). 
ROBO4 may be subject to a transcriptional regulational circuitry in liver tumors. In liver 
tissues, ROBO4 expression was significantly downregulated in poorly differentiated tumors 
suggesting that ROBO4 function is not essential for the maintenance of tumor at this step of 
hepatocarcinogenesis. Recent findings indicated that SLIT2-ROBO4 interactions inhibited 
angiogenesis, which may be an explanation for its downregulation in our analysis (Jones, 
London et al. 2008). 
 
Interestingly, we could not find ROBO3 transcript virtually in all of the HCC cell lines. The 
ROBO1 regulation in commissural axon guidance exerted by ROBO3 resulting in functional 
inhibition of ROBO1 may be a reason for this observation. Since ROBO1 was overexpressed 
and seem to be essential for tumor cells, absence of a negative regulator of ROBO1- in this 
case ROBO3- seems to be plausible in HCC.  
 
CAE of zebrafish was transcribed in most of the non-neuronal tissues while it was either 
absent or expressed at a very low level in the brain, eye, and heart. Furthermore, the isoform-
specific expression of robo2 appeared to be tightly controlled during development such that 
zebrafish larvae exhibited an expressional induction of robo2_tv1 and robo2_tv2 at around the 
mid-larval stages. These findings might implicate robo2_tv2 in a role in tissue 
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morphogenesis, during which cell growth/migration is temporally and spatially regulated. The 
differential expression of robo2 isoforms in neuronal and non-neuronal tissues could become 
a source of variation in the function of robo2, possibly directed by different regulatory 
processes. These findings point to the existence of multiple robo2 proteins; thus, it is critical 
to identify which form is involved in a specific developmental process or event in 
pathogenesis (Dalkic, Kuscu et al. 2006). Regarding the recently defined CAE and new 
ROBO2 transcript variant- ROBO2-tv2, this study is the first showing the presence of the 
ROBO2-tv2 in a pathologic condition, in this case hepatocellular carcinoma. It is interesting 
that the CAE is conserved between ROBO1, ROBO2 and ROBO4 tarnscripts in in silico 
analysis. The only member lacking CAE is ROBO3.  
 
5.2 ROBO2 knockdown phenotype in Huh7 hepatocellular carcinoma cells 
The expression of ROBO2 in HCC cell lines was appealing such that it distinguishes the AFP 
positive and negative cell lines. ROBO2 was overexpressed in AFP positive cell lines. This 
observation led us to propose that silencing of ROBO2 may furnish the AFP positive cells 
with a phenotype resembling the AFP negative cells, possibly with higher migration ability 
since AFP negative SK Hep1 was shown to be highly motile. We knocked down ROBO2 
expression in Huh7 and obtained stable clones. In wound healing assays the migratory 
behavior of ROBO2 knockdown and negative clones were not different. We found that E-
cadherin expression was upregulated in ROBO2 knockdown clones and in parallel expression 
of SLUG, which is a transcriptional suppressor of E-cadherin, was downregulated in these 
clones. These results were converse to our preliminary proposal that ROBO2 knockdown may 
result in a more motile cellular phenotype, rather expression of E-cadherin which is a cell-to-
cell adhesion molecule and conserved in epithelial cells was upregulated. But this may be 
because of the weaknesses of our experimental setup; the effect of secreted SLITs and 
receptor redundancy between ROBO members should be taken into account in other 
conditions where SLIT2 and/or ROBO1 was depleted using shRNAs targeting them since 
ROBO2 independent signaling may be in play.    
  
We also analyzed the differentially expressed genes in a microarray experiment. We found 
that QRT-PCR experiments verify our microarray experiment. In the pathway analysis, cell 
adhesion molecules (CAMs), axon guidance, ECM-receptor interaction, focal adhesion and 
regulation of actin cytoskeleton pathway genes which may be structurally or functionally 
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related to SLIT-ROBO signaling were found to be enriched. Interestingly, 
phosphatidylinositol signaling system, and complement and coagulation cascades that were 
not previously associated with any of the SLIT-ROBO genes were also in the top levels of the 
list.  
 
In the microarray analysis, we found that markers of the side population, cancer stem cell or 
pluripotency phenotypes were upregulated in ROBO2 knockdown clones. We further 
confirmed these results by semi-quantitative RT-PCR.  CD133 was recently proposed as a 
cancer stem cell marker. CD133 has seven transcripts and additionally it is 
posttranscriptionally modified and also known as AC133. We further confirmed its 
upregulation at protein level by western blot in ROBO2 knockdown clones. In HCC cell lines, 
CD133 was expressed in well-differentiated, AFP positive cells parallel to the literature data. 
Huh7 was the cell line that we used to establish stable clones, but it is known that it has 
plasticity showing the ability to give rise to senescence or replication programmed clones 
(Ozturk, Erdal et al. 2006). In order to determine whether the CD133 and other pluripotency 
marker overexpression was dependent on clonogenicity or ROBO2 knockdown we also 
performed transient transfection experiments but we could not confirmed the results that we 
obtained in stable cells. The effects of transient shROBO2 transfection in other HCC cell lines 
have not been investigated but this may result in a completely different scenario than we 
observed in Huh7 cells.   
 
p15 (CDKN2B) which is a well-known cell cycle inhibitor was another upregulated transcript 
in our microarray gene list in ROBO2 knockdown clones. We checked for its expression by 
both QRT-PCR and western blot but we could not confirm the upregulation. Furthermore, we 
found that stable ROBO2 knockdown clones have significantly lower proliferation rates. This 
seems to not depend on p15 levels, but there may be other cell cycle regulators controlling the 
proliferation of these clones.   
 
In the microarray experiment, we pooled total RNAs of 8 ROBO2 KD and 4 control clones, 
separately but we observed that individual clones differed in their expression of the analyzed 
genes. In addition, individual clones showed different EMT marker and p15 expression 
patterns. In upcoming investigations with these clones, may be it would be better to use a 
limited panel of ROBO2 KD and control clones that reflect the expected ROBO2 expression 
levels the utmost.      
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6 FUTURE PERSPECTIVES 
 
Here, we defined the overexpression of ROBO1 and the variable expression of other SLIT-
ROBO family members in HCC. Our results help increase our understanding of pathological 
expression pattern of SLIT-ROBO family in HCC with potential for diagnostic applications. 
Elucidation of the mechanisms acting on the transcriptional regulation of SLIT-ROBO 
signaling pathway, such as alternative splicing, copy number variability and ligand/ receptor 
redundancy in both HCC and other pathophysiological contexts will contribute to a better 
understanding of hepatocarcinogenesis. We propose that the use of ROBO1 and ROBO4 
expression as markers in early diagnosis of HCC shall have important implications. 
 
In our cluster analysis, we found a conserved genewise clustering in both HCC cell lines and 
liver tissues. The founder members of the two gene clusters in these analyses seem to be 
ROBO1 in one gene set and SLIT2 in the other. Several reports suggest a role for SLIT2 as a 
tumor suppressor and it was verified in different experimental setups that SLIT2 was silenced 
by methylation in tumors of various tissues including human HCC which was described in a 
quite recent report (Jin, You et al. 2009). Converse to SLIT2, ROBO1 was shown to be 
overexpressed in HCCs and proposed as a potential diagnostic and therapeutic target in HCC 
(Ito, Funahashi et al. 2006). Given the above mentioned results and our findings in HCC 
tissues, there appears a two way regulation among SLIT-ROBO genes during 
hepatocarcinogenesis. One is the possible oncogenic effect of genes clustered with ROBO1 
that are ROBO2 and SLIT1. Second is the possible tumor suppressor effect of genes clustered 
with SLIT2 that are SLIT3 and ROBO4. In fact, in a recent report it was shown that ROBO4 
maintains the vascular integrity by inhibiting the pathologic angiogenesis and endothelial 
hyperpermeability (Jones, London et al. 2008). This is in parallel to our findings showing the 
downregulation of ROBO4 in tumors when compared to normal tissues and additional 
decreasing trend in ROBO4 expression as the tumors differentiate to a poor phenotype. 
Nevertheless, these possible proposed roles of ROBO2, ROBO4, SLIT1 and SLIT3 should be 
checked in the context of HCC. The effects of individual SLIT-ROBO genes and also their 
combinatorial effects should be described in detail by functional analyses. Further studies 
investigating potential methylation and inactivation of SLIT3 and ROBO4 should be done in 
order to rule out these presumptions. 
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In the light of all these findings, it is very likely that SLIT2-ROBO1-ROBO4 might contribute 
to some of the variability associated with the differentiation status of HCC while expression 
of ROBO1 and SLIT2 also helps explain the stage differences in this cancer. However, the 
expression variability is high among liver tumors suggesting that a combinatorial code with a 
possibility of ligand redundancy might be at work in hepotocellular carcinoma, which 
prompts further functional studies that include knockdown and overexpression of the above 
mentioned individual genes. 
 
A global gene expression analysis by microarray technology in 19 HCC cell lines revealed 
two molecular subtypes depending on their AFP expression level (Lee and Thorgeirsson 
2002). Of 14 HCC cell lines that we studied, 13 were included in that study and the SLIT-
ROBO dependent subgrouping in our analysis was parallel to the AFP subgrouping previously 
observed, verifying the reliability of our cell line panel. ROBO1 and SLIT3 were the genes 
that were most significantly correlated with AFP expression in a positive and negative 
manner, respectively. Genes regulating extracellular matrix establishment or remodeling and 
cell adhesion were differentially expressed between the HCC cell line subgroups. Cells that 
were defined to be more metastatic and motile correspond to cell lines that were clustered as 
Group I in our study. Given the important roles of SLIT-ROBO associated signaling 
molecules like ENA, ABL, and several GTPase activating proteins in cytoskeletal 
reorganization and cell motility, the connection between SLIT-ROBO signaling and HCC 
tumor cell invasion and metastasis remains to be further described (Bashaw, Kidd et al. 2000; 
Wong, Ren et al. 2001). SLIT-ROBO interaction represents another level of control on Abl 
kinase which is known to be translocated (forming Philadelphia chromosome) and activated 
in chronic myelogenic leukemia (CML) patients. Furthermore, in a limited number (1.6%) of 
acute lymphoblastic leukemia (ALL) cases, this has been related to poor prognosis 
(Pakakasama, Kajanachumpol et al. 2008). The association between SLIT-ROBO interaction 
and Abl activity may have crucial implications on treatment of the above mentioned leukemic 
cases.    
 
Another observation related to CD133 was that its overexpression pattern in ROBO2 
knockdown clones did not change during long-term cultivation in cell culture. This 
observation raises the possibility that the effect of ROBO2 may be upstream of the CD133 
and at transcriptional level. A comparative genomics study on gene encoding CD133 
(PROM1) showed that tandem TCF/LEF-binding sites were present within intron 2 of the 
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gene and they were conserved among human, chimpanzee, mouse, and rat orthologs (Katoh 
and Katoh 2007). Slit induced formation of the Robo-N-cadherin complex results in a rapid 
loss of cadherin-mediated adhesion and has more lasting effects on gene transcription through 
Abl-mediated phosphorylation of β-catenin on tyrosine 489, leading to a decrease in its 
affinity for N-cadherin, loss of N-cadherin function, and targeting of phospho-Y489-β-catenin 
to the nucleus (Rhee, Buchan et al. 2007). This established connection between SLIT-ROBO 
interaction and β-catenin may be effective on human CD133 gene expression through the 
described TCF/LEF-binfing sites in intron 2 of the gene. This possible connection should be 
further examined and evaluated in an experimental setup for example using luciferase 
constructs containing several fragments of CD133 gene promoter and intron 2. 
 
The absence of ROBO3 transcript in HCC cell lines requires further investigation and 
explanation. It is plausible that ROBO3 was downregulated in a microenvironment in which 
ROBO1 was highly expressed since they are known to show contradictory roles in 
commissural axon guidance. The mechanism in which ROBO3 expression was suppressed 
should be further characterized. Indeed, ROBO3 promoter methylation analysis performed in 
our laboratory in HCC cell lines suspected epigenetic control as an operator. The situation in 
HCC tumor tissues from patients should be checked in following studies. In this respect, the 
CAE which codes for a short peptide that is present in ROBO1, ROBO2 and ROBO4 but 
lacks in ROBO3 requires further attention since the CAE is located in between conserved 
cytoplasmic regions of ROBOs and may have a role in the interaction with downstream 
molecules that have signaling activities.   
 
The cellular phenotype associated with ROBO2 should be clarified in detail. BrdU 
incorporation assays had given promising results indicating a decrease in cellular proliferation 
in ROBO2 knockdown clones. The mechanism of this change was not dependent on p15 
which is a cell cycle inhibitor but the possible connection with other cell cycle regulators in 
the light of miroarray results should further be followed. In wound healing assay, there was 
not a significant change in the migration rates of ROBO2 knockdown clones and negative 
clones. However the effect of SLIT ligands in these clones should be analyzed in another 
experimental setup like transwell migration assays and using conditioned medium with 
ROBO ligands. It is known that SLIT-ROBO interaction has inhibitory effects on other 
migration inducing ligand-receptor interactions like c-met/HGF or SDF1/CXCR4. This 
interplay between different signaling receptors should be analyzed in HCC cell migration and 
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also invasion. In these experiments, another level of complication may be the possible 
redundancy between ROBO receptors. So, the contribution of the individual ROBO receptors 
to these proccesses is an open-end to be analyzed.     
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Abstract
Background: SLIT-ROBO families of proteins mediate axon pathfinding and their expression is
not solely confined to nervous system. Aberrant expression of SLIT-ROBO genes was repeatedly
shown in a wide variety of cancers, yet data about their collective behavior in hepatocellular
carcinoma (HCC) is missing. Hence, we quantified SLIT-ROBO transcripts in HCC cell lines, and in
normal and tumor tissues from liver.
Methods: Expression of SLIT-ROBO family members was quantified by real-time qRT-PCR in 14
HCC cell lines, 8 normal and 35 tumor tissues from the liver. ANOVA and Pearson's correlation
analyses were performed in R environment, and different clinicopathological subgroups were
pairwise compared in Minitab. Gene expression matrices of cell lines and tissues were analyzed by
Mantel's association test.
Results: Genewise hierarchical clustering revealed two subgroups with coordinate expression
pattern in both the HCC cell lines and tissues: ROBO1, ROBO2, SLIT1 in one cluster, and ROBO4,
SLIT2, SLIT3 in the other, respectively. Moreover, SLIT-ROBO expression predicted AFP-dependent
subgrouping of HCC cell lines, but not that of liver tissues. ROBO1 and ROBO2 were significantly
up-regulated, whereas SLIT3 was significantly down-regulated in cell lines with high-AFP background.
When compared to normal liver tissue, ROBO1 was found to be significantly overexpressed, while
ROBO4 was down-regulated in HCC. We also observed that ROBO1 and SLIT2 differentiated
histopathological subgroups of liver tissues depending on both tumor staging and differentiation
status. However, ROBO4 could discriminate poorly differentiated HCC from other subgroups.
Conclusion: The present study is the first in comprehensive and quantitative evaluation of SLIT-
ROBO family gene expression in HCC, and suggests that the expression of SLIT-ROBO genes is
regulated in hepatocarcinogenesis. Our results implicate that SLIT-ROBO transcription profile is bi-
modular in nature, and that each module shows intrinsic variability. We also provide quantitative
evidence for potential use of ROBO1, ROBO4 and SLIT2 for prediction of tumor stage and
differentiation status.
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Drosophila slit and roundabout (robo) genes were identified
in genetic screens of mutants for embryonic patterning
and commissural axon pathfinding defects [1]. Subse-
quently, it was shown that SLIT acts as a ligand for ROBO
receptor, preventing axons from recrossing the central
nervous system (CNS) midline, and that this binding is
conserved among vertebrates including mammals [2,3].
In mammals, three SLIT (SLIT1-3) and four ROBO
(ROBO1-4) genes have been described [4,5].
SLIT and ROBO genes are mainly expressed in the CNS
but there are affirmative data that they are also expressed
in non-neuronal tissues, such as mouse lung and kidney
[6,7]. Binding of SLIT2 to ROBO1 inhibits CXCL12-
induced chemotaxis of leukocytes, T cells and monocytes
[8-10]. However, ROBO4 expression has been found to be
confined to vasculature and Robo4 signaling modulates
endothelial cell migration [11].
On the other hand, like other developmental pathways,
aberrant expression of the SLIT-ROBO genes has been
observed in a wide variety of cancers. Mice with targeted
homozygous deletion of first Ig domain of Robo1/Dutt1
died at birth because of abnormal lung development, and
few survivors eventually developed epithelial bronchial
hyperplasia [6]. In breast carcinoma tissue samples
ROBO1 was shown to be overexpressed while SLIT2
induced migration of breast cancer cell lines [12]. SLIT2-
ROBO1 signaling was involved in angiogenesis by
increasing microvessel density and tumor mass in a tumor
xenograft model [13]. In the same study, SLIT2 exhibited
overexpression in tumor cell lines and primary tumors of
a variety of tissues. In contrast, SLIT2 also was proposed
to be a tumor suppressor gene, which was silenced epige-
netically in lung, breast, colon cancers and gliomas [14-
16]. SLIT3 was silenced by promoter hypermethylation in
gliomas and colorectal cancers [17]. SLIT1 and SLIT3 were
overexpressed in prostate tumors [18], whereas along with
SLIT2 they were slightly expressed only in poorly differen-
tiated HCC [19]. CXCL12 was reported to activate the
migration of human melanoma and breast cancer cells
that express CXCR4, ROBO1 and ROBO2, while SLIT2-
ROBO interaction was demonstrated to inhibit chemo-
taxis, chemoinvasion and adhesion of breast cancer cells
[20]. Furthermore, ROBO4 was overexpressed in tumor
endothelial cells in comparison to normal adult endothe-
lial cells [21].
Despite the compiling evidence of SLIT-ROBO deregula-
tion in various tumors, only few reports with apparent
controversies exist with regard to the expression pattern of
these genes in hepatocellular carcinoma (HCC). The over-
expression of ROBO1 in HCC was recently reported and
this receptor was proposed as an HCC marker in humans
[19]. In contrast, another study reported that Robo1 heter-
ozygous mice developed spontaneous HCC tumors [22].
It was shown by immunohistochemical staining that
SLIT2 protein also was present in HCC tumor sections
[13]. Moreover, karyotyping analyses of HCC do not
reveal any chromosomal gains or losses associated with
SLIT-ROBO genes [23,24]. Therefore, in this study, we
quantified SLIT1, SLIT2, SLIT3, ROBO1, ROBO2 and
ROBO4 transcripts in HCC cell lines and tissues. We
observed that SLIT-ROBO genes could be partitioned into
two main clusters based on their expression in either the
HCC cell lines or tissues. SLIT-ROBO expression also clus-
tered the HCC cell lines in two groups according to their
AFP expression pattern. In liver tissues, differential expres-
sion of ROBO1, ROBO4 and SLIT2 was found to be asso-
ciated with clinicopathological parameters such as tumor
staging and differentiation. Herein, we describe a compre-
hensive SLIT-ROBO expression signature in HCC.
Methods
HCC Cell Lines and Tissues
13 hepatoma and 1 hepatoblastoma (HepG2) cell lines
were included in the study and cultured as previously
described [25]. Focus, Hep40, Hep3B, Hep3B-TR, HepG2,
HUH7, Mahlavu, PLC/PRF/5, SK Hep1 cells were cultured
in low-glucose DMEM supplemented with 10% FBS, 100
U/ml Penicillin-Streptomycin, and 0.1 mM non-essential
amino acids (HyClone, Utah, USA). SNU387, SNU398,
SNU423, SNU449, SNU475 cells were cultured in RPMI
1640 medium supplemented with 10% FBS, 100 U/ml
Penicillin-Streptomycin, 0.1 mM non-essential amino
acids (HyClone, Utah, USA). TissueScan Liver Cancer Tis-
sue qPCR Arrays, each containing 40 liver tumor and 8
tumor-adjacent normal tissue cDNAs, were purchased
from Origene Technologies, (Rockville, MD, USA). 5 non-
HCC tumor tissues consisting of 3 cholangiocarcinomas,
1 nodular hyperplasia and 1 liver adenoma were excluded
from the present study. Clinicopathological characteris-
tics of the tissues were presented in Additional file 1.
Primers
PCR primers for human SLITs, ROBO1 and ROBO2 were
previously described [18]. Human ROBO3, ROBO4 and
AFP (alpha-fetoprotein) primers were designed using
Primer3 and targeting exon-exon junctions in order to
prevent amplification of possible contaminating genomic
DNA [26]. Primer sequences were as follows: ROBO3 for-
ward 5'-CAGTGTCCGATGGAAGAAGG-3' and reverse 5'-
GTCCATCTCCTGCACATTGG-3', ROBO4 forward 5'-
GACACTTGGCGTTCCACCTC-3' and reverse 5'-AGAG-
CAAGGAGCGACGACAG-3', AFP forward 5'-AAAT-
GCGTTTCTCGTTGCTT-3' and reverse 5'-
CCAACACCAGGGTTTACTGG-3'. Primer pair for the
housekeeping gene GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) was described before [27]. ACTB (beta-Page 2 of 11
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Cancer Tissue qPCR Array 1 (Origene Technologies, Rock-
ville, MD, USA).
RNA Isolation and cDNA Synthesis
Cell lines were grown to confluency in 100 mm dishes.
Total RNA was extracted using RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to manufacturer's instruc-
tions. cDNA was synthesized with random hexamers from
1 μg of total RNA using DyNAmo™ cDNA Synthesis Kit
(Finnzymes, Espoo, Finland).
Real-time Quantitative RT-PCR Analyses of HCC Cell 
Lines
In cell lines and tissues, the relative expression ratio (R) of
SLIT-ROBO and AFP transcripts (target gene) was meas-
ured based on a modified ΔΔCt formula [28] and normal-
ized to GAPDH or ACTB (reference gene). In
formula, Etarget and Erefreflect PCR efficiencies of the prim-
ers for target genes and reference genes, respectively. PCR
efficiency values for each primer pair was obtained by
constructing a standard curve using threshold cycle (Ct)
values derived from 6 data points, corresponding to 2-fold
decrements of an original cDNA stock (duplicates were
prepared for each dilution). The slope of the resulting
curve was used to calculate the E value of primer pairs
according to E = 2-1/slope formula. PCR efficiencies of the
genes ranged between 1.9 and 2.0. ΔCt was the difference
between the Ct values of controls and samples.
In cell lines, GAPDH was the reference gene. ΔCt values
were obtained by subtracting Ct values of individual genes
(sample) from the average Ct value of all cell lines for that
gene (control). All reactions were performed in duplicates
and repeated at least twice using different batches of RNA
preparations. Relative expression tables were established
by representing ΔΔCt values in log2 base, and in all subse-
quent analyses these values were used.
Quantitative expression analyses were performed using
DyNAmo™ HS SYBR® Green qPCR Kit (Finnzymes, Espoo,
Finland) on an iCycler iQ real-time PCR detection system
(Bio-Rad, Richmond, CA). The PCR reaction was set
according to the manufacturer's recommendations.
Briefly for 1× reaction; 10 μl of 2× SYBR Green PCR Master
Mix, 10 μM forward and reverse primers, and 1 μl of tem-
plate cDNA were mixed in a total volume of 20 μl. After
an initial 15 minutes of denaturation at 95°C, thermal
cycling was performed at 94°C for 30 sec, 60–62°C for 30
sec (optimized for each primer pair), 72°C for 30 sec for
a total of 50 cycles and a final extension step at 72°C for
10 min. In order to validate the production of a single tar-
get-specific PCR product, the amplification was followed
by a melt curve protocol with an initial step at 55°C for 30
sec and 80 repeats of 0.5°C increments with 15 sec dwell
time, from 55°C to 95°C.
Real-time Quantitative RT-PCR Analyses of HCC Tissues
The expression of SLIT-ROBO and AFP genes in HCC was
analyzed using a 96-well plate format TissueScan Liver
Cancer Tissue qPCR Array 1 (Origene Technologies, Rock-
ville, MD), which contained tissue cDNAs normalized
against beta-actin. Real-time PCR protocol was applied as
described by the manufacturer. Briefly, 30 μl of reaction
mix containing 15 μl 2× SYBR Green PCR Master Mix and
10 μM forward and reverse primers was directly added to
PCR-plate wells. Plate was placed on ice for 15 min for
cDNAs to dissolve, and thermal cycling was performed
according to above mentioned protocol. For each gene,
mean Ct value of the normal tissue cDNAs was set as the
control group and relative quantitative expression values
were calculated with the ΔΔCt formula and were repre-
sented in log2 base by taking the ACTB Ct values as refer-
ence.
Statistical Analysis
Using one-way ANOVA in R, mean expression levels of
each gene were compared between high and low AFP
expressing groups of HCC cell lines; and also between
normal and tumor tissues of liver with respect to differen-
tiation or stage [29]. Pairwise comparisons were made
using Fisher's multiple pairwise comparison method in
Minitab® 13.20 Statistical Software (Minitab Inc. 2000).
Furthermore, two-way hierarchical cluster analysis was
used to group cell lines and liver tissues with respect to the
SLIT-ROBO expression patterns using Cluster and
TreeView [30]. Pairwise correlations between SLIT-ROBO
gene expression levels were calculated using Pearson's cor-
relation coefficient. Moreover, a Mantel's association test
was applied to compare cell line and tissue correlation
matrices [29].
Results
QRT-PCR analyses reveal an association between SLIT-
ROBO and AFP expression in HCC cell lines
We first investigated by RT-PCR the presence of SLIT-
ROBO transcripts in 13 HCC and 1 hepatoblastoma cell
lines. All genes were expressed at levels varying from none
to strong after 40 cycles of amplification (Additional file
2). Since HCC cell lines were previously reported to clus-
ter in two main molecular subtypes in terms of their alpha-
fetoprotein (AFP) expression [31] we quantified SLIT-
ROBO gene expression along with AFP transcript levels.
In our first set of qRT-PCR experiments, cell lines with
fibroblastoid morphology, including Focus, Mahlavu, SK
R E ECt control-sample Ct control-= ( ) /( )( ) (target ref
target refΔ Δ sample)Page 3 of 11
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SNU475, displayed low-AFP expression, while AFP was
found to be overexpressed in epitheloid Hep40, Hep3B,
Hep3B-TR, HepG2, HUH7 and PLC/PRF/5 cells (Figure
1). Second, we quantified SLIT-ROBO transcripts. ROBO2
and SLIT1 expression were up-regulated in high-AFP
group of cells, except HepG2, which underexpressed
ROBO2 (Additional file 3). On the other hand, both genes
were found to be overexpressed in SNU398, one of the
low-AFP group of cell lines. SLIT3 transcript levels sharply
contrasted those of ROBO2 and SLIT1. Except SNU398,
increased SLIT3 expression was found among low-AFP
expressing group of cell lines, and also in high-AFP
expressing Hep40 cell line. Interestingly, widespread
expression of ROBO1 transcripts that we observed in RT-
PCR turned out to be enhanced in cell lines with high-AFP
background (Additional file 2 and 3). ROBO4 and SLIT2
transcript levels remained variable among HCC cell lines
and no phenotype-based association could be observed
for these genes. Our attempts to calculate PCR efficiency
with two different ROBO3 primer pairs failed, and we dis-
continued qRT-PCR analysis of this gene.
A significant association of gene expression was found
among SLIT-ROBO family genes and AFP based on Pear-
son's pairwise correlation coefficients (Table 1). In partic-
ular, expressions of ROBO1 and SLIT3 were significantly
correlated with that of AFP, in a positive and negative
manner, respectively.
Cluster analyses identify two subgroups in HCC cell lines 
with respect to SLIT-ROBO expression levels
Hierarchical clustering was performed in order to under-
stand whether SLIT-ROBO expression predicts AFP-
dependent grouping of HCC cell lines. In fact, in terms of
SLIT-ROBO expression, low-AFP expressing SNU449,
SNU423, SNU475, Mahlavu, SK Hep1, SNU387, and
Focus cells grouped together (Group I), while high-AFP
expressing HepG2, PLC/PRF/5, HUH7, Hep3B-TR, HEP-
3B and Hep40 cell lines (Group II) clustered separately
from the first group (Figure 2). Exceptionally, SNU398
cell line displayed a SLIT-ROBO expression pattern con-
cordant with Group II despite its low-AFP background.
The expression of AFP significantly differed between the
two groups (p = 0.0001): Mean expression of AFP in
Group I and Group II cells was -4.65 ± 2.75 and 6.20 ±
4.68, respectively.
Hierarchical clustering analysis also revealed a genewise
segregation of SLIT-ROBO genes. Coordinate expression
was observed in two main clusters, one of which grouping
together ROBO1, ROBO2 and SLIT1, and the other
ROBO4, SLIT2, and SLIT3, respectively (Figure 2). We also
performed one-way ANOVA to identify individual SLIT-
ROBO genes, which significantly separate HCC cell lines
with high- and low-AFP expression. We validated that
ROBO1 and ROBO2 expression were up-regulated in
high-AFP group (p = 6.7 × 10-4 and p = 0.013, respec-
tively). Mean expression of ROBO1 in Group I was -1.73
± 2.15 while in Group II cells increased to 2.37 ± 0.48.
Similarly, ROBO2 mean expression values were found as -
2.37 ± 3.31 and 3.11 ± 3.73, for Group I and Group II,
respectively. In sharp contrast, SLIT3 was overexpressed in
cell lines with low-AFP profile (MeanGroupI = 3.28 ± 4.43,
MeanGroupII = -4.24 ± 4.06; p = 6.9 × 10-3).
SLIT-ROBO family expression profile in liver tissues 
correlates with that in HCC cell lines
Next, we addressed the question of whether our cell line
data translate to in vivo conditions. To this end, we quan-
tified the expression of SLIT-ROBO and AFP genes using
cDNAs of 8 tumor-adjacent normal and 35 tumor tissues
(Additional file 4). Accordingly, only ROBO1 was found
to be significantly overexpressed in tumor tissues (Mean-
Normal = 0 ± 0.63, MeanTumor = 1.57 ± 1.63; p = 0.011). We
also observed a down-regulated ROBO4 expression in
tumor tissues with a p-value near significance (MeanNormal
= 0 ± 1.03, MeanTumor = -0.89 ± 1.30; p = 0.079). AFP dis-
played a highly variable expression, yet it was overex-
pressed in more than half of the tumors (18/35)
(Additional file 4).
Hierarchical clustering grouped SLIT-ROBO genes in a
similar manner as in cell lines. ROBO1, ROBO2 and SLIT1
clustered together, whereas ROBO4, SLIT2 and SLIT3
Quantification of AFP transcript levels reveals two groups in HCC cell linesFigure 1
Quantification of AFP transcript levels reveals two 
groups in HCC cell lines. GAPDH normalized AFP expres-
sion was quantified by real-time RT-PCR and expression val-
ues of individual cell lines are calculated relative to the Ct 
average of all cell lines, and represented in log2 base. Samples 
were run in duplicates and the data are representative of two 
independent experiments.Page 4 of 11
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appeared among tissue samples; however, no significant
association of clusters was found with differentiation state
or staging of tumors (Wilcoxon rank sum test) and AFP
expression (one-way ANOVA).
Expression correlation amongst individual SLIT-ROBO
and AFP genes in liver tissues was analyzed by Pearson's
correlation analysis in R (Table 2). Accordingly, expres-
sion of ROBO1 in HCC samples was positively correlated
with that of AFP whereas ROBO4 and AFP were inversely
correlated in terms of their expression. Mantel's permuta-
tion test, performed to compare gene expression correla-
tion matrices of cell lines and tissues (described in Table
1 and Table 2, respectively), indicated that gene-to-gene
correlation patterns in both sample groups were signifi-
cantly associated (r = 0.49; p < 0.02).
ROBO1 expression differentiates normal tissues from 
tumors with respect to both stage and differentiation 
status
We also performed one-way ANOVA followed by Fisher's
multiple pairwise comparisons in order to explore
whether gene expression characteristics of SLIT-ROBO
family members discriminate among liver tissues with
respect to differentiation status and staging of the sam-
ples. The tissue samples lacking stage or differentiation
information in the pathological reports were left out of
analysis. With these criteria, a total of 43 liver tissue sam-
ples for stage and of 38 tissue samples for differentiation
status were analyzed. According to one-way ANOVA,
ROBO1 differentiated liver tissue samples on both the
stage (p = 0.018) and differentiation status (p = 0.031)
dependent manner (Figure 4A, B). ROBO4 expression sig-
nificantly discriminated tissues only with respect to their
differentiation status (p = 0.039) (Figure 4C). Moreover,
Fisher's pairwise comparison analyses revealed that
ROBO1, SLIT2 and ROBO4 significantly discriminated
between different histopathological subgroups both in
terms of differentiation status and/or tumor staging
(Table 3).
Discussion
HCC remains the fifth most common cancer worldwide
and is at the third rank in cancer-caused deaths. The prog-
nosis of patients is generally very poor with a 5-year rela-
tive survival of only 7% [32]. The elucidation of molecular
mechanisms governing hepatocarcinogenesis is therefore
of high priority not only for the better understanding of
the disease, but also to develop more effective therapies.
To achieve this goal, functional genomics studies could
provide valuable information with regard to genes differ-
entially expressed between HCC and normal liver. A col-
lective analysis of expression signature of SLIT-ROBO
family genes has not been assessed yet in liver tumor.
Here, we showed the co-regulation of SLIT-ROBO genes in
HCC. In both the HCC cell lines and liver tissues, ROBO1,
ROBO2, SLIT1, and ROBO4, SLIT2, SLIT3 showed coordi-
nate expression as two distinct modules, yet displaying
high variability at gene level within each module. Addi-
tionally, SLIT-ROBO expression was able to predict AFP
status of HCC cell lines, and thereby establishing two
groups with low- and high-AFP expressions.
Except ROBO3, all genes were found to be expressed at
different levels in our analyses. A preferential up- and
down-regulation of SLIT-ROBO genes occurred depend-
ing on the AFP expression status of HCC cell lines.
ROBO1, ROBO2 and to a lesser extent SLIT1 were overex-
pressed, whereas SLIT3 was underexpressed in high-AFP
Table 1: Genewise correlation of SLIT-ROBO and AFP genes in HCC cell lines
Gene ROBO1 ROBO2 ROBO4 SLIT1 SLIT2 SLIT3 AFP
ROBO1 1
ROBO2 0.6060* 1
ROBO4 -0.2721 -0.2653 1
SLIT1 0.4027 0.7623* -0.3288 1
SLIT2 0.1241 0.1891 0.5143 -0.0039 1
SLIT3 -0.5698* -0.6072* 0.3681 -0.5451* -0.1003 1
AFP 0.6533* 0.5108 -0.3016 0.4579 0.3544 -0.6605* 1
*: p < 0.05Page 5 of 11
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group. However, SLIT2 was expressed in most of the cell
lines, regardless of the AFP expression status.
We also quantified SLIT-ROBO expression in 8 tumor-
adjacent normal liver tissues and 35 HCC tumors. We
found that genewise clustering observed in HCC cell lines
were conserved in tissues: ROBO1, ROBO2, SLIT1 and
ROBO4, SLIT2, SLIT3 were coordinately expressed, respec-
tively. We also noticed two main subgroups in tissue sam-
ples but the observed AFP dependent subgrouping in
HCC cell lines did not translate into the tissue analysis,
except that AFP and ROBO1 expression was significantly
correlated in both HCC cell lines and tissues. This discrep-
SLIT-ROBO expression establishes two groups, which predict AFP expression levels in HCC cell linesFigure 2
SLIT-ROBO expression establishes two groups, which predict AFP expression levels in HCC cell lines. The means 
of normalized expression values of individual SLIT-ROBO genes in each cell line were used to establish the hierarchical clustering 
in Cluster program, and the results were visualized as a heatmap by TreeView. Overexpression and underexpression of indi-
vidual genes relative to Ct average of all cell lines are represented by red and green colors, respectively. Upper single-row heat-
map displays the average expression of all six genes across all cell lines. The tree at the top of the heatmap represents 
samplewise clustering. Based on their AFP expression levels, HCC cell lines are represented in two main subgroups indicated as 
Group I (low-AFP) and Group II (high-AFP) cells. The tree on the left of the heatmap (pink) represents genewise clustering.Page 6 of 11
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HCC cell lines were more homogenous when compared
to tissue samples, which may contain stromal cells,
endothelial cells, immune cells or any other tumor infil-
trating cells. Moreover, our normal liver samples were
tumor-adjacent tissues, which may harbor genetic
changes of tumor microenvironment, and therefore may
not reveal the actual molecular characteristics of a tumor-
free normal liver.
ROBO1 transcript was present in all cell lines that were
examined and it was significantly up-regulated in the ana-
lyzed HCC tissues, in which its overexpression culminated
in later stages and as tumors progress to a less differenti-
ated state. These data were in agreement with a recent
report that demonstrated ROBO1 as an HCC antigen and
proposing it as both a diagnostic marker and therapeutic
target for HCC [19]. SLIT2 was present in most of the
tumor tissues and HCC cell lines although at variable lev-
els. Such variability might explain the clustering of SLIT2
Genewise clustering of SLIT-ROBO genes in HCC cell lines translates into liver tissuesFigure 3
Genewise clustering of SLIT-ROBO genes in HCC cell lines translates into liver tissues. The normalized expression 
values of individual SLIT-ROBO genes in liver tissue samples (n = 43) were used to establish the hierarchical clustering in Cluster 
program and the results were visualized as a heatmap by TreeView. Overexpression and underexpression of individual genes 
relative to Ct average of normal tissues (n = 8) are represented by red and green colors, respectively. Upper single-row heat-
map displays the average expression of all six genes across all tissues. The tree at the top of the heatmap represents sample-
wise clustering, and the tree on the left of the heatmap (pink) represents genewise clustering. T1-35: tumors; N1-8: normal 
tissues; 0: stage 0 (non-tumor); 1, 2, 3A, 4: stage 1, stage 2, stage 3A, stage 4 HCC, respectively; N: tumor-adjacent normal tis-
sue; W: well-differentiated; M: moderately differentiated; P: poorly differentiated; N/A: not-assigned.
Table 2: Genewise correlation of SLIT-ROBO and AFP genes in liver tissues
Gene ROBO1 ROBO2 ROBO4 SLIT1 SLIT2 SLIT3 AFP
ROBO1 1
ROBO2 0.1835 1
ROBO4 -0.1879 -0.2134 1
SLIT1 0.0298 0.002 -0.3793* 1
SLIT2 -0.3679* -0.0078 0.3432* -0.1389 1
SLIT3 -0.0973 -0.0027 0.2596 -0.0965 0.6844*** 1
AFP 0.3679* 0.2324 -0.3699* 0.0924 -0.0769 -0.1638 1
***: p < 0.001; *: p < 0.05Page 7 of 11
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likely to be the main ligand for ROBO receptors. Never-
theless, this does not exclude interactions between other
SLIT and ROBO members, nor it does the possible ligand-
independent activities of ROBO receptors in HCC. Addi-
tionally, SLIT2 and ROBO1 were both upregulated in
HCCs with advanced stages and poor differentiation sta-
tus (Figure 3 and Table 3). These findings also are in agree-
ment with the expression of SLITs specifically in poorly
differentiated HCCs [19]. Furthermore, in a tumor
xenograft model, SLIT2-ROBO1 signaling was shown to
have a role in angiogenesis, which supports tumor growth
and metastasis [13].
Although ROBO4 was shown to be specific to vasculature
[11], we observed varying levels of ROBO4 transcript in
HCC cell lines. The ROBO4 transcripts in these cells might
be partly explained by the presence of side population
cells with stem cell characteristics that express markers of
the vascular endothelium [33]. One may also consider a
possible regulation of ROBO4 expression in liver tumors.
In tissue expression analyses, we found that ROBO4
ROBO1 and ROBO4 expression discriminate between different stage and differentiation groups of liver tissuesFigure 4
ROBO1 and ROBO4 expression discriminate between different stage and differentiation groups of liver tissues. 
Expression values of SLIT-ROBO genes were compared using one-way ANOVA in liver tissue samples that are stratified accord-
ing to their stages and differentiation status and represented as boxplots. (A) ROBO1 significantly differentiates one staging 
group from the others (p = 0.018). (B) The expression of ROBO1 also discriminates between different differentiation status of 
liver tissues (p = 0.031). (C) ROBO4 also significantly separates one differentiation group among all (p = 0.039).Page 8 of 11
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ferentiated tumors, indicating that ROBO4 function is not
essential for the maintenance of tumor at this step of
hepatocarcinogenesis. In fact, recent findings indicated
that SLIT2-ROBO4 interactions inhibited angiogenesis
[34].
It is very likely that SLIT2-ROBO1-ROBO4 might contrib-
ute to some of the variability associated with the differen-
tiation status of HCC while expression of ROBO1 and
SLIT2 also helps explain the stage differences in this can-
cer. However, the expression variability is high among
liver tumors suggesting that a combinatorial code with a
possibility of ligand redundancy might be at work in
hepotocellular carcinoma, which prompts further func-
tional studies that include knock-down and overexpres-
sion.
A global gene expression analysis by microarray technol-
ogy in 19 HCC cell lines revealed two molecular subtypes
depending on their AFP expression level [31]. Of 14 HCC
cell lines that we studied, 13 were included in that study
and the SLIT-ROBO dependent subgrouping in our analy-
sis was parallel to the AFP subgrouping previously
observed, verifying the reliability of our cell line panel.
ROBO1 and SLIT3 were the genes that were most signifi-
cantly correlated with AFP expression in a positive and
negative manner, respectively. Genes regulating extracel-
lular matrix establishment or remodeling and cell adhe-
sion were shown to be differentially expressed between
the HCC cell line subgroups [31]. Cells that were defined
to be more metastatic and motile correspond to cell lines
that cluster as Group I in our study. Given the important
roles of SLIT-ROBO associated signaling molecules like
ENA, ABL, and several GTPase activating proteins in
Table 3: Differentially expressed SLIT-ROBO genes between histopathological subgroups of liver tissues
Stage n Mean expression (SE) Differentially expressed gene*
0 8 0 (0.22) ROBO1
2 11 2.37 (0.41)
0 8 0 (0.22) ROBO1
3 13 1.43 (0.57)
1 9 0.79 (0.33) ROBO1
2 11 2.37 (0.41)
2 11 -2.29 (1.15) SLIT2
3 13 -0.96 (0.44)
Differentiation state n Mean expression (SE) Differentially expressed gene*
Normal 8 0 (0.22) ROBO1
Moderate 16 1.89 (0.44)
Normal 8 0 (0.22) ROBO1
Poor 6 1.84 (0.60)
Normal 8 0 (0.36) ROBO4
Poor 6 -2.02 (0.80)
Well 8 -0.60 (0.43) ROBO4
Poor 6 -2.02 (0.80)
Moderate 16 -0.66 (0.25) ROBO4
Poor 6 -2.02 (0.80)
Moderate 16 -1.28 (0.78) SLIT2
Poor 6 1.01 (0.88)
* Pairs of stage and differentiation subgroups were compared in Fisher's pairwise comparison analysis and only the genes that significantly 
discriminate between subgroups were represented (p < 0.05). SE: standard error.Page 9 of 11
(page number not for citation purposes)
BMC Cancer 2008, 8:392 http://www.biomedcentral.com/1471-2407/8/392cytoskeletal reorganization and cell motility [35,36], the
connection between SLIT-ROBO signaling and HCC
tumor cell invasion and metastasis remains to be further
described.
Conclusion
Here, we defined the overexpression of ROBO1 and the
variable expression of other SLIT-ROBO family members
in HCC. Especially, downregulation of ROBO4 and upreg-
ulation of SLIT2 mark late stage and poorly differentiated
HCCs. We have also shown that the collective expression
of these genes occurs in a coordinated fashion in two
main groups suggesting that SLIT-ROBO signaling is mod-
ular in nature, and that each module shows intrinsic vari-
ability. Our results help increase our understanding of
pathological expression pattern of SLIT-ROBO family in
HCC with potential for diagnostic applications. Elucida-
tion of the mechanisms acting on the transcriptional reg-
ulation of SLIT-ROBO signaling pathway, such as
alternative splicing, copy number variability and ligand/
receptor redundancy in both HCC and other pathophysi-
ological contexts will contribute to a better understanding
of hepatocarcinogenesis.
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